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Microbial biology is integrated with a seemingly endless number of pathways involving 
small organic molecules. The coordinated regulation of biosynthesis, export, and 
detection of metabolites confer fitness for the producing microbes in nearly every 
environment. Continued, rapid evolution has yielded small-molecule biosynthetic 
enzymes capable of catalyzing an array of reactions that produce chemical species of 
high structural complexity, diversity, and target specificity. 
The procurement rate of new chemical entities (NCEs) over the recent decades 
has decreased, largely due to the redundant discovery of previously characterized 
chemical species and an incomplete understanding of the regulation and biosynthetic 
steps involved in microbial metabolic pathways. Methodology to establish the full 
diversity of metabolites produced by a particular microbial species, its metabolome, and 
associated biosynthetic genes will greatly accelerate our ability to procure NCEs and 
explore their biological roles.  
 Metabolomics requires dedicated tools to characterize the small molecule 
products and biosynthetic potential of an organism. NMR spectroscopy and mass 
spectrometry are powerful analytical tools for unambiguously characterizing the 
structures of organic molecules. Therefore, the development of these methods for 
exploring microbial metabolism should foster access to the yet to be described 
metabolites of bacterial and fungal small molecule chemistry.  
  Described herein is the development of comparative metabolomics approaches, 
combining differential analysis by 2D NMR spectroscopy (DANS), LC/ESI-MS profiling, 
with specific gene overexpression, knock-out, or knock-down strategies to associate 
and characterize secondary metabolites with their corresponding biosynthetic genes or 
gene clusters. 
 Applied to the fungus Aspergillus fumigatus’s gli cluster, DANS has revealed nine 
novel gliZ-dependent diketopiperazines, and their identification provides insight into 
gliotoxin biosynthesis. In a project involving the bacterium Streptomyces clavuligerus’s 
hlm gene cluster, comparative NMR and LC/ESI+-MS demonstrated that the organism 
largely relies on alkylation though dimerization and/or methylation to detoxify 
deleteriously reactive thiol hlm pathway intermediates. Finally, as an extension to the A. 
fumigatus study, DANS is demonstrated to be a powerful tool for systematically 
examining the products of orphan secondary metabolic gene clusters, supporting the 
discovery of seven novel alkaloids in Aspergillus flavus. 
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PREFACE 
Microbial Small-Molecule Chemistry: The biosynthetic transformations employed by 
microorganisms (bacteria, fungi, protozoa, and microscopic plants and animals) 
produce a vast range of macromolecular and small organic molecules. Exploring these 
anabolic pathways has greatly advanced agricultural,1 nutritional,2 medicinal,3,4 and 
energy research,5,6 and has significantly added to our understanding of microorganisms’ 
influences in nature. Bacterial and fungal small molecule products (non-polymeric 
chemical species typically < 800 amu), often called natural products or secondary 
metabolites, have garnered significant interest from the chemical community, largely 
due to their often complex molecular architectures and potent biological activities.3 
These metabolites including terpenoids, polyketides, non-ribosomal peptides and mixed 
polyketide/non-ribosomal peptide hybrids are produced by a variety of biosynthetic 
enzymes, terpene cyclases, non-ribosomal peptide Synthetases (NRPSs), polyketide 
synthases (PKSs), and NRPS-PKS respectively, encoded for by secondary metabolic 
genes.7 The structural characterization and biological activity assessment of several 
bacterial and fungal secondary metabolic products have led to the development of a 
number of small molecule therapeutics.3 
 Although there is significant interest in obtaining new chemical entities (NCE) 
from bacteria and fungi, the rate of small molecule discovery from these sources has 
slowed. The decrease in discovery has been attributed to the frequent rediscovery of 
previously characterize metabolites and an incomplete understanding of secondary 
metabolic gene regulatory pathways. Bioinformatics studies of the secondary metabolic 
gene content of fully and partially sequenced bacterial and fungal genomes have 
suggested the number of compounds described from microbial sources belies the 
biosynthetic potential these organisms process to produce NCE.8 Additionally, 
secondary metabolic gene expression studies have demonstrate that laboratory culture 
conditions are often not sufficient to induce transcription of secondary metabolic genes, 
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indicating that these pathways likely require a specific set of chemical or physical 
signals to positively regulate secondary metabolic biosynthetic pathways.9-12 
 In many species of bacteria and fungi secondary metabolic gene disruption, 
through knockout or knockdown mutations, produces viable strains unable to 
biosynthesize individual or sets of secondary metabolites.7 This attribute is 
advantageous for studying the metabolic changes that occur when specific biosynthetic 
pathways are disrupted. However, because these molecular species often play 
indispensable roles in defense,13 virulence,14 signaling,15 pigmentation,16 and/or 
reproduction, disruption of their biosynthesis has also been shown to significantly retard 
microbial survivability in stressful environmental conditions.17,18 This has been 
demonstrated in studies conducted by the Keller Laboratory, University of Wisconsin-
Madison, showing that the ∆laeA strain of the fungus Aspergillus fumigatus, unable to 
produce secondary metabolites, is significantly less virulent than wild-type in murine 
pulmonary infection models.17 
Bacteria and fungi employ a host of integrated regulatory pathways to coordinate 
secondary metabolite biosynthesis, helping to confer fitness in a variety of 
environments. A common feature proposed to contribute to the regulation of secondary 
metabolite biosynthesis is the genomic location and organization of secondary 
metabolic genes.19 In bacteria and fungi secondary metabolic genes are typically 
clustered20 (fungi occasionally deviate from this observation, and include scattered 
secondary metabolic genes that are part of a unified biosynthetic pathway). The 
secondary metabolic gene clustering phenomenon has been attributed in part to intra 
and inter-kingdom horizontal gene transfer.21-24 This exchange of genetic information 
explains why some bacterial metabolites, or close analogs thereof, have been found in 
fungal species and vice versa. Chapter 3 of this dissertation highlights one such 
example where two piperazines (Figure P.1 compounds 1 and 2) discovered from the 
fungus Aspergillus flavus have close structural, and likely a related biosynthetic 
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pathway, as piperazinomycin produced by the bacterium Streptoverticillium olivoreticuli 
(Figure P.1).  
 
Figure P.1: Example for a structural motif present in both bacteria and fungi. 
Compounds 1 and 2 are products of a NRPS incorporating biosynthetic pathway used 
by the fungus A. flavus. Structurally similar compound, piperazinomycin, is a metabolite 
produced by S. olivoreticuli.  
 
In addition to providing insight into the distribution and evolution of secondary 
metabolic genes,20 the secondary metabolic gene clustering phenomenon has proven to 
be advantageous for defining the genetic components, and in turn regulatory, transport, 
and biosynthetic proteins involved in the production of a given secondary metabolite. 
The Walsh Laboratory, Harvard Medical School, has extensively utilized the clustering 
phenomenon of bacteria and fungi as an entry point to systematically examine the 
genes, and in turn proteins, involved in a given biosynthesis. Their approach often uses 
recombinant methodology to reconstitute active holo-enzymes in vitro, facilitating 
enzyme mechanistic and product identification studies. One of the major technological 
advances described by the Walsh Laboratory includes the development of Bacillus 
subtilis’s Sfp enzyme. Sfp is a promiscuous phosphopantetheinyl (PPT) transferase 
able to install an amino acid-functionalized PPT moiety onto an apo thiolation domain of 
a NRPS.25,26 This technology effectively allows one to prepare holo-NRPS chemical 
species which can be studies in vitro along with proposed tailoring enzymes, likely 
encoded for in the same cluster as the holo-NRPS. (Figure P.2).  
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Figure P.2: Scheme depicting the implementation of B. subtilis’s Sfp enzyme to 
study the enzyme KthP, and the structures of Kutznerides 2 and 8. Sfp was used to 
transfer the piperazate-functionalized PPT moiety to a free-standing thiolation domain. 
The holo-T domain was then studied in conjunction with KthP to determine the specific 
chemical reaction KthP catalyzes. Note that the stereo chemistry at C-5 of the 
characterized KthP product is S and in the natural products Kutznerides 2 and 8, that 
position in the piperazate moiety is R. 
 
In collaborative work including the author of this dissertation and the Walsh 
Laboratory, the enzymatic product of the non-heme iron halogenase KthP was 
examined. KthP was hypothesized to chlorinate a piperazate substrate that, through 
further enzyme-mediated processing, is installed into the macrocyclic 
hexadepsipeptides kutzneride 2 and 8 from Kutzneria sp. 744 (Figure P.2).27 This study 
joins a host of investigations aiming to define the scope of organic reactions accessed 
by bacteria and fungi to build complex small molecule scaffolds. However, as illustrated 
by the KthP study, these investigations can be quite laborious, and often have a narrow 
focus on one or two steps in an elaborate biosynthetic pathway. Additionally, because 
reconstituted in vitro biosynthetic pathways model complex in vivo systems that may 
contain yet to be defined factors modulating biosyntheses, complementary methods are 
needed to explore the corresponding endogenous biosynthetic pathways in vivo.28 To 
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address this need, the work described in this dissertation develops comparative 
metabolomics tools to explore the metabolic changes that occur in bacteria and fungi in 
response to specific overexpression, knockout, and knockdown mutations made to 
secondary metabolic genes and gene clusters. These studies provide facile 
methodology to associated secondary metabolic genes with their corresponding 
metabolomic influence, and often yield information about the endogenous biological 
influence of theses pathways and metabolites.  
 
Comparative Metabolomics, an Approach to Study Secondary Metabolism: NMR 
has traditionally been employed to unambiguously assign molecular structures for 
purified samples of organic molecules. Schroeder et al. published two ground breaking 
studies demonstrating that one can obtain full or partial structural information from 2D 
NMR spectra acquired for complex biological extracts containing mixtures of 
metabolites.29,30 In these studies the structures of several reactive cyclic alkaloids 
produced by myrmicaria ants were obtained by utilizing the 2D NMR experiment, double 
quantum filter correlation spectroscopy (dqfCOSY), for crude ant extracts. dqfCOSY 
experiments provide 1H-1H coupling information including chemical shifts (diagnostic for 
the chemical environment of a proton in an organic molecule) and scalar J-coupling 
values (directly related to the dihedral angle between vicinal hydrogen atoms or the 2-
bond coupling between germinal hydrogen atoms) useful values for assigning molecular 
structure.30 Additionally, dqfCOSY experiments have a large dynamic range (>200 fold) 
able to capture correlations for a number of molecular species in a metabolic extract. 
 Analysis of metabolic mixtures using dqfCOSY took another technical step 
forward when it was applied to the characterization of the small molecule products 
associated with the orphan pksX gene cluster in the bacterium B. subtilis.31 The 
secondary metabolites associated with the expression of B. subtilis’s pksX gene cluster 
had largely remained uncharacterized due to their labile nature, preventing 
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chromatographic enrichment, a step commonly utilized in natural products 
characterization to isolate molecular species of interest. To overcome the detrimental 
chromatography step, a comparative metabolomics approach was utilized where crude 
extracts corresponding to a pksX+ strain were compared to those derived from a pksX- 
strain. The comparison was carried out by acquiring dqfCOSY spectra for the pksX+ and 
pksX- extracts, revealing the presence of cross peaks in the pksX+ spectrum that were 
absent in the pksX- spectrum. These pksX+-specific signals supported the eventual 
characterization bacillaene a conjugated polyene containing an elimination-prone β-
hydroxy amide.  
Inspired by the comparative metabolomics approach utilized in the B. subtilis 
study, this dissertation extends differential analysis by 2D NMR spectroscopy (DANS) 
methodology to study the products, biosyntheses, and chemical biology of several 
bacterial and fungal secondary metabolic pathways (Figure P.3, DANS schematic). 
Additionally, parallel comparative LC/ESI-MS methods, provided an additional 
analytically orthogonal data set to enhance these studies. 
 
Preview of Chapters: The chapters of this dissertation are reformatted and updated 
first or co-first authored publications composed by the author of this dissertation and 
publication co-authors. Each chapter includes the abstract, text, and figures previously 
published. Additional text and figures not originally included in the publications have 
been inserted to give a broader picture of the data acquisition, analysis and 
interpretation process. Where appropriate, updates have been included to highlight 
recently published work relating to the various chapter topics. Supporting information is 
included in the appendices found at the end of the dissertation. The research described 
herein is the result of collaborative efforts conducted between the author and several 
labs. Therefore, the descriptions given below highlight the content of each chapter and 
the contributions made by the individual authors of the original publication. 
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Chapter 1, Identification of Cryptic Products of the Gliotoxin Gene cluster Using 
NMR-Based Comparative Metabolomics and a Model for Gliotoxin Biosynthesis32: 
Chapter 1 explores the metabolomic changes that result from knocking out gliZ (∆gliZ), 
the transcriptional regulator of the gliotoxin gene cluster in A. fumigatus. The study 
employed DANS methodology (described in the previous section) to compare 
unfractionated, or partially enriched, extracts wild-type and ∆gliZ cultures (Figure P.3). 
These studies lead to the characterization of a family of gliZ-dependent 
diketopiperazines, including nine novel chemical species. The structural information 
provided by elucidation of the gliZ-dependent metabolites supported the development of 
a proposed gliotoxin biosynthetic scheme. This scheme addresses in detail the order 
and chemistry of the biosynthetic steps involved in gliotoxin production. These 
transformations are proposed as a collection of oxidative and addition reactions 
performed on a GliP (NRPS)-thioester tethered species, GliP-S-Ser-Phe-NH2. This 
model stands in contrast to recently published work that suggest gliotoxin biosynthesis 
takes part though modification to untethered cyclo(Phe-Ser) species. As discussed at 
length at the end of Chapter 1, to date, both the tethered and untethered models seem 
to retain validity given the collection data that have been assembled pertaining to 
gliotoxin biosynthesis.  
 Authors’ contributions: Ry R. Forseth, study design, data collection, data analysis 
and interpretation, figures, and writing; Ellen M. Fox and DaWoon Chung, study design, 
data collection, and data analysis pertaining to the ∆gliI mutant; Barbara J. Howlett, 
study design, data analysis, and writing; Nancy P. Keller, study design, data analysis 
and interpretation, and writing; and Frank C. Schroeder, study design, data analysis and 
interpretation, and writing. 
 xiv 
Wild-type A. fumigatus
∆gliZWT
∆gliZ
Overlay 
SHN
NH
OH
O
O
S
OH
N N
OH
O
O OH
S S
gliotoxin
  
 
 
 
 
 
 
Figure P.3: Schematic overview of the DANS methodology as applied to the A. 
fumigatus gliZ study. Wild-type A. fumigatus expresses gliZ, the transcriptional 
regulator of the gliotoxin gene cluster, and in turn produces gliotoxin. In the ∆gliZ strain, 
a gliZ knockout mutant, expression of the gliotoxin gene cluster genes and production of 
associated metabolites is abolished. dqfCOSY spectroscopic comparison of extracts 
corresponding to wild-type and ∆gliZ reveals signals representing compounds present in 
wild-type and absent in ∆gliZ. Analysis of the wild-type unique signals provides a basis 
for structure elucidation of the gliZ-dependent metabolites. 
 
Chapter 2, A Backup Plan for Self-Protection: S-Methylation of Holomycin 
Biosynthetic Intermediates in Streptomyces clavuligerus33: Chapter 2 investigates 
the consequences of disrupting the ultimate or penultimate enzymatic steps in 
holomycin biosynthesis. The bacterium S. clavuligerus’s hlm gene cluster encodes the 
enzymes responsible for the production of a dithiolopyrrolone antibiotic holomycin 
(Figure P.5). The holomycin biosynthetic pathway utilizes NRPS-supported chemistry to 
condense two equivalents of cysteine, and oxidize/decarboxylate yet to be described 
intermediates. These steps lead to the production a dithiol analog of holomycin which 
was found to undergo HlmI-catalyzed oxidation to the corresponding disulfide. Further, 
HlmI is needed to confer producer resistance to holomycin toxicity. Unknown was the 
fate of homomycin intermediates produced by S. clavuligerus strains containing an hlmI 
knockout background (∆hlmI). Comparative metabolomics using 1H NMR, 1H,13C-HMBC 
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and comparative LC/ESI-MS revealed a number of S-methylated analogs of holomycin 
and a heterodimer species (Figure P.5). The results of these studies suggest that 
capping the free thiol with a methyl group and hetero dimerization represents two major 
transformation pathways utilized by S. clavuligerus to deal with the accumulation of 
reduced holomycin intermediates.  
Authors’ contributions: Bo Li and Ry R. Forseth contributed equally to this 
publication and conducted study design, data collection, data analysis and 
interpretation, figures, and writing; Frank C. Schroeder, study design, data analysis and 
interpretation and writing; and Christopher T. Walsh, study design, data analysis and 
interpretation and writing. 
 
Figure P.4: Representation of the various small molecule transformation 
pathways utilized by S. clavuligerus to process free thiol-containing holomycin 
intermediates. In the hlmI background S. clavuligerus produces holomycin. Disruption 
of the hlmI gene results in methylation of a common dithiol-containing intermediate that 
may be singly methylated, doubly methylated or form hetero dimeric species. 
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Chapter 3, Homologous Non-Canonical NRPS Gene Clusters Mediate Redundant 
Small-Molecule Biosynthesis in Aspergillus flavus (in press): Chapter 3 extends 
the DANS methodology described in the Chapter 1 A. fumigatus gliZ study by 
developing comparative gene knockout, knockdown, and overexpression approaches to 
probe small molecule outputs and biosynthetic pathways involving orphan secondary 
metabolic gene cluster (gene clusters for which there is no known associated 
metabolite). This chapter focuses on the orphan lna and lnb clusters from the fungus A. 
flavus. The lna and lnb clusters both contain one NRPS gene. Interestingly, the NRPS 
gene of the lna cluster (lnaA) is homologous to lnb’s NRPS gene (lnbA), and both NRPS 
genes are clustered with similar sets of genes encoding putative small molecule 
tailoring enzymes. Both lnaA and lnbA encode a three module NRPS, putatively able to 
activate, tether, and reduce one amino acid. To investigate the products associated with 
these NRPS genes, and in turn clusters, a series of lnaA knock out and overexpression 
A. flavus strains were constructed as well as several double mutants including a 
knockout lnaA and knockdown lnbA strain (∆lnaA, KD::lnbA). DANS and comparative 
LC/ESI-MS of the various A. flavus strains revealed a family of alkaloids including 
piperazines-, pyrazines-, and morpholine-containing moieties. These species are 
derived from the coupling of two equivalents of L-tyrosine. Structural and mutant 
profiling information for the discovered lna/lnb-metabolites provided insight into their 
biosynthesis. Complementing the chemical investigations of this chapter are several 
important biochemical, phenotype, and expression studies confirming the substrate 
specificity of LnaA and LnbA and providing insight into the influence of the discovered 
metabolites on phenotype and gene expression (Figure P.5). 
 Authors’ contributions: Ry R. Forseth and Saori Amaike contributed 
equally to this publication and conducted study design, data collection, data analysis 
and interpretation, figures, and writing; Daniel Schwenk, LnaA and LnbA biochemical 
study design, data collection, and data interpretation; Katharyn J. Affeldt, gene 
 xvii 
expression data collection, data analysis, and figures; Dirk Hoffmeister, study design, 
data analysis and interpretation, and writing; Frank C. Schroeder, study design, data 
analysis and interpretation and writing; Nancy P. Keller, study design, data analysis and 
interpretation and writing. 
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Figure P.5: Depiction of results from the A. flavus study. This investigation presents 
a comparative metabolomics approach to study A.s flavus’s orphan lna and lnb 
secondary metabolite gene clusters. Interestingly, these two clusters encode partially 
redundant biosynthesis pathways, responsible for the production of a series of novel 
fungal alkaloids (red box) and appear to be integrated in the regulation of sclerotial 
formation (blue box), an important survival body produced by A. flavus. 
 xviii 
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CHAPTER 1 
 
IDENTIFICATION OF CRYPTIC PRODUCTS OF THE GLIOTOXIN GENE CLUSTER 
USING NMR-BASED COMPARATIVE METABOLOMICS AND A MODEL FOR 
GLIOTOXIN BIOSYNTHESIS 
 
Abstract: Gliotoxin, a major product of the gli non-ribosomal peptide synthetase gene 
cluster, is strongly associated with virulence of the opportunistic human pathogen 
Aspergillus fumigatus. Despite identification of the gli cluster, the pathway of gliotoxin 
biosynthesis has remained elusive, in part because few potential intermediates have 
been identified. In addition, previous studies suggest that knowledge of gli-dependent 
metabolites is incomplete. Here differential analysis by 2D NMR spectroscopy (DANS) 
of metabolite extracts derived from gli knock-out and wild-type strains is used to obtain 
a detailed inventory of gli-dependent metabolites. DANS-based comparison of the wild-
type metabolome with that of ΔgliZ, a knock-out strain devoid of the gene encoding the 
transcriptional regulator of the gli cluster, revealed nine novel gliZ-dependent 
metabolites including unexpected structural motifs. Their identification provides insight 
into gliotoxin biosynthesis and may benefit studies of the role of the gli cluster in A. 
fumigates virulence. This study demonstrates the utility of DANS for correlating gene 
expression and metabolite biosynthesis in microorganisms. 
 
Introduction: Filamentous fungi produce remarkably diverse metabolomes including 
many small molecules of polyketide synthase (PKS) or non-ribosomal peptide 
synthetase (NRPS) origin that play important roles in pathogenesis.1,2 The opportunistic 
pathogen Aspergillus fumigatus, a causative agent of invasive aspergillosis, produces 
copious amounts of gliotoxin (1, Figure 1.1), a representative member of a small family 
of epipolythiodioxopiperazines (ETPs) that is strongly associated with A. fumigatus 
Adapted with permission from, Forseth, R. R.; et al. J Am Chem Soc 2011, 113, 9678. © 2011 American Chemical Society. 
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virulence.3,4 Gliotoxin and related ETPs are products of the gli NRPS gene cluster.5 
Knock-out mutations of gliP (ΔgliP), a three-module NRPS (see Appendix A, Figure A.1 
for domain architecture),5,6 gliI (ΔgliI), encoding a putative pyridoxal 5’-phosphate (PLP) 
binding domain,7,8 or gliZ (ΔgliZ), a Zn2Cys6 binuclear transcription factor, abolishes 
gliotoxin biosynthesis.9-12 ΔgliP has been shown to be significantly less virulent than the 
wild-type strain in immunosuppressed mice,11 confirming that gliotoxin and perhaps 
other gli-dependent metabolites play a role in overcoming host resistance. 
 Previous studies suggest that knowledge of gli-dependent metabolites is 
incomplete.12 In addition, the sequence of steps in the biosynthesis of the gliotoxins has 
remained unclear, in part because few potential biosynthetic intermediates or shunt 
metabolites have been identified. In this study it was hypothesized that NMR-based 
comparative metabolomics of gli-knock-out and wild-type or gli-overexpressing strains 
could provide a comprehensive overview of gli-dependent metabolites, including shunt 
metabolites and other cryptic products.13,14 Recent studies, including the identification of 
bacillaene as the product of the mixed PKS-NRPS gene cluster pksX in Bacillus 
subtilis15 and the identification of mating pheromones in Caenorhabditis elegans,16 have 
demonstrated the utility of differential analysis by 2D NMR spectroscopy (DANS) for 
connecting metabolites with their biosynthetic pathways. In these examples, DANS 
combined with HPLC-MS analyses provided a comprehensive overview of the metabolic 
changes caused by knocking out small-molecule biosynthetic genes, which in each 
case led to the identification of several previously undetected metabolites derived from 
the knocked-out pathway. 
 
DANS Comparative Metabolic Analysis, ΔgliZ and Wild-Type: For metabolic 
comparison, wild-type A. fumigatus and the mutant strain ΔgliZ were used.12 Knock-outs 
of gliZ have been shown to stop the expression of the majority of genes in the gli cluster 
with the exception of gliT.12,17,18 Therefore, DANS-based comparison of the ΔgliZ and 
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wild-type metabolomes should enable identification of any metabolites whose 
biosyntheses directly or indirectly depend on gli expression (Figure 1.1). 
 
  
Figure 1.1: Identification of gliZ-dependent metabolites via DANS. (a) Gliotoxin 
gene cluster in A. fumigatus wild-type and mutant strain ΔgliZ, in which gliZ is replaced 
by the selection marker pyrG, encoding orotidine-5’-phosphate decarboxylase. (b) 
DANS overlay technique (schematic). Signals in the DANS overlay serve as markers for 
compounds whose biosyntheses depend on gliZ expression. (c) Examples for gliZ-
dependent metabolites identified in this study and structure elucidation of 4 (1H,13C-
HMBC, blue arrows; ROESY, red arrows). 
 
In preparation for NMR spectroscopic analyses, ΔgliZ and wild-type metabolic 
extracts were fractionated into three metabolite pools of reduced complexity and limited 
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metabolites would be detected (see Appendix A, section 5) For the resulting three wild-
type pools and three ΔgliZ pools, dqfCOSY spectra were acquired. Compared to other 
2D NMR spectroscopic techniques such as TOCSY19 or HSQC,20 dqfCOSY offers 
distinct advantages for the detection of novel or unanticipated compounds, because 
cross peak fine structure in dqfCOSY spectra provides greater structural information, 
including full signal multiplicity and coupling constants.21 Furthermore, dqfCOSY cross 
peak fine structures can be easily modeled,21 which helps resolve peak overlap and 
facilitates recognition of minor components.16 dqfCOSY spectra also offer better 
sensitivity than HSQC, often enabling characterization of trace components 
representing < 0.1% of a sample.22,23  
For DANS, dqfCOSY spectra obtained for the three wild-type metabolite pools 
were compared with the corresponding ΔgliZ pools using an overlay algorithm designed 
to highlight wild-type signals that were completely absent from the ΔgliZ spectra. This 
approach excluded compounds from the analysis whose biosynthesis was not entirely 
gliZ-dependent. DANS revealed more than 20 distinct gliZ-dependent spin systems in 
wild-type pool 2 (Figures 1.2 and Appendix A, Figure A.2 and Figure A.3) and a 
smaller number of gliZ-dependent signals in wild-type pool 1. No gliZ-dependent signals 
were observed in wild-type pool 3. 
 
Characterization of gliZ-Dependent Metabolites’ Structures: DANS analysis of pool 
1 revealed two major gliZ-dependent spin systems that were accompanied by two 
closely related sets of less abundant signals. These spins systems suggested the 
presence of two structurally related gliZ-dependent compounds that feature a 5,6-
disubstituted cyclohexa-2,4-dien-1-ol bearing a methylene group in position-5 (C-8, 4) 
analogous to the A-ring of the gliotoxins (Figure 1.1). However, the dqfCOSY spectrum 
revealed an unusually large coupling constant of 16 Hz between the two methine 
protons in the A-ring moiety of the pool 1 analytes, which is significantly larger than the 
5 
 
coupling constants between the corresponding protons of gliotoxin (13-14 Hz). Initial 
attempts to isolate or enrich the major gliZ-dependent metabolite in pool 1 via 
preparative HPLC resulted in almost complete loss of the compound, indicating limited 
chemical stability. Therefore, a larger sample of pool 1 was prepared and fractionated 
using carefully conditioned flash chromatography media (Appendix A, section 8). 
Chromatographic enrichment of the 4 was monitored using diagnostic 1H NMR signals 
established in the pool 1 DANS analysis. dqfCOSY spectra acquired for the purified 
metabolite confirmed the DANS-based assignments of the 1H spin systems, and in 
conjunction with 1H,13C-HMBC and 1H,13C-HMQC data revealed that this compound 
represented a diketopiperazine based on the same serine- and phenylalanine-derived 
building blocks as the gliotoxins (1-3). Despite these similarities, the spectroscopic data 
suggested the presence of significant structural differences in the phenylalanine-derived 
portion of 4. The chemical shift of C-3 (69.6 ppm) suggested sulfur-substitution at this 
position. However, the chemical shift of C-14 (57.1 ppm) was lower than in the 
gliotoxins, which carry an amide nitrogen in this position. This suggested that C-14 in 4 
may not be attached to nitrogen, which is consistent with the observation of two amide 
protons in the NMR spectra. High resolution mass spectrometry (Appendix A, section 
10) indicated a molecular formula of C13H16N2O4S2 which, in conjunction with ROESY 
and 1H,13C-HMBC data, established the structure of 4 as shown, featuring a sulfur 
bridge between C-3 and C-14 as part of a 6,9-diaza-1-sulfaspiro[4.5]decane system. 
ROESY spectra showed correlations between the protons of the methylsulfanyl 
attached to C-6 and the proton attached to C-14 supporting the relative configuration of 
4. Compound 4 is a novel metabolite with a structural motif rarely observed in nature; a 
sulfur- and nitrogen-bound spiro atom. The second gliZ-dependent metabolite detected 
in pool 1 could not be fully identified due to its lower abundance and limited chemical 
stability. However, the available NMR spectroscopic data for the compound strongly 
suggest that it represents a stereoisomer of spiro compound 4.  
6 
 
 
 
Figure 1.2: Identification of gliZ-dependent metabolites in pool 2. (a) DANS overlay 
of wild-type and ∆gliZ spectra, (b) Section of the wild-type dqfCOSY spectrum showing 
signals representing known gliotoxin derivatives (blue), the known 10 and 11 (black), 
and novel gli-dependent compounds (red). Several cross peaks representing 
metabolites present in both wild-type and ∆gliZ were not fully suppressed in the overlay 
due to chemical shift variation (green). (c) gliZ-dependent metabolites identified in wild-
type pool 2. Structures shown in red represent novel metabolites. The relative 
configuration of 13, which occurs as one single diastereomer, could not be determined, 
but likely corresponds to that of 11. 
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unknown compounds (see Figure 1.2 and Appendix A Figure A.3 for DANS overlay 
spectra). For further structural assignments, the wild-type pool 2 sample was 
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HMBC, and ROESY spectra as well as HPLC/ positive-ion electrospray ionization 
(ESI+)-MS. These analyses confirmed the presence of the gliotoxins 1, 3 and 8, as well 
as their dehydro derivatives 5, 7, and 9.26-28 Cyclo(L-Phe-L-Ser) was also identified as a 
gliZ-dependent metabolite (10),29 not previously reported from A. fumigatus extracts nor 
other gliotoxin-producing fungi, as well as bis-N-norgliovictin (11), a known A. fumigatus 
metabolite30 not previously associated with the gli cluster. 
All other gliZ-dependent metabolites detected in wild-type pool 2 represented 
novel compounds (Figure 1.2). A reoccurring structural motif in the gliZ-dependent 
metabolites of pool 2 is a cyclo(Phe-Ser) framework decorated with different oxidative 
functionality at the α-carbon positions. Amongst these functional groups, a 
methylsulfanyl bound via sulfur to either one or both of the α-carbons was frequently 
observed (compounds 12-15). 3-bond 1H,13C-HMBC correlations from the 
methylsulfanyl to corresponding α-carbons, along with additional 1H,13C-HMBC 
correlations from the β methylene protons of either the Phe- or Ser-derived moieties 
helped to establish the diketopiperazines core structure.  
Oxidation was not limited to the α-carbons. Compounds 14a/b represent a pair of 
diastereomeric N-methoxy derivatives of 12, as was demonstrated via 1H,15N-HMBC 
showing N-methoxy protons coupling to N-1 and, in the case of compound 14a, residual 
1-bond N-4-H-4 coupling. ROESY through space correlations across the 
diketopiperazines ring established the relative stereochemistry of compounds 12, 14a/b, 
and 16. Compounds 12-15 are accompanied by two indolopyrazines, 16 and 17, 
representing nonsulfurized derivatives of gliotoxin. In addition, DANS revealed a second 
type of spirocyclic scaffold, the 6,9-diaza-1-oxaspiro-[4.5]decanes 15a and 15b. The 
two diastereomers 15a/b appear to be derived from 13 via intramolecular substitution at 
C-3, as isolated samples of 13 slowly convert into mixtures of 15a and 15b (Appendix A, 
Figure A.4). HR-MS confirmed the molecular formulas of all new compounds (see 
Appendix A, Table A.11 and Table A.12 for spectroscopic data), and the gliZ-
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dependence of their biosynthesis was corroborated via DANS and HPLC/ESI+-MS in 
two independent replicates (Appendix A, Figure A.5 and Figure A.6). 
To test whether gliZ overexpression would reveal additional gliZ-dependent 
metabolites, the A. fumigatus wild-type metabolome was compared with that of a gliZ-
overexpressing (OE) strain via DANS.12 Although differences were observed in the 
relative amounts of some of the metabolites 1-17 in the OE strain, no new gliZ-
dependent metabolites were detected. Next, the effect of deletion of two additional gli 
genes, gliP and gliI were investigated. DANS- and HPLC/ESI+-MS-based comparison of 
ΔgliP and ΔgliI mutant metabolomes with wild-type showed that none of the gliZ-
dependent compounds 1-17 are produced by these two mutant strains. These results 
further support that biosynthesis of 1-17 requires the gli cluster. 
 
Gliotoxin Biosynthetic Pathway: Of the nineteen gliZ-dependent compounds 
identified, nine represent novel compounds, several of which feature structural motifs 
not previously associated with gli products. These structural features are of interest 
considering the putative pathway of gliotoxin biosynthesis in A. fumigatus (Figure 1.3).5 
Only the first and last steps in gliotoxin biosynthesis, the condensation between L-Phe 
and L-Ser by GliP and the oxidation of dithiol gliotoxin by GliT, have been elucidated,6,17 
and many aspects of the intervening steps remain unclear. In vitro experiments 
conducted with recombinant GliP demonstrated that GliP couples the amino acids L-
Phe and L-Ser, producing a L-Phe-L-Ser-GliP intermediate.6 Further observations 
indicated that GliP is capable of producing cyclo(L-Phe-L-Ser), but kinetic data 
suggested that the rate of cyclic dipeptide formation may be too low to be enzymatically 
relevant.6 The comparative metabolomics work of this study have demonstrated that 10 
is a major component of the A. fumigatus wild-type metabolome, with a gliotoxin-to-
cyclo(L-Phe-L-Ser) molar ratio of roughly 2:1, and that this abundant production of 10 is 
gliZ-dependent. The abundance of 10 suggests that the in vivo rate of formation is much 
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greater than that in vitro, perhaps due to presence of additional factors, for example 
other gli components, in vivo. It has been proposed that 10 is an intermediate in 
gliotoxin biosynthesis;7 however, the structural features of the gliZ-dependent 
metabolites identified are consistent with pathways involving tethered intermediates 
(Figure 1.3). Furthermore, the addition of synthetic 10 to ΔgliP cultures did not rescue 
the production of any of the gliZ-dependent metabolites as assessed by DANS and 
HPLC-MS (Appendix A, section 14), suggesting that 10 may not be a biosynthetic 
intermediate. 
 
 
Figure 1.3: Proposed biogenesis of gliZ-dependent metabolites. Oxidation and 
sulfurization at C-3 (A) is followed by N-1-oxidation (B) and C-6 sulfurization (C or C’). 
Epoxidation (D) is followed by pyrollidine, thiophane, or phenol formation (black, red, 
and blue arrows, respectively). Aminolysis (E) of the resulting GliP-tethered 
intermediates and methylation of thiols (F) produce compounds 4, 10-14a/b. N-1-
methylation (G) and aminolysis (E) result in formation of dithiol, which is S-methylated 
(F) to form 8 or oxidized by GliT17 to produce gliotoxin, 1. Hydrolysis (H) of species 
oxidized (and possibly sulfurized) only at C-3 (green arrows) produces 16, which 
aromatizes (I) to form 17. 
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and sulfurization at C-3 occurs at an early stage in the biosynthesis following formation 
of the L-Phe-L-Ser dipeptide. Oxidation at C-3 could involve gliC or gliF, encoding 
putative cytochrome P450 monooxygenases. Sulfurization at C-3, yielding a C-3 thiol 
intermediate, likely involves GliG, recently demonstrated to possess glutathione S-
transferase activity in vitro.31 Compound 12 would then form via methylation of the thiol, 
either before or after aminolysis of the thioester. All sulfurized diketopiperazines 
identified in this study (except for the four ETPs) are S-methylated and thus likely 
derived from methylation of corresponding thiols, which is also suggested by the finding 
that, in Gliocladium deliquescens, gliotoxin is converted into 
bisdethiobis(methylthio)gliotoxin, 8.26 
The identification of compounds 11 and 14a/b suggests that sulfurization at C-3 
is followed by oxidation of the peptide backbone at C-6 and N-1, with O-methylation of 
the resulting hydroxamic acid derivatives by the putative O-methyltransferase GliM. 
Aside from spirocyclic 15a/b, compounds 14a/b are the only gliZ-dependent metabolites 
that occur as a pair of epimers, likely as a result of deprotonation/enolization at C-6. 
Oxidation at C-6, perhaps involving gliC or gliF, could occur independently from 
hydroxylation of N-1; however, sulfurization at C-6 could also be accomplished via 
dehydration of a hydroxamic acid intermediate followed by sulfurization of the resulting 
imine, as had been proposed previously on the basis of synthetic studies32 and a shunt 
metabolite detected in a ΔgliG strain.31 This mechanism is also suggested by the lack of 
N-hydroxylated or methoxylated compounds other than the C-6 non-sulfurized 14a/b. 
Release and methylation of the bis-3,6-disulfurized dipeptide would then produce 
compound 11. 
As a next step, the disulfurized dipeptide appears to undergo epoxidation of the 
phenyl ring by one of two putative cytochrome P450 monooxygenases, GliC or GliF. 
The relative configurations observed for compound 4 strongly suggest that this oxidation 
step is not entirely stereoselective and produces both the (13S,14R)- and (13R,14S)-
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diastereomers (Figure 1.4). Nucleophilic opening of the (13S,14R)-diastereomer by the 
C-3 amino group could lead to formation of the pyrrolidine ring of gliotoxin, whereas 
nucleophilic attack by the C-3 thiol results in formation of the thiophane ring in 4. 
Alternatively, the phenyl ring is oxidized to form the ortho-substituted phenol found in 
compound 13, perhaps via the shown epoxide intermediate. The biosyntheses of 13, 
spirocyclic compound 4, and the gliotoxins 1-3 and 8 are completed via diketopiperazine 
formation and S-methylation (in the case of 4 and 13) or N-methylation, possibly 
involving gliN, and epidithio bridge formation via GliT in the case of the EPTs.17 Lastly, 
compounds 16 and 17, which both lack oxidation at C-6, appear to be derived from 
epoxidation of an intermediate oxidized only at C-3, followed by pyrrolidine and 
diketopiperazine formation. As the relative configuration at C-3 in 16 is opposite to that 
of C-3 in all identified C-3-sulfurized compounds, the C-3-OH group in 16 could be 
derived from substitution of a thiol or methylsulfanyl group. Elimination of water from 16 
would form a dihydroindole that could easily aromatize to form 17. 
 
 
Figure 1.4: Proposed epoxide intermediate. Different configurations of putative 
epoxide intermediate 19 result in formation of either gliotoxin (1) or spirocyclic 4. 
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intermediates or diketopiperazines are the substrates of the gli-encoded oxidases and 
methyltransferases. Furthermore, variation of growth conditions could induce 
biosynthesis of additional gliZ-dependent metabolites. 
 
Conclusions: Comparison of the wild-type and ΔgliZ metabolomes via DANS revealed 
nine new compounds featuring several unexpected structural motifs, despite the fact 
that A. fumigatus’s metabolome, and specifically gliotoxin and its associated 
biosynthetic genes’ role in virulence, had already been studied extensively. In particular, 
DANS facilitated detection of minor or unstable metabolites (e.g., 4 and 13) missed by 
conventional analysis. Further investigations of the role of the gli-cluster in A. fumigatus 
virulence may benefit from the expanded knowledge of gli-associated structures and 
help clarify the biological roles of the newly identified compounds. Finally, these results 
suggest that the use of NMR-based comparative metabolomics for the examination of 
orphan PKS/NRPS gene clusters in microorganisms can significantly accelerate 
discovery of new structures and biosynthetic annotation. 
 
Elaboration of the Gliotoxin Biosynthetic Pathway GliG, GliC, and GliI: After 
publication of the work highlighted above,33 several recently studies have examined the 
details of sulfur incorporation in the gliotoxin biosynthetic pathway, including 
recombinant and mutant studies focusing on: GliG31,34, GliC34, and GliI8 (Figure 1.1). 
The results of these studies corroborate some of the hypotheses developed in the 
DANS-based gliZ study pertaining to gliotoxin biosynthesis. Figure 1.5 summarizes 
what has been reported about the small molecule transformations GliG, GliC and GliI 
can catalyze. 
 Two independent studies found that recombinant GliG can act as a glutathione 
S-transferase.31,34 A ∆gliG mutant strain was shown to produce compound 20 (Figure 
1.5), a highly oxidized cyclo(Phe-Ser) species containing: C-3 hydroxylation, N-4-
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methoxy functionality, and a C-6 exocyclic methylene. Additionally in a study of the 
cytochrome P450-encoding genes gliC and gliF, 20 was found to be absent in a ∆gliC 
mutant strain and present in ∆gliF mutant, suggesting that GliC is responsible for the N- 
and/or α-carbon-oxidation and GliF may be implicated in oxidation of the Phe phenyl 
ring. The study went on to show that a synthetic compound (21), a cyclo(Phe-Ser) 
species hydroxylated at both α-carbons, undergoes glutathione conjugation catalyzed 
by GliG resulting in the bis-glutathione adduct 22. Compound 22 was not observed in 
any reported mutant strain. An independent study probing the activity of GliG found that 
the recombinant enzyme was also able to transfer a glutathione moiety to 1,2-epoxy-3-
(4-nitrophenoxy)-propane, 1-chloro-2,4-dinitrobenzene, and 3,4-dichloro-nitrobenzene. 
 A follow up study explored the role of the aminotransferase GliI in further 
processing following sulfur installation.8 The Hertweck Laboratory explored the 
metabolites of a novel isolate of ∆gliI (independent of the ∆gliI strain described in 
Appendix A).8 From a 140 L ∆gliI mutant culture 1.5 mg of a highly water soluble 
dicysteine analog of 22 (23) was isolated and fully characterized by NMR. Compound 
23 was found to be converted to the corresponding dithiol (24) when exposed to 
recombinant GliI and coenzyme pyridoxal phosphate (PLP) in vitro. Additionally the 
authors show that this reaction results in the formation of pyruvic acid and ammonia, 
supporting the thiol formation mechanism outlined in Figure 1.5. 
 The GliG and GliI studies described above represent a firm step forward 
developing a more complete model of the gliotoxin biosynthetic pathway. The authors 
claim that the results of these mutant and in vitro experiments demonstrate that gliotoxin 
biosynthesis is largely carried out as controlled enzymatic modifications to untethered 
cyclo(Phe-Ser) analogs. However, one could argue that the results of these studies are 
also consistent with a tethered model and the observations of the DANS-based gliZ 
study. The metabolites isolated from the ∆gliG and ∆gliI mutants, 20 and 23 
respectively, could have come from modification of a GliP-S-Ser-Phe-NH2 intermediate, 
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followed by the off-loading mechanism proposed for the shunt metabolites depicted in 
Figure 1.3. 
 
Figure 1.5: Overview of recently published work describing the chemistry of GliC, 
GliG and GliI. (a) Compound 20 was found in a ∆gliG mutant. Subsequently, compound 
21 was tested as a substrate for GliG, demonstrating the addition of glutathione (G-S-) 
affording 22. (b) GliI was demonstrated to act as a carbon-sulfur lyase, converting 23 to 
24 and yielding the side products pyruvic acid and ammonia. 
 
Although it is clearly demonstrated that the recombinant enzymes can carry out 
transformations on the model diketopiperazines utilized in the GliG and GliI studies, no 
rate constants are offered for these reactions. As demonstrated by Balibar and Walsh, 
enzyme rate constants are important parameters to measure to provide evidence 
pertaining to the likelihood that a given enzymatic transformation occurs at a 
physiologically relevant rate.6 This was demonstrated in their examination of GliP, found 
to produce cyclo(Phe-Ser) but not at a rate that would suggest that GliP functions to 
produce this chemical species. The importance of establishing enzyme reaction rates is 
echoed in the results of Davis et al., described above, where GliG appears to have 
substrate flexibility, conjugating glutathione to several nitro-containing aromatic 
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substrates.31 These findings suggesting that GliG could potentially also act on a the 
NRPS thioester-tethered dipeptide intermediate GliP-S-Ser-Phe-NH2. As a potential 
complement to the in vitro work already done with recombinant GliG and GliI, further 
experiments incorporating GliP-S-Ser-Phe-NH2 may provide additional insight into the 
tethered versus untethered gliotoxin biosynthetic models.  
 
Examination a Wild-type and OE::rsmA A. fumigatus Mouse Infection Model: 
Aspergillus fumigatus uses several strategies to regulate secondary metabolic gene 
expression, including global (LaeA)35 and gene-cluster specific (GliZ)12 expression 
control. A. fumigatus poses a significant threat to immunocompromised hosts, and 
gliotoxin has received significant attention as a potential virulence factor involved in 
modulating A. fumigatus’s efficacy of infection. Therefore, systematic studies of 
gliotoxin’s biosynthetic regulatory pathways in A. fumigatus will help to deconvolute the 
relative importance of this metabolite in pathogenicity. The methodology and 
metabolites described in the DANS-gliZ study presents an analytical platform to monitor 
how the gli cluster, and overall gliotoxin biosynthesis, responds to perturbations in 
secondary metabolite gene regulations. Described herein is a study exploring one such 
perturbation, by the gliZ regulatory protein RsmA. 
 Recently a suppressor mutagenesis screen in Aspergillus nidulans identified 
rsmA, encoding a bZIP transcriptional enhancer, that when overexpressed could 
partially restore secondary metabolism in ∆laeA.36 Overexpression of rsmA (OE::rsmA) 
increased sterigmatocystin production in A. nidulans more than 40-fold through 
transcriptional activation of aflR.37 In continuation of the gliZ regulatory studies, an 
investigation of the A. fumigatus rsmA ortholog, also called rsmA, was undertaken both 
in culture and a mouse infection model.  
 Utilizing the established extraction protocols and HPLC/ESI+-MS methodology 
established in the DANS-gliZ study described above,33 compounds 1-17 were profiled in 
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cultures of wild-type and OE::rsmA (Figure 1.6). Standards derived from enriched and 
NMR-characterized samples of the gliZ-dependent metabolites (1-17) were utilized to 
confirm the identity of observed metabolites via HPLC retention time and MS 
fragmentation patterns. Comparison of peak areas for wild-type and OE::rsmA samples 
demonstrated that the majority of compounds (1, 3, 10, 12, 14a/b, 15a/b, and 17) are 
greater than 10-fold upregulated in OE::rsmA relative to wild-type. Compounds 2, 8, 9, 
and 11 were 0.1-5-fold more abundant in OE::rsmA relative to wild-type.  
 In addition to culture analysis, the lungs of seven sacrificed female Swiss ICR 
mice, immunosuppressed via administration of cyclophosphamide and infected with 
wild-type, OE::rsmA, ∆gliZ, or OE::rsmA A. fumigatus, were profiled for the presence or 
absence of compounds 1-17. Given the limited amount of sample (each pair of mouse 
lungs ~ cm3), lungs from a given treatment set were pooled. To ensure the highest 
detection sensitivity for the metabolite profiling experiment, HPLC/ESI+-SIMMS was 
carried out, restricting the mass spectral data acquisition to the most abundant ions for 
each metabolite profiled. Of compounds 1-17 only gliotoxin and cyclo(Phe-Ser) (10) 
were detected; however, compound 10 had not previously been described as a 
metabolite found in A. fumigatus-infected mice (Figure 1.7). The OE::rsmA sample 
contained about 2-fold more gliotoxin and 10 than wild-type. Survival experiments 
running in parallel to the lung metabolite profiling work showed that both wild-type- and 
OE::rsmA-infected mice do not survive as long as OE::rsmA, ∆gliZ-infected mice, and 
that there is no significant difference between the wild-type and OE::rsmA-infected mice 
survival times. 
 The greatly enhanced production of numerous gli cluster metabolites in 
OE::rsmA was striking and supported results from the DANS-gliZ study, showing that 
gliotoxin is not the only metabolite produced by the gli gene cluster. Two pertinent 
observations from this study include further support for GliT as an oxidase responsible 
for disulfide formation from dithiol-containing metabolites.17 Notably, the lesser 
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accumulation of the methylsulfanyl containing compounds (8, 9, and 11) would be 
expected in the OE::rsmA strain, as gliT expression was particularly upregulated in this 
strain. GliT is also responsible for A. fumigatus self-resistance to gliotoxin, and likely 
other gli metabolites and, along with bis(methylthio)gliotoxin (8),38 has been proposed 
as an antigen for diagnosis of invasive aspergillosis.39 The profiling work here reveals 
an additional metabolite, cyclo(L-Phe-L-Ser) (10), which may also present an alternative 
molecule for invasive aspergillosis diagnosis. Compound 10, along with gliotoxin, is 
produced in high amounts by the fungus both in vivo and in vitro and, furthermore, 
remains stable over time as would be required in a diagnostic setting. 
 
 
Figure 1.6: Profiling compounds 1-17 in OE::rsmA relative to wild-type. Relative 
amounts of compounds 1-17 in OE::rsmA compared to wild-type. Compounds 4, 13, 
and 16 were detected neither in OE::rsmA nor in wild-type cultures. Compounds 15a/b 
and 17 were not detected in wild-type; values shown for these two compounds 
represent the measured S/N ratio as determined by their diagnostic mass ion 
chromatograms. Error bars represent one standard deviation (n = 3 cultures). 
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Figure 1.7: HPLC/ESI+-SIMMS profiling results for OE::rsmA, ∆gliZ-, wild-type-, 
and OE::rsmA-infected mouse lung samples. (a) Compound 10 is present in 
OE::rsmA, somewhat less abundant in wild-type, and absent in OE::rsmA, ∆gliZ. (b) 
Gliotoxin is present in OE::rsmA, somewhat less in wild-type, and absent in OE::rsmA, 
∆gliZ. 
  
19 
 
REFERENCES 
 
(1) Nierman, W. C. et al. Nature 2005, 438, 1151. 
(2) Rohlfs, M.; Albert, M.; Keller, N. P.; Kempken, F. Biol Lett 2007, 3, 523. 
(3) Kupfahl, C.; Michalka, A.; Lass-Florl, C.; Fischer, G.; Haase, G.; Ruppert, T.; 
Geginat, G.; Hof, H. Int J Med Microbiol 2008, 298, 319. 
(4) Lewis, R. E.; Wiederhold, N. P.; Chi, J.; Han, X. Y.; Komanduri, K. V.; 
Kontoyiannis, D. P.; Prince, R. A. Infect Immun 2005, 73, 635. 
(5) Gardiner, D. M.; Howlett, B. J. FEMS Microbiol Lett 2005, 248, 241. 
(6) Balibar, C. J.; Walsh, C. T. Biochemistry 2006, 45, 15029. 
(7) Fox, E. M.; Howlett, B. J. Mycol Res 2008, 112, 162. 
(8) Scharf, D. H.; Chankhamjon, P.; Scherlach, K.; Heinekamp, T.; Roth, M.; 
Brakhage, A. A.; Hertweck, C. Angew Chem Int Ed Engl 2012, 51, 10064. 
(9) Cramer, R. A., Jr.; Gamcsik, M. P.; Brooking, R. M.; Najvar, L. K.; Kirkpatrick, W. 
R.; Patterson, T. F.; Balibar, C. J.; Graybill, J. R.; Perfect, J. R.; Abraham, S. N.; 
Steinbach, W. J. Eukaryot Cell 2006, 5, 972. 
(10) Kupfahl, C.; Heinekamp, T.; Geginat, G.; Ruppert, T.; Hartl, A.; Hof, H.; 
Brakhage, A. A. Mol Microbiol 2006, 62, 292. 
(11) Sugui, J. A.; Pardo, J.; Chang, Y. C.; Zarember, K. A.; Nardone, G.; Galvez, E. 
M.; Mullbacher, A.; Gallin, J. I.; Simon, M. M.; Kwon-Chung, K. J. Eukaryot Cell 2007, 6, 
1562. 
(12) Bok, J. W.; Chung, D.; Balajee, S. A.; Marr, K. A.; Andes, D.; Nielsen, K. F.; 
Frisvad, J. C.; Kirby, K. A.; Keller, N. P. Infect Immun 2006, 74, 6761. 
(13) Challis, G. L. J Med Chem 2008, 51, 2618. 
(14) Forseth, R. R.; Schroeder, F. C. Curr Opin Chem Biol 2010, 15, 38. 
(15) Butcher, R. A.; Schroeder, F. C.; Fischbach, M. A.; Straightt, P. D.; Kolter, R.; 
Walsh, C. T.; Clardy, J. PNAS USA 2007, 104, 1506. 
(16) Pungaliya, C.; Srinivasan, J.; Fox, B. W.; Malik, R. U.; Ludewig, A. H.; Sternberg, 
P. W.; Schroeder, F. C. PNAS USA 2009, 106, 7708. 
(17) Scharf, D. H.; Remme, N.; Heinekamp, T.; Hortschansky, P.; Brakhage, A. A.; 
Hertweck, C. J Am Chem Soc 2010, 132, 10136. 
(18) Schrettl, M.; Carberry, S.; Kavanagh, K.; Haas, H.; Jones, G. W.; O'Brien, J.; 
Nolan, A.; Stephens, J.; Fenelon, O.; Doyle, S. PLoS Pathog 2010, 6, e1000952. 
(19) Zhang, F.; Bruschweiler, R. Angew Chem Int Ed Engl 2007, 46, 2639. 
(20) Fan, T. W.; Yuan, P.; Lane, A. N.; Higashi, R. M.; Wang, Y.; Hamidi, A. B.; Zhou, 
R.; Guitart, X.; Chen, G.; Manji, H. K.; Kaddurah-Daouk, R. Metabolomics 2010, 6, 165. 
(21) Claridge, T. D. W. High-resolution NMR techniques in organic chemistry; 2nd ed.; 
Elsevier: Amsterdam ; Boston, 2009. 
20 
 
(22) Taggi, A. E.; Meinwald, J.; Schroeder, F. C. J Am Chem Soc 2004, 126, 10364. 
(23) Gronquist, M.; Meinwald, J.; Eisner, T.; Schroeder, F. C. J Am Chem Soc 2005, 
127, 10810. 
(24) Fukuyama, T.; Nakatsuka, S.; Kishi, Y. Tetrahedron 1981, 37, 2045. 
(25) Kirby, G. W.; Rao, G. V.; Robins, D. J. J Chem Soc Perk T 1 1988, 301. 
(26) Kirby, G. W.; Robins, D. J.; Sefton, M. A.; Talekar, R. R. J Chem Soc Perk T 1 
1980, 119. 
(27) Safe, S.; Taylor, A. J Chem Soc C 1970, 432. 
(28) Hanson, J. R.; Oleary, M. A. J Chem Soc Perk T 1 1981, 218. 
(29) Campo, V. L.; Martins, M. B.; da Silva, C. H. T. P.; Carvalho, I. Tetrahedron 
2009, 65, 5343. 
(30) Zhao, W. Y.; Zhu, T. J.; Han, X. X.; Fan, G. T.; Liu, H. B.; Zhu, W. M.; Gu, Q. Q. 
Nat Prod Res 2009, 23, 203. 
(31) Davis, C.; Carberry, S.; Schrettl, M.; Singh, I.; Stephens, J. C.; Barry, S. M.; 
Kavanagh, K.; Challis, G. L.; Brougham, D.; Doyle, S. Chem Biol 2011, 18, 542. 
(32) Herscheid, J. D. M.; Nivard, R. J. F.; Tijhuis, M. W.; Ottenheijm, H. C. J. Journal 
of Organic Chemistry 1980, 45, 1885. 
(33) Forseth, R. R.; Fox, E. M.; Chung, D.; Howlett, B. J.; Keller, N. P.; Schroeder, F. 
C. J Am Chem Soc 2011, 133, 9678. 
(34) Scharf, D. H.; Remme, N.; Habel, A.; Chankhamjon, P.; Scherlach, K.; 
Heinekamp, T.; Hortschansky, P.; Brakhage, A. A.; Hertweck, C. J Am Chem Soc 2011, 
133, 12322. 
(35) Bok, J. W.; Keller, N. P. Eukaryot Cell 2004, 3, 527. 
(36) Shaaban, M. I.; Bok, J. W.; Lauer, C.; Keller, N. P. Eukaryot Cell 2010, 9, 1816. 
(37) Yin, W. B.; Amaike, S.; Wohlbach, D. J.; Gasch, A. P.; Chiang, Y. M.; Wang, C. 
C.; Bok, J. W.; Rohlfs, M.; Keller, N. P. Mol Microbiol 2012, 83, 1024. 
(38) Domingo, M. P.; Colmenarejo, C.; Martinez-Lostao, L.; Mullbacher, A.; Jarne, C.; 
Revillo, M. J.; Delgado, P.; Roc, L.; Meis, J. F.; Rezusta, A.; Pardo, J.; Galvez, E. M. 
Diagn Micobiol Infect Dis 2012, 73, 57. 
(39) Shi, L. N.; Li, F. Q.; Huang, M.; Lu, J. F.; Kong, X. X.; Wang, S. Q.; Shao, H. F. 
BMC Microbiol 2012, 12, 11. 
21 
 
CHAPTER 2 
 
A BACKUP PLAN FOR SELF-PROTECTION: S-METHYLATION OF HOLOMYCIN 
BIOSYNTHETIC INTERMEDIATES IN STREPTOMYCES CLAVULIGERUS 
 
Abstract: Biosynthesis of the dithiolopyrrolone antibiotic holomycin in Streptomyces 
clavuligerus involves the closure of a pair of enethiols to a cyclic disulfide. It has been 
demonstrated that the dithiol oxidase HlmI is responsible for the disulfide formation and 
this enzyme also plays a role in self-protection. This study examines how S. 
clavuligerus deals with the proposed toxic dithiol intermediates when hlmI is deleted. 
Comparative metabolomics employing differential NMR spectroscopy and mass 
spectrometry were used to profile the metabolomes of hlmI deletion mutants along with 
the wild-type strain and a holomycin-overproducing strain. A number of metabolites 
unique to the ∆hlmI strains were identified. In these metabolites the enethiols have been 
incapacitated by a combination of mono- and di-S-methylation. Also observed was an 
intriguing dimeric thioether adduct in low quantities in the wild-type strain and at much 
higher levels in the ∆hlmI strains. The structures of these novel metabolites highlight the 
reactivity of the dihydrodithiolopyrrolone scaffold. Furthermore, bioassays suggest that 
modification of the enethiol by S-alkylation provides a host strategy for detoxification, 
one that is shared amongst multiple species producing such bioactive disulfide natural 
products. 
 
Introduction: Holomycin is a member of the N-acylated dithiolopyrrolone class of 
natural product antibiotics reported to interfere with bacterial RNA metabolism.1-3 The 
antibiotic scaffold contains an unusual bicyclic core (1, Figure 2.1) comprising a cyclic 
ene-disulfide fused to an aminopyrrolone ring. While a much more compact framework 
than the mycotoxin gliotoxin or the FDA approved histone deacetylase inhibitor FK228 
Adapted with permission from, Li, B.; et al. Chembiochem 2012, 26, 2521. © 2012 John Wiley and Sons. 
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(Figure 2.1), holomycin joins these molecules in that it possesses a disulfide-bridged 
heterocycle which is essential to its biologic activity. Disulfides in these molecules are 
likely to be precursors, reduced in cells to their active dithiol forms.4,5 In Streptomyces 
clavuligerus, holomycin biosynthesis proceeds via the formation of a tethered Cys-Cys-
S-enzyme intermediate on a Non-ribosomal peptide synthetase (NRPS) template. 
Subsequent oxidation by four flavoproteins6 likely contributes to the formation of a pair 
of enethiols (one endocyclic, the other exocyclic) that undergo enzymatic oxidation to 
close the disulfide imbedded in the bicyclic scaffold. For gliotoxin it has been 
established that the enzyme GliT, which acts late to convert dithio-gliotoxin (Figure 2.1, 
Figure 1.3) to its isolated disulfide, plays a self-protective role in the producing 
Aspergilli.7 In Aspergillus fumigatus the deletion of gliT resulted in mutants that are 
much more sensitive to gliotoxin when compared to the wild-type. This heightened 
sensitivity is presumably due to decreased ability of the producer to sequester gliotoxin 
as the disulfide, resulting in consequent buildup of the active dithiol form. Toxicity of the 
dithiol form of gliotoxin may result from modification of host proteins or redox-cycling, to 
generate reactive oxygen species.8 By analogy, it was recently shown that hlmI, part of 
the holomycin (hlm) biosynthetic gene cluster in S. clavuligerus, encodes a comparable 
flavin-dependent dihydroholomycin (2, Figure 2.1) oxidase that converts 2 to the 
bicyclic oxidized form (1).9 To examine the hlm pathway in detail one can take 
advantage of the dramatic upregulation of the hlm pathway in the S. clavuligerus 
ORF15 deletion mutant (∆ORF15). ORF15 is involved in the biosynthesis of another 
antibiotic, clavulanate, but the ∆ORF15 strain overproduces holomycin ten- to 100-fold 
relative to the wild-type.10 In both S. clavuligerus wild-type and ∆ORF15 background, 
deletion of the hlmI gene resulted in a 100- to 1000-fold decrease in production of 
holomycin and a significantly heightened sensitivity to exogenously added holomycin.9 
Unresolved was the fate of any presumptively toxic dihydroholomycin accumulating in 
the ∆hlmI and ∆hlmI/∆ORF15 strains and how these mutants might deal with such a 
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dithiol load. Herein, LC/ESI+-MS- and NMR-based comparative metabolomics strategies 
are described for the identification of dihydroholomycin and dihydroholothin derivatives 
that accumulate in the ∆hlmI and ∆hlmI/∆ORF15 strains and methodology to investigate 
the related bacterial self-protection mechanisms. 
 
 
Figure 2.1: Compounds containing biologically active disulfides. (a) The 
conversion of the dihydro-forms of antibiotics holomycin (1) and gliotoxin to their 
disulfide forms by dithiol oxidases HlmI and GliT, respectively. (b) The structure of the 
drug FK228, the biological activity of which also depends on an intramolecular disulfide. 
 
Detection of S-Methylated Forms of Dihydroholomycin: To gain insight into whether 
dihydroholomycin intermediates build up in the hlmI deletion mutants, the metabolomes 
of the ∆hlmI/∆ORF15 and ∆ORF15 strains were compared through HPLC/ESI+-high 
resolution (HR) MS. Peaks with masses corresponding to dihydroholomycin (m/z calcd 
for C7H9N2O2S2: 217.0100) and dihydroholothin (m/z calcd for C5H7N2OS2: 174.9994) 
were not observed. Instead, two strong peaks (m/z found: 231.0244 [M+H]+, m/z calcd 
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for C8H11N2O2S2: 231.0256) were present in ∆hlmI/∆ORF15 but not ∆ORF15 (Figure 
2.2 top trace). The mass difference of 14.0157 amu relative to dihydroholomycin 
indicated the addition of a CH2 unit, suggesting possible S-methylation (3, Figure 2.2 
regio and/or cis/trans stereoisomers) or addition of a methyl group to the N-3 amide 
nitrogen of the dithiolopyrrolone scaffold, as observed in the structure of the related 
natural product thiolutin.11 As a first pass to distinguish between S- or N-methylation, an 
excess of thiol-alkylating agent iodoacetamide (IAA) was added to the culture 
supernatant of ∆hlmI/∆ORF15. After incubation at room temperature for one hour, the 
m/z 231.0256 peak disappeared and two well-separated new peaks emerged, both of 
which had molecular ions (m/z found: 288.0466 [M+H]+, m/z calcd for C9H11N3O3S2 : 
288.0471) suggestive of two IAA adducts (Figure 2.2, middle trace). Additionally, both 
new peaks retained the signature UV absorption at 370 nm, suggesting that they are 
related to, and retain the chromophore of holomycin12 (dihydroholomycin has a unique 
UV absorption at 330 nm, different from that of holomycin or alkylated 
dihydroholomycin, see Figure B.2, Appendix B). However, no bis-IAA adduct was 
detected, whereas a control reaction with authentic dihydroholomycin led exclusively to 
formation of the bis-IAA adduct (Figure 2.2, bottom trace, m/z found: 331.0553 [M+H]+, 
m/z calcd for C11H15N4O4S2 : 331.0529). The proposed structure for the bis-IAA adduct 
(4) is shown in Figure 2.2. These findings indicate that ∆hlmI/∆ORF15 does not yield 
detectable quantities of dihydroholomycin and that at least two mono-S-methylated 
dihydroholomycin isomers (Figure 2.2, top trace) are present in its stead. 
 
Comparative Metabolome Analysis through NMR Spectroscopy: To further 
characterize biosynthetic intermediates or shunt metabolites that accumulate as a result 
of the hlmI deletion, NMR spectroscopy-based comparison of the ∆hlmI/∆ORF15 and 
∆ORF15 metabolomes was employed. Differential analyses of 1D and 2D NMR spectra 
(DANS) enables largely unbiased comparisons of related metabolome samples to be   
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Figure 2.2: Identification and characterization of metabolites related to the hlm 
pathway in the ∆hlmI/∆ORF15 mutant. (a) Characterization of the holomycin + 
14.0157 amu metabolite (m/z of 231.0256) in ∆hlmI/∆ORF15 by HPLC/ESI+-MS and 
chemical derivatization with iodoacetamide (IAA). Shown are the extracted ion 
chromatograms (EIC) of ∆hlmI/∆ORF15 (top, [M+H]+, 231.0256), ∆hlmI/∆ORF15 treated 
with IAA (middle, [M+H]+, 288.0471), and dihydroholomycin standard treated with IAA 
(bottom, [M+H]+, 331.0529). (b) The structures of hlm biosynthetic pathway 
intermediates, semi-synthetic derivative, and select disulfide containing metabolites. 
Compounds 3, 5, 6, and 8-11 are all novel compounds upregulated in the 
∆hlmI/∆ORF15 mutant. Compounds, or portions of compounds, colored in red represent 
structural elements that were supported by UPLC/ESI+-HRMS(MS) analysis, but could 
not fully be characterized by NMR spectroscopy. Blue arrows represent HMBC 
correlations that support the structural assignments in these compounds. IPEA: 2-iodo-
N-(1-phenylethyl)acetamide. 
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made, and has previously been employed in microbial13,14 and animal systems15 to 
identify metabolites associated with genetic or environmental perturbations.16 Initial 1H 
spectra acquired for crude extracts of ∆hlmI/∆ORF15 and ∆ORF15 revealed at least 
nine ∆hlmI/∆ORF15-unique singlets between 5.5 and 6.7 ppm (Figure 2.3, for full 
spectra see Figures B.5 and B.6). DANS comparison of dqfCOSY spectra acquired for 
extracts of ∆hlmI/∆ORF15 and ∆ORF15 revealed no additional differential proton 
signals. To identify the ∆hlmI/∆ORF15-upregulated metabolites through 1H,13C -HMQC 
and 1H,13C-HMBC spectra, partial fractionation of the ∆hlmI/∆ORF15 and ∆ORF15 
samples was required as the compounds of interest accounted for less than 2% of the 
total ∆hlmI/∆ORF15 metabolome (extracted from 500 mL of a two-day culture at an 
OD600 nm value of ~16). Reversed-phase flash chromatography of the ∆hlmI/∆ORF15 
and ∆ORF15 extracts yielded three metabolite pools, of which pool 1 contained the 
most polar metabolites and pool 3 the least polar metabolites. 1H spectra were acquired 
for these six pools (Appendix B, section 3). 
 
Identification of a Methylated Asymmetric Dimeric Holomycin Derivative: 
Comparison of 1H spectra corresponding to pool 3 ∆hlmI/∆ORF15 and pool 3 ∆ORF15 
samples showed two groups of singlets (three peaks between 6.3-5.7 ppm and four 
peaks between 2.5-2.0 ppm) dramatically upregulated in the ∆hlmI/∆ORF15 spectrum 
(Figure B.11). 1H,13C-HMBC and 1H,13C-HMQC spectra acquired for ∆hlmI/∆ORF15 
pool 3 revealed that the ∆hlmI/∆ORF15-upregulated singlets belong to two new 
compounds with correlation patterns and chemical shifts similar to those observed for 
holomycin (1) and dihydroholomycin (2). Based on 1H,13C-HMBC and an additional 
ROESY spectrum, one of the two unknown compounds was identified as bis-S-
methylated dihydroholothin (5) (Figure 2.2). The remaining ∆hlmI/∆ORF15-dependent 
analyte in pool 3, like compound 5, appeared to contain a primary, non-acylated amine 
substituent that showed 3-bond 1H,13C-HMBC correlations from its NH2-protons to an. 
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Figure 2.3: Comparative 1H NMR and 2D HPLC/ESI+-MS analysis of crude extracts 
of ∆hlmI/∆ORF15 and ∆ORF15. (a) Region of 1H spectra containing proton singlets 
diagnostic for H-1 or H-1’ of compounds 3, 5, 6, and 8-11. Peaks marked with a red X 
remain uncharacterized, but may belong to compounds 8 and/or 9. (b) Comparison of 
mass spectra (m/z 175-470) versus retention time (3-12 min) plots corresponding to 
extracts of the two mutants ∆hlmI/∆ORF15 and ∆ORF15 revealed a number of cross 
peaks diagnostic for compounds 3, 5, 6, and 8-11 that are exclusively found, or 
dramatically upregulated, in ∆hlmI/∆ORF15.  
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amide carbonyl carbon and a methylsulfanyl-substituted olefin carbon. Notably, an 
exocyclic olefinic proton, analogous to H-1 of 5, coupled with carbons of the enamine 
ring system and a second N-7-acetylated pyrrolone ring system suggesting a thioether 
linkage. ROESY correlations between H-1 and H-1’ further supported these structural 
assignments and determined the stereochemistry of this compound (6, Figure 2.2). 
Subsequent acquisition of UPLC/ESI+-HRMS data confirmed the molecular formulae for 
both 5 and 6. The pool 3 1H,13C-HMBC spectrum further indicated the presence of at 
least four minor stereoisomers of compound 6.  
 
S-Methylated Dihydroholomycin Derivatives: Comparison of the pool 1 1H spectra 
revealed three 1H singlets (5.97, 5.90, and ~2.3 ppm) in the ∆hlmI/∆ORF15 spectrum 
that were absent from the ∆ORF15 spectrum. 1H,13C-gHMBC spectra indicated that the 
two protons at 5.97 and 5.90 ppm belong to similar 1H,13C spin systems. Both protons 
couple with carbons belonging to a methylsulfanyl moiety (~17 ppm) and appear to be 
attached to carbons that are part of a holomycin-like olefinic system. The proton at 5.97 
ppm showed an additional correlation to another olefinic carbon that does not couple 
with any other protons. Additionally, the pool 1 ∆hlmI/∆ORF15 1H,13C-gHMBC spectrum 
showed two major correlations from methyl protons (~1.8 ppm) to carbons at ~170 ppm, 
suggesting the presence of acetylated enamines. The absence of any additional 
methylsulfanyl correlations in the 1H,13C-gHMBC spectrum further supported the 
hypothesis that these compounds are a pair of monomethyl dihydroholomycin 
stereoisomers (3) and possibly its trans-stereoisomer, (Figure 2.2). Because of poor 
spectroscopic line shapes of the proton signals in the 1H,13C-HMBC spectrum, not all 
carbons in the proposed structures 3 could be detected. Derivatization with 2-iodo-N-(1-
phenylethyl)acetamide (IPEA) under basic conditions led to isolation of a compound 
whose 1H, 1H,13C-HMQC and 1H,13C-HMBC and UPLC/ESI+-HRMSMS spectra were 
consistent with the structure 7, confirming the presence of 3 in the ∆hlmI/∆ORF15 pool 
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1 sample. The trans-stereoisomer of 7 was not observed. UPLC/ESI+-HRMS analysis of 
pool 1 and the IPEA derivative further supported these structural assignments. In 
addition, high- and unit-resolution HPLC/ESI+-MS analysis of ∆hlmI/∆ORF15 extracts 
showed several chromatographic peaks whose mass spectra suggested that they 
represent disulfide-bridged dimers of 3 such as 8 and 9, which likely formed as a result 
of nonenzymatic oxidation during processing of the samples (Appendix B, section 8). 
 
Pool 2 Comparative Metabolomics: Comparison of 1H spectra acquired for the pool 2 
∆hlmI/∆ORF15 and ∆ORF15 samples (Figure B.9 and B.10) showed several singlets 
(1H, 6.22, 5.83, 5.50, and six between 2.89-1.97 ppm) upregulated in ∆hlmI/∆ORF15 
relative to ∆ORF15. A 1H,13C-gHMBC spectrum acquired for the pool 2 ∆hlmI/∆ORF15 
sample reveled two major spin systems belonging to the pool 2 ∆hlmI/∆ORF15-
upregulated compounds. The most downfield signal (1H, 6.22 ppm) showed 1H-13C 
correlations and chemical shifts similar to those observed for 5; where an exocyclic 
olefinic proton couples with a 13C of a methylsulfanyl (16.6 ppm) and two endocyclic 
olefinic 13C atoms; one weak correlation (13C, 132.3 ppm, two bond) and one strong 
correlation (13C, 133.1, three bond). Additionally, three methyl protons coupled to, and 
only to, a 13C atom at 133.1 ppm. These initial data suggested a bis-methylated 
dihydroholomycin structure (10). However, the 1H-13C correlations needed to confirm 
this structural hypothesis were not observed. The second ∆hlmI/∆ORF15-upregulated 
spin system of pool 2 had markedly different 13C chemical shifts, but showed a similar 
1H-13C coupling pattern as the first spin system. 1H,13C-HMBC spectra acquired for this 
metabolite showed a proton at 5.83 ppm that coupled to a 13C atoms at: 145.2, 95.7, 
and 40.9 ppm. Intriguingly, the 40.9 ppm 13C atom belonged to a methyl group (1H, 2.47 
ppm) that coupled exclusively with the carbon bearing the 5.83 ppm proton (13C, 111.5 
ppm). Three methyl protons (2.16 ppm) also coupling to, and only to, the 13C atom at 
95.7 ppm. Taken together, the second ∆hlmI/∆ORF15-upregulated compound of pool 2 
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appeared to represent a structure similar to 10 (Figure 2.2), where the sulfur of the C-1 
methylsulfanyl had been oxidized to a methyl sulfoxide substituent (11). As with 
compound 10, not all 1H-13C correlations needed to fully characterize this compound 
were observed. 
To reduce the dynamic range of ∆hlmI/∆ORF15 pool 2, 10 and 11 were enriched 
by flash chromatography (Appendix B, section 5) and 1H spectra were acquired for 
select fractions (Appendix B, section 5). Although samples enriched with 10 and 11 
were obtained, as was the case with compound 3, 1H line shape had worsened for 
these samples relative to the pre-fractionated pool 2 sample. Therefore, to test the 
hypothesized structures of 10 and 11 UPLC/ESI-HRMS studies were undertaking to 
further probe these metabolites, providing data consistent with the proposed structures 
of 10 and 11 (m/z found: 245.0401 [M+H]+, m/z calcd for C9H13N2O2S2: 245.0413 for 10, 
and m/z found: 219.0240 [M+H]+, m/z calcd for C7H11N2O2S2: 219.0256 for 11).  
 
Targeted Metabolite Profiling of Wild-Type, ∆ORF15, and ∆hlmI S. clavuligerus 
Strains: Having established several chemical species unregulated in ∆hlmI/∆ORF15 
relative to ∆ORF15, theses metabolites were profiled for their presence/absence in wild-
type strain, and their relative quantities were assessed. For this purpose, targeted 
HPLC/ESI+-MS-based profiling was utilized, searching for the diagnostic mass spectral 
fragmentation patterns and retention times established for the ∆hlmI/∆ORF15-
dependent metabolites 3, 5, 6, and 8-11 (Figure 2.3). Of compounds 1, 3, 5, 6, and 8-
11, only 1 and 6 are found in all the strains profiled (Figure B.1). The ∆ORF15 mutation 
increases the amount of compound 6 by approximately tenfold relative to the wild-type, 
whereas the ∆hlmI/∆ORF15 double mutations increase the amount of 6 by two and 
three orders of magnitude, respectively. The primary enamine-containing compounds 5, 
9, and 11 were only observed in extracts of the ∆hlmI/∆ORF15 mutant.  
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Activity of Dimethyldihydroholomycin against S. clavuligerus Strains: To evaluate 
the effect of S-methylation on the activity of dihydroholomycin, a S,S’-
dimethyldihydroholomycin standard was chemically synthesized. Attempts to synthesize 
the S-monomethyldihydroholomycin was unsuccessful due to apparent rapid formation 
of the dimethyl species. Therefore the inhibitory effect of monomethylated compounds 
were not tested. The 1H and 13C NMR spectroscopic data of the synthetic S,S’-
dimethyldihydroholomycin were consistent with those of the isolated sample of 
compound 10, confirming structural assignments (Figures B.13 and B.14).17 The 
antimicrobial activity of S,S’-dimethyldihydroholomycin was tested in a bioassay against 
S. clavuligerus wild-type, ∆ORF15, ∆hlmI, and ∆hlmI/∆ORF15 strains in parallel with the 
same concentrations of holomycin. S,S’-dimethyldihydroholomycin did not inhibit the 
growth of any of the tested strains, whereas holomycin displayed inhibitory effect 
against all four strains, especially for the ∆hlmI mutants (Figure B.3) as observed in 
previous work.9 These results suggest that the dithiol groups of reduced holomycin are 
relevant to the biological activity of this antibiotic and S-methylation of the dithiols in the 
producing bacteria significantly decrease that antimicrobial activity as a self-protection 
mechanism. However, the activity of dihydroholomycin could not be tested directly as it 
is oxidized in minutes to holomycin in air.9 
 
Conclusions: These studies were undertaken with the specific question of how S. 
clavuligerus protects itself during holomycin production when it has insufficient capacity 
(e.g., in the hlmI-null mutant) to oxidize the presumed proximal toxin, dihydroholomycin, 
to the disulfide that is normally excreted into the medium. More generally the study 
probes the question of what chemical strategies producer microbes utilize to blunt the 
reactivity of unwanted thiol groups when disulfide formation is suppressed. Our findings 
indicate that S-methylation in combination with dimerization plays a major role. Building 
upon previous studies that utilized NMR- and LC/MS-based comparative metabolomics 
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to connect metabolic outputs to specific biosynthetic pathway gene mutations,14 we 
have profiled the chemical species upregulated in the ∆hlmI/∆ORF15 mutant relative to 
∆ORF15. The three ∆hlmI/∆ORF15-upregulated metabolites fully characterized in this 
study-3, 5 and 6-all represent novel secondary metabolites, one of which, the dimeric 6, 
is also consistently produced by the wild-type strain. The structures of several additional 
∆hlmI/∆ORF15-upregulated compounds were proposed with high confidence, although 
their characterization by NMR spectroscopy remained incomplete due to the 
characteristically poor line-shapes of these compounds. It was demonstrated that a mix 
of mono- and dimethyl thioethers, with and without N-acetylation, accumulate in the 
mutant extracts (Figure 2.4). From prior in vitro studies HlmA and HlmI were assigned 
as enzymes catalyzing the last two steps in the holomycin biosynthetic pathway. 
assembly.6,9 Results of the current study are consistent with these roles, although either 
step could be the ultimate step. The unusual dimeric adduct 6 detected at higher levels 
in the ∆hlmI/∆ORF15 mutant, relative to all the other S. clavuligerus strains probed, has 
a thioether bridge from the exocyclic ene-sulfur of one pyrrolone unit to the C-6 position 
of the N-acylaminopyrrolone moiety of a second unit (Figure 2.2). In this adduct, two of 
the sulfurs are S-methylated, as found in the monomeric adducts noted above (3). One 
might have expected an intermolecular disulfide from the two remaining thiols (the 
disulfide can be seen but only after oxidation during workup of crude extracts) but this 
adduct instead contains a thioether linkage, and thus one of the anticipated sulfur atoms 
appears to have been lost. One possible path to its formation would be for a 
monomethylated dihydroholomycin, with a free exocyclic enethiol to add into the C5=C6 
double bond of a second molecule through conjugate addition (Figure 2.4). The 
resultant tetrahedral adduct could then eliminate -SH or -SCH3, depending on the state 
of the sulfur that is departing, to yield the dimeric thioether.18 This route illustrates the 
nucleophilic character of the exocyclic enethiol of reduced holomycin, and demonstrates 
why the producer organism would go to substantial lengths to avoid its accumulation. It 
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also reveals the potential electrophilicity of the cyclic enamide. The reactivity of this 
enamide is presumably enhanced by acylation of the exocyclic amine by HlmA; 
however, it may also be further augmented by oxidation of one or other of the sulfur 
atoms, such as in compound 11.18 
 
Figure 2.4: Proposed (bio)synthetic pathways. In the ∆hlmI/∆ORF15 mutant strain 
generation of (a) mono- and bismethylated intermediates (including 3, 5, and 10) that 
have been characterized by MS and/or NMR, and (b) heterodimeric compound 6. SAM: 
S-adenosylmethionine. 
 
In particular, these results summarize the biochemical consequence of 
upregulating holomycin production in S. clavuligerus (due to the deletion of the ORF15 
gene) when the last-step oxidation is disabled. In absence of the dithiol oxidase HlmI S. 
H2N
SH
O
OH
Hlm pathway
NH
HS
HS
O
H2N
SAM SAM
hlmI
NH
S
O
H2N
S
HlmINH
S
S
O
H2N
NH
S
S
OH
N
HlmI
NH
HS
HS
OH
N
O O
HlmA HlmA
SAM
hlmI
NH
HS
OH
N
S
O
SAM
NH
S
OH
N
S
O5
3
alkylating
agent
H
N
O
I
H
N
O
S
NH
OH
N
S
O
2X
(a)
(b)
NH
RS
OH
N
S
O
H
N
S
O
H2N
S
NH
OH
N
S
O
HN
SO
H2N
S
SR
RS
NH
OH
N
S
O
HN
SO
NH2
S
R = H or CH3
6
34 
 
clavuligerus is subjected to build-up of the active (reduced) form of its own toxin. One 
way to blunt this activity is to remove the nucleophilicity of the enethiol groups. While S-
acetylation possibly provides an alternate detoxification strategy, the resultant thioesters 
would be readily hydrolysable and rather create a reactive acylating agent. Instead S-
methylation, likely the result of methyl transfer from S-adenosylmethionine (SAM), is 
observed. This process could be sequential with monomethyl species as free 
intermediates (Figure 2.4). The inactivity of the dimethyldihydroholomycin standard 
observed in the bioassay supports the role of S-methylation as a back-up plan for self-
protection. Another possible route of detoxification is for dihydroholomycin to react with 
mycothiol or mycothione, an abundant cellular thiol in actinomycete,19 through disulfide 
exchange or nucleophilic addition. However, mycothiol-holomycin adducts were not 
detected. The identity of the putative SAM-dependent methyltransferase in S. 
clavuligerus producers is as yet unknown. One might expect an analogous S-
methylation self-protection strategy in the ∆gliT mutants of A. fumigatus to blunt the 
nucleophilicity and consequent toxicity of the dithiol form of gliotoxin. In fact, a wild-type 
gliotoxin producer, Gliocladium deliquescens adopts this thiol methylation strategy, and 
has been reported to irreversibly methylate gliotoxin to yield bisdethiobis(methylthio)- 
gliotoxin.20 Similarly, bismethylthiol forms of gliotoxin have been isolated from other 
fungal strains.21,22 These are exactly the metabolites that should arise from 
bismethylation of the dihydro form of gliotoxin in detoxification routes. The bisthioether 
versions of gliotoxin have been shown to be substantially less toxic than gliotoxin 
itself.21,23 Additionally, as described in the DANS-based study described in Chapter 1, 
both mono- and bismethylation species were detected on incompletely processed 
scaffolds.14 The S-methylation may be catalyzed by the methyltransferase GliN encoded 
as a backup plan to protect the producer from the toxicity of the biosynthetic 
intermediates. S-methylation of dithiols in bacterial and fungal strains, using the readily 
available SAM as an electrophilic methyl donor, may thus be the preferred protection 
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mechanism against endogenous and exogenous dithiol forms of toxic metabolites when 
the native dithiol oxidase is absent. Indirectly, this study strengthens the hypothesis that 
the molecular species with antibiotic properties is the penultimate metabolite in the 
holomycin pathway, dihydroholomycin. In the producing organism, this metabolite is 
rapidly converted to the bicyclic disulfide through HlmI action and then exported to the 
extracellular matrix. When taken up by a susceptible neighboring microbe, the disulfide 
will be in a microenvironment rich in thiols. Reduction to the mixed disulfide and/or the 
dithiol in a target cell may be nonenzymatic or enzymatic and generate the reactive 
nucleophilic enethiol forms of the antibiotic. It is possible that dihydroholomycin, like the 
dihydro form of gliotoxin, exerts some of its toxicity through redox cycling to generate 
reactive oxygen species, in which case S-methylation can also prevent that toxicity. 
Although inhibition of RNA synthesis has been proposed as an end effect of the 
holomycin class of antibiotics2,3 the molecular targets of this compact yet latentlyreactive 
framework remain to be fully characterized.  
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CHAPTER 3 
 
 
HOMOLOGOUS NON-CANONICAL NRPS GENE CLUSTERS MEDIATE 
REDUNDANT SMALL-MOLECULE BIOSYNTHESIS IN ASPERGILLUS FLAVUS  
 
Abstract: In the opportunistic human pathogen Aspergillus flavus, two highly 
homologous orphan gene clusters, lna and lnb, are regulated by LaeA, a global 
regulator of secondary metabolism, morphogenesis, and virulence. The lna and lnb 
clusters contain two non-canonical non-ribosomal peptide synthetase (NRPS) genes, 
lnaA and lnbA, that both lack a conventional condensation domain and share homology 
to reductases participating in fungal L-lysine biosynthesis. By employing 2D NMR-based 
comparative metabolomic analyses of knock-out, overexpression, and knock-down 
strains of lnaA and lnbA, this study demonstrates that the two clusters encode enzymes 
that produce partially overlapping sets of metabolites, including previously undescribed 
piperazines, pyrazines, and morpholines. These results provide evidence for functional 
redundancy of the lna and lnb clusters and suggest that one primary function of the 
NRPSs LnaA and LnbA is the reduction of their substrate, L-tyrosine. Additionally, 
morphological studies demonstrate that mutations of lna pathway genes interfere with 
sclerotia formation patterns and that one of the identified lnaA- and lnbA-dependent 
metabolites strongly affects expression of lnaB, a putative reductase/epimerase, 
suggesting that the lna and lnb pathways are part of a signaling network regulating A. 
flavus sclerotia formation. 
 
Introduction: Fungi are among the most prolific sources of pharmacologically relevant 
natural products.1 This large diversity of fungal small molecules serves important 
functions in fungal ecology, for example as virulence factors or as chemical defense 
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agents. However, only a fraction of the biosynthetic capabilities suggested by genomic 
analyses has been observed under laboratory conditions, because expression of many, 
perhaps even most biosynthetic pathways depends strongly on environmental 
conditions.2-4 This study demonstrate the use of comparative metabolomics5-8 for the 
analysis of specific secondary metabolic gene knockout, overexpression and 
knockdown strains to determine the metabolic output of two non-ribosomal peptide 
synthetase (NRPS) gene clusters in the ascomycete fungus Aspergillus flavus, a crop 
contaminant9,10 and opportunistic pathogen, causing aspergillosis in 
immunocompromised humans.11,12 
Although the A. flavus genome encodes at least 25 polyketide synthase (PKS), 
18 NRPS, and two hybrid NRPS-PKS gene clusters,13 assignments have been made for 
only four metabolites.14 Many A. flavus secondary metabolite pathways are under the 
control of the protein LaeA, a global regulator of morphogenesis and virulence factor in 
A. flavus and other pathogenic fungi.15 Two LaeA-regulated clusters, which were named 
lna and lnb, exhibit a striking level of genetic similarity (Figure 3.1, Table C.1). The lna 
and lnb clusters contain two non-canonical NRPS genes with high sequence homology 
(58% identical at the amino acid level), lnaA and lnbA, respectively, which are 
accompanied by matching sets of genes likely coding for tailoring enzymes. lna and lnb 
are orphan clusters that have no known associated metabolites and belong to a family 
of NRPS genes that consist of an adenylation (A) domain, a peptidyl carrier protein 
(PCP) domain, and a thioester reductase (R) domain, but lack a canonical condensation 
(C) domain (Figure 3.1). The functions of this unusual family of NRPSs, which share 
homology to reductases participating in fungal L-lysine biosynthesis,16 have not been 
explored. In the studies described herein, it is demonstrated that the lna and lnb clusters 
encode sets of enzymes that produce overlapping sets of previously undescribed 
metabolites, and one primary function of the non-canonical NRPSs LnaA and LnbA 
likely consists in reduction of L-tyrosine. Furthermore, the lna and lnb biosynthetic 
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pathways appear to be part of a signaling network that controls the formation of 
sclerotia, a resilient overwintering structure. 
 
 
Figure 3.1: lna and lnb gene clusters and characterized A. flavus compounds. (a) 
A. flavus lna and lnb gene clusters. Both lna and lnb include non-canonical NRPS 
genes including adenylation (A), carrier protein (PCP), and a short-chain 
dehydrogenase/reductase domain (R-domain). There is no lnaD analog in the lnb gene 
cluster. See also Appendix C, Table C.1. (b) Metabolites identified in this study and the 
known piperazinomycin (9). Compounds marked with an asterisk* have been previously 
described. 
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Comparative Metabolomics Reveals lna-Dependent Metabolites: To identify lna-
associated metabolites via comparative metabolomics, deletion and overexpression17 
mutants were created for NRPS gene lnaA (ΔlnaA and OE::lnaA [two isolates obtained], 
respectively) as well as two double mutant strains ΔlnaA, KD::lnbA and OE::lnaA, 
KD::lnaB, where KD indicates a knockdown of gene expression using RNAi (strains are 
listed in Table C.3). The overexpression of the NRPS gene lnaA was chosen as the 
primary method of lna pathway upregulation because the lna and lnb clusters lack 
apparent cis-acting regulatory genes, advantageous genetic targets for promoting 
cluster expression.18 This strategy has been adopted previously to increase titers of 
penicillin by overexpression of its NRPS gene acvA in A. nidulans.19,20 Unexpectedly, in 
the ΔlnaA, KD::lnbA double mutant strain, in which both the lna and lnb pathways are 
disrupted, formation of sclerotia was strongly suppressed relative to wild-type (see 
Appendix C, Figure C.1).  
To compare the metabolomes of the wild-type, ∆lnaA and OE::lnaA strains,  
differential analysis by 2D NMR spectroscopy (DANS) was employed.6,8,21 dqfCOSY 
spectra acquired for crude and pre-fractionated wild-type, ∆lnaA, and OE::lnaA (both 
isolates) extracts were compared pair-wise using an overlay algorithm designed to 
highlight strongly up- or downregulated signals.8 Whereas comparison of the 2D NMR 
spectra of the two different OE::lnaA strains showed no differential signals, comparison 
of the OE::lnaA spectra with either wild-type or ∆lnaA revealed a large number of spin 
systems present only in the OE::lnaA spectra (Figure 3.2). The most prominent 
OE::lnaA-upregulated spin system showed a singlet at ~4.5 ppm with long range-
couplings (< 1 Hz) to an aromatic AA'BB'-spin system at 6.7 and 7.1 ppm as well as 
long-range coupling to a singlet at 8.4 ppm. These data suggested a chemical structure 
featuring a p-hydroxy substituted-benzyl group bound to an N-heteroaromatic system. In 
addition, OE::lnaA-specific dqfCOSY signals were observed indicating the presence of 
at least three structurally related compounds as well as a second group of at least four  
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  (a) 
  (b) 
 
Figure 3.2: Pool 3 OE::lnaA and DANS spectrum. (a) dqfCOSY spectrum of OE::lnaA 
metabolite fraction used for characterization of lnaA-dependent compounds detected via 
DANS. (b) Section of the pool-3 DANS overlay of the OE::lnaA dqfCOSY spectrum with 
the ∆lnaA dqfCOSY spectrum. For both panels, cross peaks marked with red boxes or 
arrows represent novel lnaA-dependent compounds. Black boxes mark the known 
compound 8 that is upregulated in OE::lnaA. Cross peaks marked blue represent 
species that were not reproducibly differential or were suppressed incompletely in the 
overlay due to chemical shift variation.   
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different compounds, all of which appeared to include a 3-(p-hydroxyphenyl)-substituted 
1,2-diaminopropane- or 2-amino-1-hydroxypropane-derived moiety. Using available 
structure databases, it was determined that the OE::lnaA-upregulated partial structures 
did not match any known metabolites from Aspergilli or other fungi. 
For further characterization of the lnaA-dependent metabolites, scaled-up 
OE::lnaA cultures (TSA7.51) were fractionated using reverse-phase chromatography. 
Comparison of 1H and dqfCOSY spectra of crude and fractionated extracts indicated 
that the OE::lnaA-upregulated compounds were not altered by chromatography. Using 
DANS-detected diagnostic NMR signals, fractions containing the OE::lnaA-upregulated 
compounds were selected for further analysis. For one major OE::lnaA-upregulated 
compound, 1H,13C-HMBC and 1H,13C-HSQC spectra (for NMR spectroscopic data, see 
Tables C.4-C.10) were consistent with an O-substituted derivative of the known 
actinopolymorphol (3, Figure 3.1).22 Chemical shift values of protons and carbons of 
one of the aromatic rings suggested O-sulfonation23 and thus a molecular formula of 
C18H16N2O5S for this compound (4, Figure 3.1), which was confirmed by positive 
electrospray ionization- (ESI+/-) high-resolution- (HR-) MS (Appendix C, section 13). 
Compound 4 was accompanied by smaller amounts of compound 3 and two additional 
highly polar derivatives of 3. The NMR spectroscopic data of one of these compounds 
suggested N-oxidation, which was confirmed by UPLC/ESI+-HRMS analysis indicating a 
molecular formula of C18H16N2O4, thus revealing an unusual N,N-dioxide, (for a 
structurally related synthetic compound, see24). NMR spectroscopic data of the second 
derivative of compound 3 indicated substitution at C-3. UPLC/ESI+/--HRMS spectra 
revealed a molecular formula of C18H16N2O5S (Appendix C, section 13), indicating C-
sulfonylation in this metabolite, compound 6. 
Analysis of fractions containing the putative (p-hydroxyphenyl)-substituted 1,2-
diaminopropane- or 2-amino-1-hydroxypropane derivatives revealed two compounds 
with very similar 1H chemical shift and coupling constant values. dqfCOSY and 1H,13C-
44 
 
HMBC spectra confirmed that these compounds incorporate 3-(p-hydroxyphenyl)-
substituted 1,2-diaminopropane moieties. HPLC/ESI+/--MS and UPLC/ESI+/--HRMS 
analyses indicated that both analytes have a molecular formula of C18H22N2O2. Taken 
together; these spectroscopic data suggested the pair of diastereomeric piperazines 1 
and 2. Comparison with synthetic samples prepared via cyclo(L-Tyr-L-Tyr) and cyclo(D-
Tyr-L-Tyr) derivatives confirmed these assignments (Appendix C, section 8). The 
structures of 1 and 2 are closely related to piperazinomycin (9),25 a bacterial metabolite 
first identified from Streptomyces olivoreticuli, which may be derived from oxidative 
macrocyclization of 1-like precursors.  
Another (p-hydroxyphenyl)-substituted propane derivative included a quaternary 
carbon at 93.1 ppm as well as two isolated methylene groups and a CH2O-CH-CH2-
phenyl moiety. ESI+-HRMS demonstrated a molecular formula of C18H21NO4, which in 
conjunction with the dqfCOSY and 1H,13C-HMBC data led to identification of the 
hemiacetal-containing morpholine 7. ROESY correlations between the hydroxy-proton 
with the axial proton at C-6 defined the relative configuration of 7 as (2R*,5S*). 
HPLC/ESI+-MS analysis of samples containing 7 showed two similarly large 
chromatographic peaks with mass spectra and fragmentation pattern consistent with the 
structure of 7, suggesting that under the HPLC conditions used 7 undergoes 
epimerization. The piperazines 1 and 2 and morpholine 7 are accompanied by 3-(p-
hydroxyphenyl)-1,2-propanediol (8), a previously described fungal metabolite26.  
All described OE::lnaA-upregulated compounds (1-8) were consistently present 
in OE::lnaA rich media cultures and undetectable by NMR spectroscopy in WT and 
∆lnaA rich media cultures. Of the OE::lnaA-upregulated compounds characterized, 
seven represent novel metabolites (1, 2, and 4-7) and two have not previously been 
reported from A. flavus (3 and 8). In addition, comparative metabolomic analyses 
occasional showed the production of several other metabolites (11-13) whose structures 
appeared unrelated to those of 1-8, suggesting that they are not directly derived from 
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lna cluster genes. In one set of cultures (liquid stationary GMM cultures), DANS 
analysis revealed five spin systems in wild-type and OE::lnaA extracts that were absent 
in ∆lnaA. Further analysis suggested one 4-proton spin system representing an indole 
moiety, whereas the other four spin systems appeared to belong to an oxygenated 
aliphatic ring system including several methyl doublets. A search of the established 
partial structures using Reaxys and SciFinder suggested that they represent 
undescribed chemical structure(s) perhaps related to a family of previously described 
idole-containing A. flavus compound, the aflavinines27. 
The analyte of interest was enriched using semi-preparative HPLC applied to 
combined wild-type and OE::lnaA extracts (Appendix C, section 9). 2D NMR analysis of 
the enriched sample using 1H,13C-gHMBCAD, 1H,13C-HSQC, and dqfCOSY supported 
the structure of 10 (Figure 3.1). Similar to the aflavinines, compound 10 showed strong 
3-bond 1H,13C-correlations from the methyl protons of C-26, 27, 28 and 29 to several 
key 13C atoms establishing the oligocyclic carbon skeleton. Additionally, 1H,13C-
gHMBCAD correlations from the protons of C-12, 16, 23, and 28 to the central tertiary 
C-14 helped connect the several contiguous 1H,1H-spin systems observed in the 
dqfCOSY to each other (Figure 3.3). ROESY spectra further confirmed the molecular 
architecture of 10, demonstrating that the C-2 proton of the indole moiety is positioned 
proximal to the C-26 and C-29 methyl groups. The positioning of the indole further 
confirms the relative stereo chemistry of C-10 and C-11. ROESY correlations between 
the C-15 proton with the C-18 proton suggested that the 6-membered ring formed by C-
15 through C-19 is in a boat conformation. The adjacent 6-membered ring formed by C-
19 through C-23 and C-14 shows J-coupling values and ROESY correlations consistent 
with a chair conformation (Figure 3.3). These 2D NMR spectroscopic data in 
combination with HRMS data support the structural assignment of 10 (Table C.11). 
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Figure 3.3: Diagnostic structural correlations for compound 10. Key HMBC 
correlations are displayed as blue signally headed arrows. Key through space ROESY 
correlations are displayed as red double headed arrows. 
 
LC/ESI-MS Profiling of the OE::lnaA-upregulated Metabolites in the Wild-type, 
ΔlnaA, and ΔlnaA, KD::lnbA A. flavus Strains: Given that compounds 1-8 were 
produced when lnaA was overexpressed, studies were undertaken to determine if 1-8 
production can be elicited in wild-type A. flavus under specific culture conditions, and 
whether these metabolites are in fact strictly lna-dependent (see Table 3.1). Highly 
sensitive single ion-monitoring MS (SIMMS) analysis of ΔlnaA, wild-type, and OE::lnaA 
extracts derived from cultures grown using conditions previously shown to support lnaA 
expression,4 revealed the presence of piperazines 1 and 2 in WT, although at ~100-fold 
lower concentrations than OE::lnaA (see Appendix C, section 11). Pyrazine 3 was found 
only in some, but not all wild-type extracts, whereas 4-8 were not detected. OE::lnaA 
produced compounds 1-3, 7 and 8, whereas 4-6 were absent under these culturing 
conditions. Notably, SIMMS also detected very small quantities of 1 and 2 in ΔlnaA 
extracts, at levels roughly 10 times lower than in wild-type. This suggested that 1 and 2 
are perhaps also produced by enzymes encoded by the homologous lnb cluster. To test 
this hypothesis, extracts derived from two different ΔlnaA, KD::lnbA double mutant 
strains were analyzed by HPLC/ESI+-SIMMS, which showed that compounds 1-8 are 
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completely absent in the double mutants, whereas wild-type and ΔlnaA, grown as 
positive controls in parallel, produced 1 and 2 as before (Figure C.3). These results 
indicate that the amounts of 1 and 2 found in ΔlnaA are derived from lnbA expression 
and thus the lna and lnb clusters (Figure 3.1) encode partially redundant biosynthetic 
pathways.  
 
Compound 
OE::lnaA 
(rich media) 
OE::lnaA 
OE::lnaA, 
KD::lnaB 
Wild type ∆lnaA 
∆lnaA, 
KDlnbA 
1 +++ +++ +++ ++ + - 
2 +++ +++ +++ ++ + - 
3 +++ +++ +++ ++* - - 
4 +++ - - - - - 
5 +++ - - - - - 
6 +++ - - - - - 
7 +++ +++ +++ - - - 
8 +++ +++ +++ - - - 
 
Table 3.1: A. flavus strains and occurrence of lna/lnb-associated metabolites 1-8. 
“+++” = abundant, detected by DANS and MS, ”++“ = detected by MS only (“*” = 
occasionally detected), and "+" = detected by MS, ~10 fold less abundant than in WT. 
Strains were cultured on GMM unless indicated otherwise. 
 
Determination of LnaA and LnbA Substrate Specificity: Given that the structures of 
1-8 appear to be tyrosine (Tyr) derived, the two putative NRPS proteins LnaA and LnbA 
were tested for their ability to specifically activate D/L-Tyr by assaying amino acid-
dependent ATP-[32P]-pyrophosphate exchange activity.28 Both LnaA and LnbA 
specifically activated L-Tyr, although LnaA was somewhat D/L-unspecific and also 
activated D-Tyr (Figure 3.4). However, neither lnaA nor lnbA include a condensation 
domain, and correspondingly, none of the lna- or lnb-associated metabolites identified in 
the wild-type nor OE::lnaA background feature a peptide bond. In addition, neither 
protein activated the L-Tyr-L-Tyr dipeptide (Figure C.4). However, both lnaA and lnbA 
include C-terminal R- (putative short-chain reductase and/or epimerase) domains, with 
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amino acid sequence similarity to other microbial reductase domains.29,30 Based on the 
chemical structures of the identified lna- and lnb-dependent metabolites, it appeared 
likely that the R-domains in LnaA and LnbA are involved in reduction of L-Tyr or L-Tyr 
derivatives. In a biosynthetic model, LnaA and/or LnaB-derived L-Tyr aldehyde (15) may 
form a dimer such as 17, perhaps via a tethered intermediate, e.g. 16 (Figure 3.5). 
 
Figure 3.4: Substrate specificity of recombinant LnaA and LnbA. LnaA (black bars) 
and LnbA (grey). were tested for their ability to adenylate various amino acids. Shown 
are relative activity values normalized to L-Tyr activity. Error bars, SD. 
 
2D NMR and LC/ESI-MS-based Metabolomic Study of the Putative Reductase 
Encoding Gene lnaB: Formation of the most abundant lna- or lnb-associated 
metabolites requires additional reduction from aldehydes or imines to corresponding 
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amines and alcohols. These reductive steps seemed likely to involve putative NmrA-like 
proteins encoded by lnaB or lnbB (Figure 3.1), as NmrA-like proteins are believed to 
serve enzymatic functions as epimerases or reductases,31 in addition to possible roles 
in gene regulation.19 
To examine the putative role of LnaB in the biosynthesis of 1 and 2, the 
metabolite profile of an OE::lnaA, KD::lnaB double mutant strain was compared to that 
of OE::lnaA by 2D NMR and HPLC/ESI+-SIMMS. These analyses showed that the 
morpholine 7 is much more abundant in OE::lnaA, KD::lnaB than in the OE::lnaA 
background, relative to the piperazines 1 and 2 (Figure 3.5). This shift towards a 
relatively greater production of morpholine 7, whose biosynthesis requires one reduction 
step less than production of 1 and 2, suggests that LnaB participates in the reduction of 
LnaA-derived intermediates. Knockdown of LnaB would result in increased 
accumulation of 17, which may partially undergo hydrolysis leading to increased 
production of 7 (Figures 3.5 & C.5). Notably, production of piperazines 1 and 2 is not 
fully abolished in the OE::lnaA, KD::lnaB strain, and formation of morpholine 7 from L-
Tyr aldehyde (15) or 17 still requires one reductive step. The residual reductase activity 
in the OE::lnaA, KD::lnaB double mutant could result from expression of the second 
nmrA-like gene lnbB (or another related gene proximal to lnbB, Table C.1) or 
incomplete silencing of lnaB. Lastly, whereas cyclization of 17 to a corresponding 
diimine followed by LnaB- (or LnbB-) mediated reduction leads to piperazines 1 and 2, 
oxidation, non-enzymatically or catalyzed by putative oxidases LnaC, LnaD, or LnbC, 
would explain formation of pyrazine 3.  
HPLC/ESI+-SIMMS further showed that the ratio of the two diastereomers 1 and 
2, is significantly greater in wild-type than in ΔlnaA (Figure 3.6 and Figure C.6), 
suggesting that the lnb pathway produces relatively larger amounts of the (2R*,5S*)-
isomer, 2, than the lna pathway. Given that LnbA activates L-Tyr with high selectivity, it 
seems unlikely that this greater relative abundance of 2 results from incorporation of  
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Figure 3.5: Simplified biosynthetic model for compounds 1, 2, 3, and 7 and ion 
chromatogram comparison of A. flavus strains OE::lnaA and OE::lnaA, KD::lnaB. 
(a) Proposed biosynthesis of lnaA-dependent metabolites (see also Figure C.6). 
Tethered L-Tyr (14) is reduced to 15 by R-domains of LnaA or LnbA, resulting in 
formation of a dimeric imine (17) potentially via a tethered intermediate (16). Cyclization 
and reduction by LnaB (and perhaps LnbB) leads to formation of 1 or 2, whereas 
oxidation yields 3. In the absence of LnaB, isomerization of 17 (or a related 
intermediate) to the enamine followed by loss of ammonia leads to increased formation 
of 7. (b) HPLC/ESI+-SIMMS analysis corresponding to 1, 2, and 7 for the OE::lnaA and 
OE::lnaA, KD::lnaB strains. The OE::lnaA, KD::lnaB strain shows a dramatic increase in 
production of 7 relative to 1 and 2, compared to the OE::lnaA strain.  
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both D-Tyr and L-Tyr. Instead, these stereochemical differences probably originate from 
different degrees of epimerization at the aldehyde or imine stage. Next, it was asked 
asked whether the ratio of diastereomers is actively regulated at the gene expression 
level. Northern analysis of wild-type cultures incubated with synthetic 1 or 2 showed that 
treatment with 2 did not lead to any significant changes in lna gene expression, whereas 
addition of 1 to wild-type cultures greatly increased expression of lnaB (Figure 3.6). 
This result strongly suggests metabolite-mediated crosstalk between the lna and lnb 
pathways. 
 
 
Figure 3.6: The ∆lnaA mutation modulates the compound 1 / compound 2 ratio 
and the influence of compound 1 on lna cluster expression. (a) Comparison of the 
diastereomeric ratios of compounds 1 and 2 in WT and ΔlnaA metabolite extracts. Error 
bars, 1 SD. (b) Effect of supplementation with synthetic 1 or 2 on lna gene cluster 
expression. Northern analysis showed that addition of 1, but not 2 increased lnaB 
expression. rRNA served as loading control. 
 
Conclusions: Employing comparative metabolomics with appropriate lna cluster 
mutations revealed eight lna-associated metabolites, 1-8, of which 1-3 could be 
detected in wild-type A. flavus. The two most consistently produced lna metabolites, 1 
and 2, are also produced under participation of lnb genes, providing a first example for 
partially redundant biosynthesis involving an NRPS-like pathway. LnaA and LnbA 
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deviate from canonical NRPS domain structures in that they lack condensation 
domains, and thus, as the structures of identified metabolites suggest, do not act as 
peptide synthetases. Instead, LnaA and LnbA follow the domain layout of Lys2 and 
related fungal enzymes that serve as α-aminoadipate semialdehyde reductases in 
fungal L-lysine biosynthesis (24% and 25% identity of LnaA and LnaB to A. flavus Lys2, 
respectively16). Examination of fungal genomes showed that LnaA-like proteins are 
primarily confined to the Ascomycete order Onygenales, with 1-5 different LnaA-like 
proteins in different Aspergilli. Recently published genomes (e.g., of Serpula lacrymans 
and Heterobasidion annosum32,33) show that LnaA/LnbA-type enzymes are also 
encoded in both basidiomycete genomes. The piperazinomycin-producing bacteria 
(Streptomyces sp.) have not been sequenced; however, available Streptomyces 
genomes contain a number of putative genes encoding proteins with high (up to 38%) 
amino acid sequence similarity to LnaA. The close similarity of some bacterial NRPS-
like proteins to LnaA/LnaB despite bacteria not synthesizing lysine via the Lys2 pathway 
suggests a complex evolution of these proteins34.  
This work provides the first evidence that Lys2-type enzymes also function in 
secondary metabolism and additionally suggests that NRPS-like proteins may serve as 
amino-acid reductases, indicating that a reaction hitherto considered as an NRPS-
offloading mode can stand by itself. This study also demonstrates the consequences of 
lnaA/lnbA gene disruption/silencing and the concomitant loss of 
piperazine/pyrazine/morpholine secondary products on fungal development, linking 
sclerotia formation in A. flavus and the lna/lnb metabolic pathways. This observation 
adds a unique role to previously known functions of NRPS genes in fungi. The 
occurrence of a functionally duplicated biosynthetic pathway can be interpreted as a 
safeguard to ensure timely sclerotial production and hence, persistence during 
unfavorable environmental conditions. The results of this study are suggestive of a 
complex signaling network regulating biosynthesis of the lna- and lnb-pathway 
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metabolites, which may include cross-pathway interactions mediated by sensing of 1 
and 2 or shared biosynthetic intermediates. Detailed analysis of the metabolomes and 
associated phenotypes of lna/lnb single and double knock-out strains will be required to 
clarify the extent of interactions between the lna/lnb clusters and determine the roles of 
the identified metabolites for sclerotia formation and other aspects of A. flavus biology. 
 
Follow Up Investigation of ∆lnaA, KD::lnbA (TSA 22.1): During the A. flavus lna/lnb 
gene cluster studies, several interesting observations were made relating to the ∆lnaA, 
KD::lnbA strain (TSA 22.1). It has been demonstrated previously that wild-type A. flavus 
shows less sclerotial production when grown in the light compared to cultures incubated 
in the dark. In the course of studying TSA 22.1 it was observed that this double mutant 
strain shows the opposite behavior, producing many sclerotia in the light and few to no 
sclerotia in the dark (Figure 3.7). Several studies have described regulatory pathways 
that are affected by the absence or presence of light, including the global regulator of 
secondary metabolisms LaeA35 and the related VelB-VeA-LaeA complex.36 This 
association directly implicates secondary metabolic regulation and pathways that 
respond to light. Given the observed phenotypes of TSA 22.1 and the established 
relationship between secondary metabolite production under light/dark conditions, a 
comparative metabolomic study was undertaken comparing wild-type and TSA 22.1 
cultured in the light/dark (wild-type-light/dark and TSA 22.1-light/dark respectively). 
 Initial comparative HPLC/ESI+-MS analysis of extracts derived from wild-type-
light and TSA 22.1-light cultures showed an ion with m/z 241.2 dramatically upregulated 
in TSA 22.1-light (~12 fold) relative to wild-type-light. The m/z 241.2 ion was 
accompanied by an ion m/z 543.2 with the same retention time and ion chromatogram 
peak shape as m/z 241.2. A search for know A. flavus metabolites with the mass 240.1 
amu (assuming m/z 241.2 represent a [M+H]+ ion) resulted in one compound, hydroxy 
aspergillic acid (18, Figure 3.8). Supporting the hypothesis that m/z 241.2 represents 
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18, the diagnostic isotopic pattern of m/z 543.2 suggested the presence of a Zn atom 
(Figure 3.8), which would be consistent with a Zn(II)[18 - H+]2 metal complex. Such a 
complex could form through tautomerization and deprotonation of two equivalents of 18 
to the corresponding hydroxamate followed by coordination to a Zn2+ ion (19, Figure 
3.8). A close analog of 19 derived from aspergillic acid (20) has previously been 
reported from Aspergillus sojae.37 
 
 
Figure 3.7: A. flavus Wild-type and ∆lnaA, KD::lnbA’s response to light. GMM 
cultures of wild-type and ∆lnaA, KD::lnbA were incubated in either light or dark 
conditions. Wild-type shows ample sclerotial (small black dots) production in the dark 
and reduced sclerotial production in the light. ∆lnaA, KD::lnbA shows no sclerotial 
production in the dark and ample sclerotial production in the light. 
 
The initial HPLC/ESI+-MS-based comparison of wild-type- and TSA 22.1-light 
extracts were complemented with DANS analysis, demonstrating that compound 19 is 
upregulated in TSA 22.1 relative to wild-type, and no other metabolites appeared to be 
differential between these strains (Appendix C, Figure C.11). Additional reports of 
iron(III)- and copper(II)-containing aspergillic acid complexes suggested that profiling 
the various wild-type and TSA 22.1 extracts for these chemical species may provide a 
more complete picture of the chemical variability between the wild-type and TSA 22.1 A. 
flavus strains and light/dark conditions.38,39 Further, because the A. flavus cultures were 
grown on chemically defined GMM media (metal ions: Mn2+, Fe3+, Co2+, Cu2+, Zn2+, 
Wild-type ∆lnaA, KD::lnbA (TSA 22.1)
Dark DarkLight Light
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Mo6+) a short list of possible aspergillic acid or hydroxy aspergillic acid metal complexes 
could be generated and quickly searched for in wild-type and TSA 22.1 LC/ESI+-MS 
data. For this study LC/ESI+-MS offered a distinct advantage over NMR-based 
comparative metabolic profiling because many potential metal-containing chemical 
species, such as Fe3+-containing derivatives, are paramagnetic, resulting in short 
nuclear relaxation times and as a result poor NMR spectroscopic line-shape. MS 
isotopic distribution patterns of transition metals are often diagnostic and, along with 
exact mass MSMS fragmentation patterns, were used to elucidate structures with high 
confidence (Figure 3.8). 
 
 
Figure 3.8: Aspergillic acid analogs and MS(MS) analysis. (a) Oxidation of 
aspergillic acid (21) to hydroxy aspergillic acid (18) followed by tautomerization, 
deprotonation and coordination to Zn2+ forms compound (19). (b) Example of diagnostic 
isotopic pattern for compound 19 demonstrating the presence of a zinc ion. (c) 
Fragmentation patterns used to assess the presence of 18-containing metal complexes. 
M+ represents any of the metal centers present in a 2+ oxidation state. 
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Qualitative structural elucidation using high resolution UPLC/ESI+-HRMS(MS) 
profiling of wild-type- and TSA 22.1-light/dark cultures revealed four 18- or 21-
containing chemical structures, including the previously observed Zn(II)-containing 
species 19 and 20 as well as two Fe(III)-containing compounds 22 and 23 (Figure 3.9, 
Appendix C, section 13). HPLC/ESI+-MS ion chromatograms acquired for wild-type- and 
TSA 22.1-light/dark samples were used to compare the relative amounts of 19, 20, 22, 
and 23 for each sample (Figure 3.9). 
Compounds 19, 20, 22, and 23 all appear to be upregulated in wild-type-light 
compared to wild-type-dark. This observation is consistent with previously established 
models demonstrating that deletion of laeA (∆laeA) results in the loss of secondary 
metabolic production save aspergillic acid,35 and that the formation of the VelB-VeA-
LaeA complex, responsible for coordination of development and secondary 
metabolisms, is suppressed by light.36 Interestingly, TSA 22.1 showed 19, 20, 22, and 
23 production pattern opposite to wild-type, producing more of these compounds in the 
dark compared to the light. Lastly, TSA 22.1 showed reduced 20 and 23 production 
when exposed to the light. These two chemical species both lack hydroxylation of 
aspergillic acid’s sec-butyl moiety, suggesting that, for the TSA 22.1 mutant, the 
presence of light upregulates aspergillic acid oxidation pathways. As before, the 
opposite behavior was observed for wild-type.  
 Further investigations are needed to understand the mechanism by which TSA 
22.1 reverses both the phenotypic and metabolic behaviors observed in wild-type 
sclerotial and aspergillic acid production. The exceptional behavior of the strain TSA 
22.1 is even more apparent when compared to TSA 22.6 (also ∆lnaA, KD::lnbA) which 
does not show all of the TSA 22.1 behaviors described here. Taken together these 
results suggest that the RNAi plasmid used to create TSA 22.1 may have been 
incorporated into a portion of the genome involved in light-mediated regulation, perhaps 
by disrupting a yet to be described genetic element involved in controlling aspergillic 
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acid production. Future efforts to sequence the genomic region adjacent to TSA 22.1’s 
RNAi construct should help generate candidate genes to investigate. Knockout or 
overexpression of candidate genes may also help to illuminate TSA 22.1’s phenoptypic 
and metabolic mechanisms. Indispensable in this next step will be the LC/ESI+-MS 
methods developed during this study to characterize and profile resulting metabolic 
changes. 
Figure 3.9: Characterized aspergillic acid-derived compounds and wild-type-/TSA 
22.1-light/dark sample profiling. Compounds 19, 20, 22, and 23 were characterized 
via UPLC/ESI+-MS(MS) analysis. HPLC/ESI+-MS was then used to profile these 
chemical species in wild-type- and TSA 22.1-light/dark extracts. Each sample 
represents 25 pooled culture plates. 
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CHAPTER 4 
 
CONCLUSIONS AND OUTLOOK 
 
DANS- and LC-MS-Based Comparative Metabolomics in Microorganisms: One of 
most striking results from the comparative metabolomics A. fumigatus and S. 
clavuligerus studies, Chapters 1 and 2 respectively, is the discovery of novel 
endogenous secondary metabolites from wild-type organisms and secondary metabolic 
pathways that are relatively well-studied.1,2 These observations suggest that our current 
knowledge of metabolites associated with many metabolic pathways may be 
substantially incomplete.3 Given the important roles that small-molecules and 
associated catabolic and anabolic pathways play in every kingdom of life, continued 
development and incorporation of facile tools to study the metabolomes of biological 
systems will be indispensable in advancing chemical biology. 
 As demonstrated in this dissertation, comparative metabolomics incorporating 
DANS- and LC/ESI-MS-based methodology is highly effective for studying the metabolic 
pathways of microbial organisms. Chapter 3’s treatise on A. flavus’s orphan lna/lnb 
gene clusters represents the first example where DANS was implemented in concert 
with several modulators of gene expression, such as overexpression, knockout, and 
knockdown mutations, not only to identify pathway metabolites, but also to develop a 
broader view of the pathway's role in A. flavus’s biology. Specifically, perturbations to 
individual genes in the lna/lnb pathway at a genetic level could be detected and 
contextualized using the small-molecule structural information obtained via DANS 
and/or LC/ESI-MS. The results of the A. flavus study have established an analytical and 
genetic platform for the systematic examination of all the small-molecule biosynthetic 
pathways of A. flavus, potentially extending into other microbial and perhaps more 
complex organisms’ biology. 
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Statistical Treatment of DANS Spectra: Although the DANS methodology discussed 
in the preceding chapters offers clear advances in metabolite characterizing and 
profiling technology, it falls short of the ultimate objective of metabolomics, to know the 
complete content and dynamic ranges of all metabolites in an organism’s metabolome 
("full characterization").4 Full characterization is an analytical goal that will always be 
limited by the sensitivity of the instrumentation used; in the case of NMR and MS 
roughly µM5 and nM (A. flavus study) concentrations of analytes, respectively. Many 
metabolomic techniques circumvent full characterization by focusing only on those 
metabolites in an organism that are have previously been associated with a specific 
biological readout, for example monitoring gliotoxin levels in A. fumigatus-infected 
mice.6 DANS also reduces the necessity of full characterization by examining only those 
metabolites that are differential between comparative sets of biological samples. 
However, given the highly integrated nature of may biological pathways, only examining 
metabolites whose production is entirely dependent on a specific pathway may bias 
one’s view of a system’s response to specific perturbations (gene distribution, 
environmental, chemical) and belie other subtle biologically-significant changes.  
 In pursuit of capturing the most information from a DANS-based comparative 
metabolomics approaches, one could envision a statistical treatment of 2D NMR 
spectra to be compared, such that resulting comparative data sets would assign a 
statistical significance to an observed spectroscopic change. Future efforts with DANS 
technology will greatly benefit from the incorporation of statistical tests such as principal 
component analysis, tools that will enable a more quantitative overview of small-
molecule metabolism, including subtle metabolic changes.4,7,8 This work is currently 
being undertaking by the Schroeder Laboratory, and is called mvaDANS. 
 Like DNAS, mvaDANS relies on 2D NMR spectra, using comparison of replicates 
and reference spectra (example, 3 wild-type spectra versus 3 knockout spectra) to 
quantify and assign statistical significance to changes observed between sets of 
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dqfCOSY spectra. LC/ESI-MS can also be integrated into the mvaDANS-based 
approaches, providing analytically orthogonal data sets, also amenable to multivariate 
analysis.9  
 Although the mvaDANS and LC/ESI-MS statistical approaches offer methodology 
to more completely capture information from metabolomics studies, they too fall short of 
the general “full characterization” metabolomics principle discussed above. However, 
perhaps full characterization becomes less important as one obtains a broader picture 
of how a biological system responds to a given perturbation. To this end, future efforts 
combining metabolomic (NMR and MS), proteomic, genomic, and other omic data sets 
may greatly accelerate our ability to study the chemistry of complex biological systems. 
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Appendix A 
 
IDENTIFICATION OF CRYPTIC PRODUCTS OF THE GLIOTOXIN GENE CLUSTER 
USING NMR-BASED COMPARATIVE METABOLOMICS AND A MODEL FOR 
GLIOTOXIN BIOSYNTHESIS 
 
1. General Analytical Methods and Equipment: (A) NMR spectroscopy, NMR 
spectroscopic instrumentation: a Varian INOVA 600 MHz NMR spectrometer (600.0 
MHz 1H reference frequency, 150.6 MHz for 13C) equipped with an HCN indirect-
detection probe, a Varian 900 MHz NMR spectrometer (899.9 MHz 1H reference 
frequency, 226.7 MHz for 13C) equipped with a 5 mm 1H (13C/15N) Cryogenic Probe, and 
a Bruker AVANCE 600 MHz NMR spectrometer (600.7 MHz 1H reference frequency, 
149.9 MHz for 13C) equipped with a 5 mm TXI probe. Non-gradient phase-cycled 
dqfCOSY spectra were acquired using the following parameters: 0.600 s acquisition 
time, 500-900 complex increments, 8-32 scans per increment. ROESY spectra were 
acquired using the following parameters: 0.25 s acquisition time, 0.2-0.4 s mixing time, 
200-400 increments, 16-32 scans per increment. Gradient and non-gradient HSQC[AD], 
HMQC, and HMBC[AD] spectra were acquired with these parameters: 0.25 s acquisition 
time, 300-600 increments, 4-32 scans per increment. 1H,13C-HMBC spectra were 
optimized for JH,C = 6 Hz. 
1H,15N-gHMBCAD spectra were optimized for JH,15N = 8 Hz. 
Susceptibility-matched NMR tubes (Shigemi) were used for sample amounts smaller 
than 2 mg. NMR spectra were processed using Varian VNMR and MestreLabs 
MestReC and MNOVA software packages.  
(B) Mass spectrometry, High-resolution mass spectrometry was performed on a 
LTQ Orbitrap Velos (Thermo Scientific) or a SYNAPT HDMS: (Q-IMS-TOF). HPLC 
system equipped with a diode array detector and connected to a Quattro II spectrometer 
(Micromass/Waters) operated in positive-ion electrospray ionization (ESI+) mode was 
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used for HPLC/ESI+-MS analysis. Data acquisition and processing for the HPLC/ESI+-
MS was controlled by Waters MassLynx software.  
(C) Chromatography, Flash chromatography was performed using a Teledyne 
ISCO CombiFlash system. For semi-preparative HPLC Supelco Discovery HS C18 
column (25 cm x 10 mm, 5 μm particle diameter). An Agilent Zorbax Eclipse XDB-C8 
column (4.6 x 150 mm, 5 µm particle diameter) was used in HPLC/ESI+-MS analysis. 
 
2. Fungal Strains and Experimental Growth Conditions: A. fumigatus strains: AF293 
(wild-type), TDWC5.6 (∆gliZ:: A. parasiticus pyrG; pyrG1), ARC2 (∆gliP::A. parasiticus 
pyrG pyrG1) donated by William J. Steinbach; Duke University, gliI (gliI:A. parasiticus 
pyrG; pyrG1). Strains were maintained as glycerol stocks and were cultured at 25°C on 
glucose minimal medium (GMM).1  
For preparation of spore suspensions, two week old cultures of wild-type, OE, 
∆gliZ, ∆gliP, and ∆gliI, grown on GMM plates, were flooded with 1 mL 0.01% Tween 20. 
100 µL of the fluid from the flooded plates was diluted with 0.8 mL 0.01% Tween 20 to 
make the spore suspensions for inoculation. 7 µL of the spore suspension was point 
inoculated onto the middle of GMM plates. For initial and replicate studies of wild-type, 
∆gliZ, and ∆gliI twenty plates of each strain were cultured. For DANS comparison 
studies of OE to wild-type, and ∆gliZ, three GMM plates of each strain were grown. 
Cultures were grown for two weeks at 25.0 °C in the dark. 
For DANS comparison of ∆gliP and wild-type, an additional 2 mL of sterile filtered 
(0.2 µm, pore size, Nalgene sterile filter) deionized water was pipetted onto the GMM 
plates prior to inoculation. For these studies sets of three to five GMM plates of each 
∆gliP and wild-type were set up. Plates were point inoculated and incubated as 
described in the previous paragraph. 
 
67 
 
3. Construction of gliI Knock Out Mutants (∆gliI): To delete gliI in A. fumigatus, the 
plasmid pDWC8.5 was designed as follows. A PCR amplicon of 898 bp of the gliI 
upstream sequence was digested using SalI and EcoRI, and ligated into SalI-EcoRI 
digested pJW24 vector carrying A. parasiticus pyrG. The resulting vector was digested 
using BamHI and NotI and ligated with a BamHI-NotI digested PCR amplicon of 889 bp 
of the gliI downstream sequence. This final vector was designated as pDWC8.5. To 
generate the ∆gliI strain (TDWC7.49 and TDWC7.54), DNA of pDWC8.5 was 
transformed into A. fumigatus wild-type AF293.1. Homologous recombination of the gliI 
knock-out construct was verified by PCR and Southern blot analysis (Figure A.8). 
 
4. Assesment of gliZ and gliP Expression in ∆gliI Mutant: Northern analysis was 
used to assess gene expression in A. fumigatus strains. Total RNA was extracted from 
lyophilized mycelia of A. fumigatus using TRIzol (Invitrogen) and separated on a 
denaturing formaldehyde/agarose gel. RNA was transferred from the gel to a nylon 
membrane (HybondTM-N+, Amersham Pharmacia Biotech) by capillary blotting with 10 x 
SSC. RNA was irreversibly bound to the membrane using a UV cross linker at 1200 
J3cm-2. Blots of A. fumigatus RNA were hybridized with the following fragments, which 
had been amplified from A. fumigatus genomic DNA and labeled with [32P] dCTP: a 
653 bp fragment of gliI (primers 5’-TGTTGATCGAGACGCCGTTCTG-3’ and 5’-
CAGAGCGGCTCGATTCTGGTG-3’), a 1211 bp fragment of gliZ (primers 5’-
AAGGGCCGGTAGTCTACCTCTTC-3’ and 5’-CGATCTGGTAGCTGCCCAGCTGGA 
AG-3’) and a 173 bp fragment of gliP (primers 5’-AAACCCCTGTGAATGCAGAC-3’ and 
5’-CCCCTTGAGATGAAAGGTGA-3’) (Figure A.8). 
 
5. Metabolome Extraction and Initial Fractionation: Fungal cultures including fungal 
tissue and agar media were cut into small ~1 x 1 cm cubes and placed into individual 1 
L round bottom flasks, frozen using a dry ice acetone bath, and lyophilized. Two 
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different protocols were used for extraction of fungal cultures: (1) lyophilized wild-type 
and ΔgliZ cultures were extracted with ethyl acetate and a mixture of 5% ethyl acetate, 
15% water, and 80% acetonitrile; (2) for additional analysis of wild-type and ΔgliZ 
cultures and for analyses of the ΔgliP and ΔgliI cultures 100% ethyl acetate followed by 
100% acetonitrile were used to extract the lyophilized fungal cultures. All extracts were 
filtered over Celite and a glass frit. Subsequently, the extracts were adsorbed onto 
Celite (~1 g of Celite for 100 mg of dried extract) and fractionated on a 100 g RediSep 
Reverse-Phase (RP) C18 flash chromatography column using a water-acetonitrile 
solvent gradient, starting with 20 min of 5% acetonitrile followed by a linear increase to 
100% acetonitrile over 40 min, followed by 10 min of 100% acetonitrile. Fractions were 
combined into three pools; pool 1, 0.5% acetonitrile isocratic elution, fractions 21-44; 
pool 2, 0.5-55% acetonitrile, fractions 45-101; pool 3, 55-100% acetonitrile, fractions 
102-140. Pools were evaporated to dryness and suspended in ~0.2 mL of acetonitrile-
d3 (in the case of pool 1, ~0.2 mL 1:2 D2O:acetonitrile-d3). The suspension was 
centrifuged to remove insoluble materials; this was repeated two additional times, and 
the supernatant was subjected to NMR spectroscopic analysis.  
 
6. Differential Analysis by 2D-NMR Spectroscopy (adapted from reference2): High-
resolution dqfCOSY spectra were acquired using the following parameters: acquisition 
time 0.6 s; 500 increments (ni). Phase cycling was used for coherence selection, and 
MestReC was used to process the resulting data, zero-filling the spectra to 8096 
complex data points in the directly detected dimension (F2) and 4096 data points in the 
indirectly detected dimension (F1). Bitmaps derived from absolute-value processed 
dqfCOSY spectra were then imported into Adobe Photoshop CS3 and overlayed as 
described in reference.3 
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Figure A.1: GliP domain architecture. GliP includes two adenylation (A), three 
thiolation (T), and two condensation domains.4 
 
 
Figure A.2: Magnitude-mode processed dqfCOSY spectrum of A. fumigatus wild-type 
(600 MHz, solvent acetonitrile-d3). 
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Figure A.3: DANS overlay of wild-type pool 2 and ΔgliZ pool 2, based on 
magnitude-mode processed dqfCOSY spectra (600 MHz, acetonitrile-d3). Insert: 
4.55-2.75 ppm section enhanced to reveal minor components. gliZ-dependent signals 
detected via DANS are boxed, representing known gliotoxin derivatives (blue), the 
known 10 and 11 (black), and novel compounds 12-17 (red). 
 
7. Characterization of Compounds 10-14a/b, 16, and 17: The wild-type-derived pools 
used for DANS analysis described above were fractionated using a Supelco Discovery 
HS C18 column (25 cm x 10 mm, 5 μm particle diameter) and a water-acetonitrile 
solvent gradient, starting with 5 min at 5% acetonitrile, followed by a linear increase to 
23% acetonitrile over 1 min, and a more gradual increase reaching 50% acetonitrile at 
49 min. A total of 18 fractions were collected. Fractions 1-18 were evaporated to 
dryness in vacuo and dissolved in acetonitrile-d3, followed by 
1H-NMR spectroscopic 
analysis of each fraction. Comparison with data from DANS analyses indicated that 
71 
 
fraction 1 contained nearly pure compound 10, and fraction 5 contained nearly pure 
compound 11. Comparison with the DANS data further indicated that compounds 12, 
14b, and 16 were present in fraction 2, and compounds 13, 14a, and 17 in fraction 4. 
Fractions 2 and 4 were further purified using the same column and solvent 
system described above. Fraction 2 was separated to obtain samples of 12, 14b, and 
16 using a solvent gradient starting at 5% acetonitrile for 30 min, followed by a linear 
increase to 20 % acetonitrile over 30 min, which was followed by 10 min at 20% 
acetonitrile. Fraction 4 was fractionated further to obtain samples of 13, 14a, and 17 
using a solvent gradient of 30 min at 5% acetonitrile with a linear increase to 20 % over 
5 min followed by 12 min 20% acetonitrile. In each case collected fractions were 
evaporated to dryness in vacuo and dissolved in acetonitrile-d3, followed by NMR 
spectroscopic analysis of each fraction. 
 
8. Purification of Compound 4: 20 wild-type cultures grown on GMM plates, as 
described above, were extracted using a mixture of 5% ethyl acetate, 15% water, and 
80% acetonitrile (section 2). These extracts were initially used to determine an 
appropriate enrichment protocol for compound 4. Wild-type extracts were dissolved in 
~50 % acetonitrile/water and absorbed onto Celite. Solvent was removed in vacuo. The 
sample, absorbed onto Celite, was subjected to flash chromatography using a 
CombiFlash chromatography system equipped with a 100 g RediSep Gold RP-18 flash 
chromatography column using acetonitrile and 0.1% acetic acid in water as solvents, 
starting with 3.5 min at 1% acetonitrile, followed by a linear increase to 10% acetonitrile 
over 16 min, which was followed by an increase to 100% acetonitrile over 3.5 min, 
holding at 100% acetonitrile for 3.5 min. Fractions were evaporated to dryness, and 1H 
NMR spectra of individual fractions were acquired in methanol-d4. Signals diagnostic for 
compound 4, including signals representing olefinic, methylene, and methyl sulfanyl 
protons, indicated that 4 elutes at ~9% acetonitrile under these conditions. Fractions 
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containing 4 were pooled together. For purification of a larger amount of compound 4, 
this procedure described above was repeated twice more using extracts from two 90-
plate-batches of wild-type. Fractions containing 4 were pooled to give a single sample of 
enriched 4 which was subjected further 2D NMR spectroscopic and HR-MS analysis. 
 
9. Isolation of Compounds 15a/b: The remaining extract from the 200 wild-type 
cultures used for isolation of compound 4 was adsorbed onto Celite and subjected to 
flash chromatography using a CombiFlash chromatography system equipped with a 100 
g RediSep Gold RP-18 column. The water-acetonitrile solvent gradient used is 
described in section 5 of Appendix A. Fractions eluting at 10-50% acetonitrile were 
pooled and evaporated in vacuo. The residue was dissolved in acetonitrile, filtered over 
acetonitrile-washed cotton, and subjected to preparative HPLC using instrumental setup 
and solvent systems described in section 6 of Appendix A. A water-acetonitrile solvent 
gradient was used that started at 5% acetonitrile for 30 min, followed by a linear 
increase to 20% acetonitrile over 30 min. (Compounds 15a/b were found to elute at 13-
14% acetonitrile under these conditions) Solvent was removed from the HPLC fractions 
in vacuo and samples were redissolved in acetonitrile-d3, and 
1H NMR spectra were 
acquired for each HPLC fraction. Diagnostic signals present in the DANS spectrum of 
pool #2 indicated the presence of 15a/b. 
 
10. High Resolution Mass Spectrometric Analysis for Compounds 4, 5-7, 9, 12, 
and 13-17: Enriched samples of compound 4, 5, 7, 9, and 15a/b were diluted to 0.01 
mg/mL by dissolving the samples in either 20% acetonitrile and 80% of 0.1% formic acid 
in water, 4; or 50% acetonitrile and 50% of 0.1% formic acid in water, 5-7, 9 and 15a/b. 
These sample were infused into a LTQ Orbitrap Velos mass spectrometer running in 
ESI+ ionization mode with a mass range at or within 1-2000 m/z. 
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Compound 
HR-ESI+MS obseved 
(m/z) Ion 
Calculated for Ion 
Formula Calculated m/z 
4 351.0434 [M+Na]+ C13H16N2NaO4S2 351.0438 
5 325.0321 [M+H]+ C13H13N2O4S2 325.0311 
6 357.0039 [M+H]+ C13H13N2O4S3 357.0032 
7 388.9760 [M+H]+ C13H13N2O4S4 388.9753 
9 377.0601 [M+Na]+ C15H18N2NaO4S2 377.0600 
15a/b 317.0564 [M+Na]+ C13H14N2NaO4S 317.0566 
 
Samples of compounds 12, 13, 14a/b, 16, and 17 were diluted to a concentration 0.01 
mg/mL in acetonitrile. An aliquot of the diluted sample was acidified using formic acid 
(final concentration 0.1%). Samples 12, 13, 14a/b, 16, and 17 were infused into a 
SYNAPT HDMS: (Q-IMS-TOF). Mass spectra were acquired using ESI+ ionization with 
a mass range of 1-1000 m/z.  
 
Compound 
HR-ESI+MS 
obseved (m/z) 
Ion 
Calculated for Ion 
Formula 
Calculated m/z 
12 281.107 [M+H]+ C13H17N2O3S 281.095 
13 365.055 [M+Na]+ C14H18N2NaO4S2 365.060 
14a/b 333.106 [M+Na]+ C14H18N2NaO4S 333.088 
16 303.087 [M+Na]+ C13H16N2NaO5 303.095 
17 261.079 [M+H]+ C13H13N2O4 261.087 
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Figure A.4: Formation of a mixture of diastereomers of spirocyclic 15 from 
diketopiperazine 13. (a) 6.5-6.9 ppm section of the 1H NMR spectrum of a sample of 
diketopiperazine 13, showing signals for protons 11-H and 13-H of 13 in addition to a 
small signal for 13-H of 15a and 15b (600 MHz, DMSO-d6). (b) Same sample after 
several days at room temp., showing increasing amounts of 15a/b (600 MHz, DMSO-
d6). (c) After two weeks at room temp., most of 13 has converted to 15a/b (900 MHz, 
DMSO-d6). (d) Sample of a mixture of 15a and 15b (600 MHz, DMSO-d6), containing 
small amounts of impurities (signals at 6.84 and 6.53 ppm). (e) Compounds 13 and 
15a/b.  
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11. HPLC-MS-based Comparison of Wild-Type and Mutant Extracts: Unfractionated 
wild-type and mutant extracts prepared as described in section 2 were dissolved in 
acetonitrile (~1 mL solvent/10 mg sample). Post-HPLC (using the RP-8 column) and UV 
spectroscopic analysis (200-400 nm), samples were infused into a Quattro II ESI MS 
running in ESI+ mode. Enriched samples of NMR- and MS-characterized gliZ-dependent 
metabolites served as elution time and ionization standards. Testing for the presence of 
compounds 1-3, 8, 10-12, 14a/b, and 17 in wild-type and mutant extracts a 
water/acetonitrile gradient was used starting with 5 min at 5% acetonitrile followed by a 
linear increase to 20% acetonitrile over 5 min, this was followed by a linear increase to 
45% acetonitrile over 110 min (for chromatograms, see Figure A.5 and Figure A.6. For 
testing the presence or absence of compounds 13 and 16 in wild-type and ∆gliZ 
extracts a different water/acetonitrile gradient was used starting with 5 min at 5% 
acetonitrile followed by a linear increase to 25% acetonitrile over 55 min. 
12. Relative Abundance of gliZ-Dependent Compounds: Using NMR solvent signals 
as internal standards, relative abundances of compounds 1-17 were estimated based 
on integration of their 1H NMR spectroscopic signals in partially purified samples derived 
from a set of 20 wild-type plates. Abundance of gliZ-dependent metabolites relative to 
that of gliotoxin (1): compound 4, 30:1; compound 10, 2:1; compound 12, 4:1; 
compound 11, 8:1; compound 13, 8:1; compound 14a, 20:1; compound 14b, 60:1; 
compound 16, 50:1; compound 17, 10:1, and compounds 2, 3 and 8 ~1:1. Abundance 
of compounds 4 and 16 are likely underestimated significantly because of partial 
decomposition of these compounds during purification. 
 
13. DANS of ΔgliP and Wild-Type: GMM plates were prepared as described in section 
2, except that an additional 200 μL of sterile filtered (0.2 μm, pore size, Nalgene sterile 
filter) deionized water was pipetted onto the GMM plates prior to inoculation. For these 
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studies sets of five GMM plates of each ΔgliP and wild-type were used. Plates were 
point inoculated, incubated, and extracted as described in above (sections 2 and 5). 
 
14. ΔgliP Feeding Experiment: In parallel to the wild-type and ΔgliP cultures described 
above, five plates of ΔgliP supplied with synthetic compound 10 ("ΔgliP+10") were 
grown. For these cultures, 13 mg of 10, purchased from Sigma-Aldrich, was dissolved in 
3 mL deionized water and sterile filtered. 200 μL of this solution was pipetted onto each 
plate. Subsequently, plates were inoculated, incubated, and extracted as described 
above (Apendix A, sections 2 and 5). DANS comparison as well as HPLC-MS analysis 
of extracts derived from wild-type (positive control), ΔgliP (negative control), and 
ΔgliP+10 (treatment) revealed that none of the gliZ-dependent metabolites were 
rescued by addition of 10 to ΔgliP.  
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Figure A.5: HPLC/ESI+-MS ion chromatograms for gliZ-dependent metabolites 1, 
8, 10, 11, 12, 14a, 14b, and 17. Ion chromatograms were obtained via HPLC-MS 
analysis of partially purified samples derived from A. fumigatus wild-type cultures. For 
each compound, a chromatogram representing the most abundantly produced ion is 
shown: m/z compound 1, [M-S2+H]
+ = 263.1; compound 10, [M+1] = 235.1; compound 
12, [M-SMe]+ = 233.1; compound 11, [M-SMe]+ = 279.1; compound 14a, [M-SMe]+ = 
263.1; compound 14b, [M-SMe]+  = 263.1; compound 17, [M+H]+ = 261.1; and 
compound 8, [M+H]+ = 357.1.  
Time
12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00
%
0
100
10
12
14b
11
14a
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Figure A.6: HPLC/ESI+-MS ion chromatograms for gliZ-dependent metabolites 1, 
8, 13, 14a, and 16. Chromatograms were obtained via HPLC/ESI+-MS analysis of 
partially purified samples derived from A. fumigatus wild-type cultures. Chromatograms 
for compounds 13 and 16 were obtained using single-ion monitoring MS. For each 
compound, a chromatogram representing the most abundantly produced ion is shown: 
m/z compound 16, [M+1] = 281.1; compound 13, [M-SMe]+ = 295.1; compound 14a, [M-
SMe]+ = 263.1; compound 1, [M-S2+H]
+ = 263.1; and compound 8, [M+H]+ = 357.1. 
  
Time
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100
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Figure A.7: gliP, gliI, and gliZ expression in the wild-type (Af293) ∆gliI, ∆gliI:gliI2 
strains. Total RNA was extracted from shaking cultures grown in Czapek Dox medium 
at 37 C for two days. RNA was probed with a fragment of gliotoxin biosynthetic genes 
gliP (173 bp), gliI (653 bp)  and gliZ (1211 bp). Transcript sizes are marked. Ethidium 
bromide-stained 18S rRNA is shown as a control for RNA loading. (a) Transcripts of gliP 
and gliI were undetected in the gliI mutant, but present in similar amounts in isolates 
Af293 and gliI:gliI2 (∆gliI complemented with gliI). (b) Transcripts of gliZ were not 
detected in the gliI mutant in one biological replicate and reduced in the second 
biological replicate, compared to that in Af293. The level of gliZ transcription was 
restored to wild-type level in isolate gliI:gliI2 in both biological replicates 
  
(a)
(b)
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Figure A.8: ∆gliI mutants’ construction. The construction of ∆gliI mutants was 
confirmed by Southern analysis of genomic DNA from wild-type (WT) and two 
transformants (T1 and T2), indicating gliI replacement by pyrG in T1 and T2. (a) Wild 
type and two gliI replacement strains were probed with a 3,435 bp fragment of DNA 
covering approximately 1 kb up and down stream of gliI ORF as well as the gliI ORF. (b) 
Xhol does not cut within the gliI ORF, rather Xhol cuts regions flanking gliI generating a 
single DNA fragment of 3,435 bp. The DNA from transformants in which pyrG replaces 
gliI is cut by Xhol into two fragment of 2,900 and 2,000 bp each. (c) Southern blot 
analysis of wild-type and T1 and T2 after DNA treatment with BamHI and Xhol agree 
with predicted Xhol treatment DNA restriction products, confirming that gliI is present in 
wild-type and has been replaced by pyrG in T1 and T2. 
  
gliI Southern WT 5’->3’ template
pyrG
5’ 3’
3’5’
5’ 3’pyrG
gliI
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Xhol Xhol
Xhol
XholXhol
2900 bp 2000 bp
3435 bp
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WT WT
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4,800bp
4,500bp
T1 T2T2T1
WT: wild-type
T1, T2: transformants
3,435bp
2,900bp
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Table A.1: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 4 
in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm.  
13C chemical shifts were determined via HMQC and 
HMBC spectra. (1H,1H)-coupling constants were determined from the 1H-NMR spectrum 
or the dqfCOSY spectrum. HMBC correlations (optimized for 6 Hz) are from the 
proton(s) stated to the indicated carbon. ROESY correlations were observed using a 
mixing time of 275 ms. Abbreviation: wk = weak, but clearly discernible ROESY 
correlation. 
 
S HN
NH
O
OOH
S
OH
4
63
110
14
8
Position δC  Proton δH (JHH [Hz]) HMBC ROESY 
1-NH   1-NH 9.32 3, 5 7-Ha, 6-S-CH3  
2 167.9        
3 69.6        
4-NH   4-NH 9.07 2, 5, 6, 8 8-Ha, 13-H (wk) 
5 165.1        
6 65.3        
6-S-CH3  12.2 6-S-CH3 2.12  
7-Ha 7-Hb, 14-H 
(wk) 
7 63.6 7-Ha 3.57 (J7-Ha,7-Hb = 11) 5, 6 7-Hb 
 
 7-Hb 3.88 2, 5, 6   
8 44.7 8-Ha 
2.89 (J8-Ha,8-Hb = 16,  
J8-Ha,10-H = 2,  
J8-Ha,12-H <1,  
J8-Ha,13-H < 1) 
2, 3, 9, 10, 14 7-Hb, 10-H 
 
 8-Hb 
3.40 (J8-Hb,10-H = 2,  
J8-Ha,12-H <1,  
J8-Hb,13-H < 1,  
J8-Hb,14-H = 2)  
2, 3, 9, 10, 15 14-H, 10-H 
9 141.1        
10 115.8 10-H 5.77 (J10-H,11-H = 6.7) 14 11-H 
11 123.9 11-H 
5.85 (J11-H,12-H = 10,  
J11-H,13-H = 3) 
9 12-H 
12 133.1 12-H 
5.66 (J12-H,13-H = 3,  
J12-H,14-H < 1) 
10, 13, 14 13-H 
13 73.3 13-H 4.44 (J13-H,14-H = 15) 9, 14   
14 57.1 14-H 4.21 9, 13 7-Ha, 6-S-CH3 
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Table A.2: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 5 in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. 13C chemical shifts were determined via HMQC and HMBC spectra. (1H,1H)-coupling 
constants were determined from the 1H-NMR spectrum or the dqfCOSY spectrum. HMBC 
correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
Abbreviation: wk = weak, but clearly discernible HMBC. 
 
Position δC  Proton δH (JHH [Hz]) HMBC 
1-N         
1-N-CH3  27.8 1-N-CH3 3.20 2, 6 
2 165.9       
3 74.6       
4-N         
5 162.7       
6 78.1       
7 60.4 7-Ha 4.35 (J7-Ha,7-Hb = 13)  5, 6 
    7-Hb 4.46 5 
7-OH   7-OH     
8 36.9 8-Ha 
3.40 (J8-Ha,8Hb = 19, 
J8-Ha,10-H < 1,  
J8-Ha,12-H < 1)  
2, 3, 8, 9, 10, 
11(wk), 14 
    8-Hb 
4.19 (J8-Hb,10-H < 1, 
J8-Hb,12-H < 1) 
2, 3, 8, 9, 10, 
11(wk), 13, 14 
9 132.0       
10 117.1 10-H 6.88 (J10-H,11-H = 8)  8, 14 
11 129.6 11-H 7.16 (J11-H,12-H = 7)  9, 13 
12 117.9 12-H 6.83 14 
13 145.9       
13-OH   13-OH 10.73 11(wk), 12, 13, 14 
14 124.9       
N N
OH
O
O
HO
S S
5
6
3
1
10
13
83 
 
Table A.3: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 9 in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. 13C chemical shifts were determined via HMQC and HMBC spectra. (1H,1H)-coupling 
constants were determined from the 1H-NMR spectrum or the dqfCOSY spectrum. HMBC 
correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
Abbreviation: wk = weak, but clearly discernible HMBC. 
 
Position δC  Proton δH (JHH [Hz]) HMBC 
1-N         
1-N-CH3  29.0 1-N-CH3 3.12 2, 6 
2 165.8       
3 72.1       
3-S-CH3 14.8 3-S-CH3 2.21 3 
4-N         
5 165.7       
6 73.4       
6-S-CH3 13.6 6-S-CH3 2.31 6 
7 64.4 7-Ha 
3.91 (J7-Ha,7-Hb = 12,  
J7-Ha,7-OH = 2)  
2, 6 
    7-Hb 4.29 (J7-Hb,7-OH = 2) 2 
7-OH   7-OH 5.74   
8 40.0 8-Ha 
3.47 (J8-Ha,8Hb = 17,  
J8-Ha,10-H < 1,  
J8-Ha,12-H < 1)  
3, 9, 10, 14 
    8-Hb 
3.55 (J8-Hb,10-H < 1,  
J8-Hb,12-H = < 1) 
2, 3, 9, 10, 13(wk), 
14 
9 132.9       
10 117.4 10-H 6.90 (J10-H,11-H = 8)  8, 12, 13, 14 
11 129.8 11-H 7.19 (J11-H,12-H = 7)  9, 13  
12 118.1 12-H 6.86 10, 13, 14 
13 147.3       
13-OH   13-OH 10.27 11, 12, 13, 14 
14 128.6       
 
N N
OH
O
O
HO
S
S
9
6
3 1
10
13
84 
 
Table A.4: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 12 in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. 13C chemical shifts were determined via HSQCAD and HMBC spectra.  (1H,1H)-
coupling constants were determined from the 1H-NMR spectrum or the dqfCOSY spectrum. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-NH   1-NH 6.40 or 6.85   
2 166.2      
3 69.1      
3-S-CH
3
  13.2  2.18 3 
4-NH   4-NH 6.40 or 6.85   
5 166.5      
6 57.6 6-H 
3.15 (J
6-H,7-Ha
 = 7,  
J
6-H,7-Hb
 = 6)  
5 
7  63.5 7-Ha 
3.53 (J
7-Ha,7-Hb 
= 12,  
J
7-Ha,7-OH
 = 8)  
  
 
 7-Hb 3.66   
7-OH   7-OH 3.17   
8 45.6 8-Ha 2.96 (J8-Ha,8-Hb = 13)  2, 3, 9, 10, 14 
 
 8-Hb 3.51 3, 9, 10, 14 
9 135.7      
10, 14 131.5 10-H, 14-H 7.25 8, 10, 12, 14 
11, 13 129.1 11-H, 13-H 7.30 9, 11, 13 
12 128.6 12-H 7.27 10, 14 
 
  
HN
NH
OH
O
O
S
12
6
3
110
85 
 
Table A.5: 1H (600 MHz) NMR spectroscopic data for compound 12 in DMSO-d6. Chemical 
shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm. (
1H,1H)-coupling constants were 
determined from the 1H-NMR spectrum. ROESY correlations were observed using a mixing time 
of 350 ms. Coupling multiplicities are annotated as: s, singlet; d, doublet; dd, doublet of 
doublets; m, multiplet. 
 
Position Proton δH (J [Hz]) ROESY  
1-NH 1-NH 8.04 (s) 6-H, 7-Ha, 7-OH 
2      
3      
3-S-CH
3
  3-S-CH3 2.18 (s) 4-H, 8-Hb, 7-OH 
4-NH 4-NH 8.80 (s) 8-Ha, aromatic-H (7.20) 
5      
6 6-H 3.14 (m) 7-OH 
7 7-Ha 3.42 (m) 7-Hb, 7-OH 
 
7-Hb 3.63 (m) 7-Ha, 7-OH 
7-OH 7-OH 4.96 (dd, J = 5, J = 6)    
   (No signal upon D2O addition)   
8 8-Ha 2.92 (d, J = 13)  8-Hb, aromatic-H (7.24) 
 
8-Hb 3.41 (d, J = 13) 8-Ha, aromatic-H (7.24) 
9      
phenyl  7.25 - 7.21   
  
HN
NH
OH
O
O
S
12
6
3
110
86 
 
Table A.6: 1H (900 MHz) and 13C (227 MHz) NMR spectroscopic data for compound 13 in 
DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via gHMQC and gHMBCAD 
spectra. (1H,1H)-coupling constants were determined from the 1H-NMR spectrum. Coupling 
multiplicities are annotated as: s, singlet; d, doublet; dd, doublet of doublets; and t, triplet. 
ROESY correlations were observed using a mixing time of 250 ms. gHMBCAD correlations 
(optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (J [Hz]) ROESY gHMBC 
1-NH  1-NH 8.67 (s) 6-S-CH3  3, 5 
2 165.7  
  
  
3 65.0   
  
  
3-S-CH3 13.0 3-S-CH3 2.25 (s)  
3 
4-NH  4-NH 8.51 (s) 3-S-CH3, 10-H  2, 6 
5 165.3  
  
  
6 65.6  
  
  
6-S-CH3 14.4 6-S-CH3 2.14 (s)  
6 
7 64.6 7-Ha 
3.45 (dd, J7Ha,7Hb = 11
,  
J7Ha,OH = 6) 
7-OH 5, 6 
 
 7-Hb 
3.65 (dd, J7Ha,7Hb = 11,  
J7Hb,OH = 6) 
7-OH   
7-OH  7-OH 5.14 (t, J = 6) 
 
  
8 45.9 8-Ha 3.16 (d, J8Ha,8Hb = 15)  
2, 3, 9, 14 
 
 8-Hb 3.41 (d, J8Ha,8Hb = 15) 10-OH  10 
9 122.0  
  
  
10 130.3 10-H 7.20 (d, J = 8) 8-Ha, 8-Hb 12 
11 118.6 11-H 6.63 (t, J = 8) 10-H 9, 13 
12 127.5 12-H 7.00 (t, J = 8) 11-H 10 
13 114.9 14-H 6.76 (d, J = 8) 12-H, 10-OH, 11 
14 155.3  
  
  
14-OH  14-OH 9.41 (s) 13-H 9, 14 
  
HN
NH
OH
O
O
S
S
OH
13
6
3
1
10
87 
 
Table A.7: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 14a in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. (1H,1H)-coupling constants were determined from the 1H-NMR spectrum or the 
dqfCOSY spectrum. 13C chemical shifts were determined via HSQCAD and HMBC spectra. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-N        
1-N-O-CH3  62.0 1-N-O-CH3 3.52   
2 163.0      
3 68.8      
3-S-CH3 13.4 3-S-CH3 2.19 3 
4-NH  4-NH 7.02   
5 165.2      
6 63.3 6-H 
3.46 (J6-H,7-Ha = 5,  
J6-H,7-Hb = 5)  
5 
7 59.2 7-Ha 3.77 (J7-Ha,7-OH = 6)  5 
 
 7-Hb 3.78 (J7-Hb,7-OH = 6)    
7-OH  7-OH 3.12   
8 46.9 8-Ha 3.00 (J8-Ha,8-Hb = 13)  2, 3, 9, 10, 14 
 
 8-Hb 3.51 2, 3, 9, 10, 14 
9 135.3      
10, 14 131.7 10-H, 14-H 7.20 
8, 12, 11, 10, 
13, 14 
11, 13 129.4 11-H, 13-H 7.30 9, 11, 13 
12 128.5 12-H 7.28   
  
HN
N
OH14a
O
O
S
O
6
3
110
88 
 
Table A.8: 1H (600 MHz), and 15N (62 MHz) spectroscopic data for compound 14a DMSO-d6. 
Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm. (
1H,1H)-Coupling constants 
were determined from the 1H-NMR spectrum. Coupling multiplicity are annotated as: s, singlet; 
d, doublet; ddd, doublet of doublets of doublets; t, triplet; m, multiplet. ROESY correlations were 
observed using a mixing time of 250 ms. 15N-gHMBCAD correlations (optimized for 8 Hz) are 
from the proton(s) stated to the indicated nitrogen. 
 
Position Proton δH (J [Hz]) ROESY 
15N-gHMBC δ 15N  
1-N        185.4  
1-N-O-CH3  3.44 (s) aromatic-H (7.18 ppm) 1-N   
2          
3          
3-S-CH3  2.17 (s) 
4-H, 8-Ha, 8-Hb,  
7-OH 
    
4-NH 4-NH 9.00 (s) 
8-Ha, aromatic-H 
(7.18 ppm) 
4-NH (residual 
1 bond) 
130.0  
5          
6  3.57 (t, J = 2)  7-Ha, 7-Hb, 7-OH     
7 7-Ha 
3.62 (ddd, J = 
11,  
J = 5, J = 3)  
7-Hb     
 
7-Hb 
3.67 (ddd, J = 
11,  
J = 5, J = 2) 
7-Ha     
7-OH 7-OH 5.11 (t, J = 5)        
8 8-Ha 2.99 (d, J = 13) 
8-Hb, aromatic-H  
(7.18 ppm, 7.22 ppm) 
    
 
8-Hb 3.38 (d, J = 13)  
8-Ha, aromatic-H  
(7.18 ppm, 7.22 ppm) 
4-N    
9          
phenyl  7.28-7.19 (m)       
  
HN
N
OH14a
O
O
S
O
6
3
110
89 
 
Table A.9: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 14b in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. 13C chemical shifts were determined via HSQCAD and HMBC spectra. (1H,1H)-
coupling constants were determined from the 1H-NMR spectrum or the dqfCOSY spectrum. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-N        
1-N-O-CH3  62.9 1-N-O-CH3 3.74   
2 163.8      
3 68.2      
3-S-CH3  13.1 3-S-CH3 2.14 3 
4-NH   4-NH 6.75   
5 165.9      
6 64.6 6-H 
4.28 (J6-H,7-Ha = 4,  
J6-H,7-Hb = 3 ) 
5 
7 60.1 7-Ha 
3.56 (J7-Ha,7-Hb = 12,  
J7-Ha, 7-OH = 6)  
  
 
 7-Hb 3.61 (J7-Hb,7-OH = 6)    
7-OH   7-OH 2.78   
         
8 44.9 8-Ha 3.11 (J8-Ha,8-Hb = 14)  2, 3, 9, 10 
 
 8-Hb 3.55   
9 135.3      
10,14 132.0 10-H, 14-H 7.24 8, 10, 14, 12 
11,13 129.2 11-H, 13-H 7.30   
12 128.3  7.26   
  
HN
N
OH14b
O
O
S
O
6
3
110
90 
 
Table A.10: 1H (600 MHz), and 15N (62 MHz) spectroscopic data for compound 14b DMSO-d6.  
Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm . (
1H,1H)-Coupling constants 
were determined from the 1H-NMR spectrum. Coupling multiplicity are annotated as: s, singlet; 
d, doublet; t, triplet; and m, multiplet. ROESY correlations were observed using a mixing time of 
250 ms. 15N-gHMBCAD correlations (optimized for 8 Hz) are from the proton(s) stated to the 
indicated nitrogen. 
 
Position Proton δH (J [Hz]) ROESY 
15N-gHMBC δ 15N  
1-N        184.5  
1-N-O-CH3  1-N-O-CH3 3.67 (s) 3-H, 6-H, 3-S-CH3,  1-N   
2          
3          
3-S-CH3  3-S-CH3 2.15 (s) 6-H     
4-NH  8.85 (s) 
8-Ha, 8-Hb, 
aromatic-H (7.20 
ppm)  
    
5          
6 6-H 4.32 (broad-t, J = 3)  7-Ha, 7-Hb     
7 7-Ha 3.51 (m) 7-Hb, 7-OH     
 
7-Hb 3.51 (m) 7-Ha, 7-OH     
7-OH 7-OH 4.67 (t, J = 5)        
   
(No signal upon D2O 
addition) 
      
8 8-Ha 3.03 (d, J = 14)  
aromatic-H (7.20 
ppm)  
    
 
8-Hb 3.49 (d, J = 14)  
aromatic-H (7.20 
ppm)  
    
9          
phenyl  7.23-7.19 (m)       
  
HN
N
OH14b
O
O
S
O
6
3
110
91 
 
Table A.11: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 15a 
(major diastereomer, diastereomeric ratio 15a:15b = 6:4) in DMSO-d6. Chemical shifts were 
referenced to δ(CHD2SOCD3) = 2.50 ppm and δ(
13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts 
were determined via HMQC and HMBC spectra. (1H,1H)-coupling constants were determined 
from the 1H-NMR spectrum or the dqfCOSY spectrum. HMBC correlations (optimized for 6 Hz) 
are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-NH   1-NH 9.06 3, 5 
2 164.7       
3 91.8       
4-NH   4-NH 9.61 2, 6 
5 165.8       
6 66.2       
6-S-CH3  12.2 6-S-CH3 2.19 6 
7 64.6 7-Ha 
3.53 (J7-Ha,7-Hb = 11, 
J7-Ha,7-OH = 5) 
5 
    7-Hb 3.89 (J7-Hb,7-OH = 6    
7-OH   7-OH 5.41 6 
8 38.5 8-Ha 3.19 (J8-Ha,8-Hb = 16) 2, 3, 9, 14 
    8-Hb 3.83 2, 9, 14 
9 125.4       
10 124.3 10-H 7.23 (J10-H,11-H = 7) 12 
11 120.9 11-H 6.89 (J11-H,12-H = 7) 9, 13 
12 127.7 12-H 7.13 (J12-H,13-H = 7) 10, 14 
13 108.7 13-H 6.77 9, 11 
14 156.9 14-H     
  
O N
NH
O
O
OH
S
H
63
110
714
15a
92 
 
Table A.12: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 15b 
(minor diastereomer, diastereomeric ratio 15a:15b = 6:4) in DMSO-d6. Chemical shifts were 
referenced to δ(CHD2SOCD3) = 2.50 ppm and δ(
13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts 
were determined via HMQC and HMBC spectra.  (1H,1H)-coupling constants were determined 
from the 1H-NMR spectrum or the dqfCOSY spectrum. HMBC correlations (optimized for 6 Hz) 
are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-NH   1-NH 8.99 3, 5 
2 164.8       
3 91.5       
4-NH   4-NH 9.56 2, 6 
5 165.1       
6 68.2       
6-S-CH3  11.6 6-S-CH3 2.07 6 
7 64.6 7-Ha 
3.52 (J7-Ha,7-Hb = 11, 
J7-Ha,7-OH = 5) 
5 
    7-Hb 3.89 (J7-Hb,7-OH = 6    
7-OH   7-OH 5.54   
8 40.3 8-Ha 3.23 (J8-Ha,8-Hb = 16) 2, 9, 14 
    8-Hb 3.74   
9 125.5       
10 124.3 10-H 7.20 (J10-H,11-H = 7) 12 
11 120.8 11-H 6.88 (J11-H,12-H = 7) 9, 13 
12 127.9 12-H 7.13 (J12-H,13-H = 7) 10, 14 
13 108.5 13-H 6.76 9, 11 
14 157.4 14-H     
  
O N
NH
O
O
OH
S
H
63
110
714
15b
93 
 
Table A.13: 1H (900 MHz) and 13C (227 MHz) NMR spectroscopic data for compound 16 in 
DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via gHMBCAD spectra. 
(1H,1H)-coupling constants were determined from the 1H-NMR spectrum. Coupling multiplicities 
are annotated as: s, singlet; d, doublet; t, triplet; dt, doublet of triplets; and m, multiplet. 
gHMBCAD correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
carbon. ROESY correlations were observed using a mixing time of 250 ms. 
 
Position δC Proton δH (J [Hz]) gHMBC ROESY 
1-N          
1-N-CH3  32.0 1-N-CH3 2.93 2, 6 6-H, 7-H 
2 165.4        
3 88.9        
3-OH   3-OH 6.25 (d, J = 1)  8, 3 7-Ha, 7-Hb, 8-Ha 
4-N          
5 168.6        
6 64.9 6-OH 4.21 (t, J = 3 ) 5 7-Ha, 7-Hb, 8-Hb 
7 59.9 7-Ha 
3.81 (dt, J = 4,  
J = 11)  
  7-OH 
 
 7-Hb 
3.91 (dt, J = 4,  
J = 11)  
  7-OH 
7-OH   7-OH 6.47 (t, J = 4)  7, 6   
8 40.3 8-Ha 2.72 (d, J = 16)  3, 9, 10, 14 10-H, 14-H 
 
 8-Hb 2.82 (d, J = 16)    10-H 
9 117.8        
10 134.5 10-H 5.89 (m)   11-H 
11 118.4 11-H 5.89 (m)   12-H 
12 130.4 12-H 5.58 (m) 11 13-H 
13 73.7 13-H 4.52 (d, J = 14)    13-OH 
13-OH   13-OH 5.98 (s) 12, 13, 14 14-H 
14 67.9 14-H 4.69 (d, J = 14)      
N N
OH
O
O
HO
OH
6
3 1
10
13
16
94 
 
Table A.14: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 17 in 
acetonitrile-d3. Chemical shifts were referenced to δ(CHD2CN) = 1.94 ppm and δ(
13CHD2CN) = 
1.3 ppm. 13C chemical shifts were determined via HSQCAD and HMBC spectra. (1H,1H)-
coupling constants were determined from the 1H-NMR spectrum or the dqfCOSY spectrum. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated carbon. 
 
Position δC Proton δH (JHH [Hz]) HMBC 
1-N        
1-N-CH3  31.6 1-N-CH3 3.07 2, 6 
2 157.8      
3 117.7 (DMSO-d6)       
4-N        
5 166.0      
6 67.0 6-H 
4.32 (J6-H,7-Ha = 2,  
J6-H,7-Hb = 3)  
2, 5 
7 62.4 7-Ha 
3.99 (J7-Ha,7-Hb = 12,  
J7-Ha,7-OH = 6)  
  
 
 7-Hb 4.08 (J7-Hb,7-OH = 6)   
7-OH   7-OH 3.35   
8 110.1 8-H 7.36 9, 10, 13, 14 
9 119.1      
10 108.9 10-H 7.90 (J10-H,11-H = 8) 9, 12 
11 129.8 11-H 7.34 (J11-H,12-H = 9) 13, 14 
12 110.6 12-H 6.81 9, 10, 14 
13 151.9      
13-OH    7.70   
14 137.0      
  
N N
OH
O
O
HO
17
6
3 1
13
10
95 
 
Table A.15: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 17 in 
DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via HMBC spectra and 
HSQCAD. HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
carbon. (1H,1H)-coupling constants were determined from the 1H-NMR spectrum. Coupling 
multiplicities are annotated as: s, singlet; d, doublet; t, triplet; dd, doublet of doublets; ddd, 
doublet of doublet of doublets; m, multiplet. 
 
Position δC Proton δH (J [Hz]) HMBC 
1-N        
1-N-CH3  30.5 1-N-CH3 3.02 (s) 2, 6 
2 156.3      
3 117.7      
4-N        
5 165.1      
6 65.8 6-H 4.49 (broad-t, J = 2)  5 
7a 60.4 7-Ha 
3.85 (ddd, J = 12, J = 6, J 
= 2) 
  
 
 7-Hb 
3.98 (ddd, J = 11, J = 5, J 
= 3) 
  
7-OH   7-OH 5.36 (t, J = 6)   
8 108.7 8-H 7.33 (d, J < 1)  3, 11, 14 
9 118.1      
10 106.6 10-H 7.79 (d, J = 8)  9, 12 
11 128.5 11-H 7.31 (t, J = 8)  13, 14 
12 109.7 12-H 6.76 (dd, J = 8, J < 1)  9, 10, 14 
13 152.0      
13-OH    10, 19 (s)  9, 12, 13, 14 
14 135.4      
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Appendix B 
A BACKUP PLAN FOR SELF-PROTECTION: S-METHYLATION OF HOLOMYCIN 
BIOSYNTHETIC INTERMEDIATES IN STREPTOMYCES CLAVULIGERUS 
1. General Analytical Methods and Equipment: (A) NMR-spectroscopy. NMR 
spectroscopic instrumentation: a Varian INOVA 600 MHz NMR spectrometer (600 MHz 
reference frequency for 1H, 151 MHz for 13C) equipped with an HCN indirect-detection 
probe. 1H,13C-(g)HMBC spectra were acquired using the following parameters: 0.25 s 
acquisition time, 256 increments and 64-128 scans per increment. PW90 was 
determined for each sample individually. Spectra were optimized for JH,C = 6 Hz. 
Gradient and non-gradient 1H,13C-HMQC[AD] spectra were acquired using the following 
parameters: 0.25 s acquisition time, 300-600 increments, 32-64 scans per increment. 
ROESY spectra were acquired using the following parameters: 0.25 s acquisition time, 
0.275 s mixing time, 200 increments, 64 scans per increment. Susceptibility-matched 
NMR tubes (Shigemi) were used for sample amounts smaller than 5 mg. NMR spectra 
were processed and baseline corrected using Varian VNMR and MestReC and 
MestReNova software packages.  
(B) Mass spectrometry. High-resolution mass spectrometry (HRMS) was 
performed on a Waters nanoACQUITY UPLC system equipped with a Waters Acquity 
UPLC HSS C18 column (2.1 x 100 mm, 1.8 µm particle diameter) connected to a Xevo 
G2 QTof Mass Spectrometer. For HPLC-MS analysis, the eluent of an Agilent 1100 
HPLC system, equipped with a diode array detector, was injected into a Quattro II 
spectrometer (Micromass/Waters) operated in positive-electrospray ionization mode 
(ESI+). HPLC/ESI+-MS data acquisition and processing was controlled by Waters 
MassLynx software.  
(C) Chromatography. Flash chromatography was performed using a Teledyne 
ISCO CombiFlash system. An Agilent Zorbax Eclipse XDB-C8 column (4.6 x 150 mm, 5 
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μm particle diameter) was used in the HPLC/ESI+-MS mutant profiling analysis and the 
crude ∆hlmI/∆ORF15 TCEP reduction experiment. 
 
2. Bacterial Strains and Experimental Growth Conditions: Bacterial strains used in 
this study include S. clavuligerus wild-type, ΔORF15, and ΔhlmI/ΔORF15. The wild-type 
and ΔORF15 were provided by Dr. Kapil Tahlan (Memorial University of Newfoundland, 
Canada). The mutant strain ΔhlmI/ΔORF15 was generated in previous work1. S. 
clavuligerus wild-type and mutants were grown in parallel under the same conditions. 
The seed cultures were started using frozen spore stocks of each strain and grown in 
250 mL flasks containing 50 mL Tryptic Soy Broth (TSB) at 30 °C for 24-36 h until 
dense. The OD600 nm was measured after a 16-fold dilution. The amount of seed culture 
for inoculation was calculated to achieve an inoculating OD600 nm of 0.25 in a 50 mL 
volume. The normalized amount of seed cultures was spun down and the pellets were 
washed and used to inoculate 50 mL of production medium modified GSPG in 20 × 250 
mL flasks for a 500 mL-scale growth. The modified GSPG medium contains the 
following ingredients in one liter: glycerol, 5 g; proline, 2.5 g; glutamic acid, 1.5 g; NaCl, 
5 g; K2HPO4, 2 g; CaCl2, 0.4 g; MnCl2•4H2O, 0.1 g; FeCl3•6H2O, 0.1 g; ZnCl2, 0.05 g; 
MgSO4•7H2O, 1 g; and distilled water at pH 7. The production cultures were incubated 
at 30 °C for 48 h with shaking. The resulting cultures were harvested as a mixture of 
cells and culture supernatant and frozen at −20 °C. 
 
3. Culture Extraction, Sample Enrichment, and NMR Sample Preparation: Whole 
liquid cultures of the various S. clavuligerus mutants examined were frozen and 
lyophilized. The residue was extracted with a 10% water in acetonitrile solution v/v (1 
mL extraction solution per 5 mL liquid culture). The resulting extract was filtered over 
acetonitrile- and water-washed cotton. The extraction process was repeated twice more 
(1 mL extraction solution per 10 mL liquid culture). The extracts were evaporated to 
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dryness and absorbed onto 3 g of octadecyl-functionalized silica gel. The samples were 
then fractionated on a 100 g RediSep Reverse-Phase (RP) C18 Gold flash 
chromatography column using a water-acetonitrile solvent gradient (flow rate 75 
mL/min), starting with 5 min of 5% acetonitrile followed by a linear increase to 20% 
acetonitrile over 12.5 min, followed by a linear increase to 65% acetonitrile over 5 min, 
followed by a linear increase to 100% acetonitrile over 2 min, and ending with 6 min of 
100% acetonitrile isocratic elution. Fractions were combined into three pools; pool 1, 5-
12% acetonitrile; pool 2, 12-32% acetonitrile; pool 3, 32-100% acetonitrile. Pools were 
evaporated to dryness using rotary evaporation in vacuo at room temperature. Pool 1 
samples were dissolved in 0.6 mL 99.9% d DMSO-d6 and placed in an NMR tube. Pool 
2 and pool 3 samples were suspended in ~0.2 mL of acetonitrile-d3. The resulting 
suspensions were centrifuged to remove insoluble materials; this was repeated two 
additional times, and the supernatant was subjected to NMR spectroscopic analysis. 
4. Pool 1 Fractionation: To enrich a sample of compound 3, the pool 1 ∆hlmI/∆ORF15 
sample (see previous section, Appendix B) was subjected to flash chromatography. The 
sample was dissolved in a 10% water/acetonitrile (v/v) solution and silica gel was added 
to the solution. Solvent was removed in vacuo using rotary evaporation. The silica gel-
adsorbed sample was transferred to a loading column. Using a CombiFlash system 
equipped with a 24 g RediSep column, the sample was chromatographed utilizing a 
10% water in acetonitrile/dichloromethane (v/v) gradient (flow rate 35 mL/min) starting 
with 0% water-acetonitrile solution for 2 min, followed by a linear increase to 10% water-
acetonitrile solution over 3 min, followed by a linear increase to 20% water-acetonitrile 
solution over 2 min, followed by a linear increase to 70% water-acetonitrile solution over 
4 min, followed by a linear increase to 100% water-acetonitrile solution over 1 min, and 
ending with 6 min of 100% water-acetonitrile. The 1H spectrum for fraction 58 (eluting at 
14 min, 100% water-acetonitrile) indicated the presence of 3. 
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5. Pool 2 Fractionation: To enrich samples of 10 and 11 the pool 2 ∆hlmI/∆ORF15 
sample (see above) was subjected to flash chromatography. The sample was dissolved 
in water and deposited onto a loading column containing 4 g of octadecyl-functionalized 
silica gel. Using a CombiFlash system equipped with a 13 g RediSep C18 column, the 
sample was chromatographed utilizing a water (containing 0.1% acetic acid)/acetonitrile 
gradient (flow rate 30 mL/min) starting with 5% acetonitrile for 0.9 min, followed by a 
linear increase to 20% acetonitrile over 3 min, followed by a linear increase to 55% 
acetonitrile over 0.9 min, followed by a linear increase to 100% acetonitrile over 0.4 min, 
and ending with 0.9 min of 100% acetonitrile. The 1H spectra acquired for pooled 
fractions 12-15 (17-19% acetonitrile) and fractions 18-23 (32-65% acetonitrile) showed 
the presence of compounds 10 and 11, respectively. 
6. HPLC-ESI+-MS Mutant Extract Profiling and ∆hlmI/∆ORF15 TCEP-Reduction 
Experiment: Unless otherwise specified, samples utilized in our HPLC/ESI+-MS studies 
were prepared by suspending the crude bacterial extract in 1 mL of a 9:1 mixture of 
water and acetonitrile (v/v), followed by filtration of the extract through cotton. 3 µL of 
sample was injected into an Agilent 1100 series HPLC equipped with an Agilent Zorbax 
Eclipse XDB-C8 column. A water (0.1% acetic acid)/acetonitrile gradient starting with 
5% acetonitrile (v/v) for 5 min, followed by a linear increase to 100% acetonitrile over 15 
min and ending with 10 min of 100% acetonitrile, was used as mobile phase. The HPLC 
eluent was split (1:10) into a Quattro II triple quadrupole mass spectrometer operated in 
ESI+ mode. HPLC/ESI+-MS data were processed in MassLynx software, and peak 
areas were measured using a peak-to-peak amplitude of 20 with no smoothing applied 
(see Appendix B Figure B.4 for ion chromatograms corresponding to compounds 3, 5, 
6, and 8-11.)  
7. MS and MSMS Analysis of Compounds 3, and 5-11: (A) HRMS, compounds 3, 
and 5-11. Enriched samples of 3, and 5-11 were dissolved in 200–500 µL of either 10% 
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water in acetonitrile (v/v) or 100% acetonitrile and injected into the UPLC/ESI+-HRMS 
system described above. Various chromatographic solvent gradients were used; all 
using water (0.1% formic acid) and acetonitrile (0.1% formic acid) as solvents. Mass 
spectra were acquired in ESI+ mode. 
Compound Observed 
m/z 
Ion Ion Formula Calculated 
m/z 
3 231.0257 [M + H]+ C8H11N2O2S2
+ 231.0256 
3 253.0081 [M + Na]+ C8H10N2NaO2S2
+ 253.0076 
3 189.0160 [M + H - C2H2O]
+ C6H9N2OS2
+ 189.0151 
5 203.0309 [M + H]+ C7H11N2OS2 203.0307 
6 385.0456 [M + H]+ C14H17N4O3S3
+ 385.0457 
7 392.1107 [M + H]+ C18H22N3O3S2
+ 392.1097 
8 459.0284 [M + H]+ C16H19N4O4S4
+ 459.0284 
8 481.0095 [M + Na]+ C16H18N4NaO4S4
+ 481.0103 
8 229.0103 [M - -C8H9N2O2S2]
+,  
heterolytic S-S bond 
cleavage, 
C8H9N2O2S2
+ 229.0105 
8 231.0260 [M + 2H - 
C8H9N2O2S2]
+, 
homolytic S-S bond 
cleavage 
C8H11N2O2S2
+ 231.0256 
9 438.9987 [M + Na]+ C14H16N4NaO3S4
+ 438.9997 
9 231.0248 [M + 2H - C6H7N2OS2]
+, 
homolytic S-S bond 
cleavage 
C8H11N2O2S2
+ 231.0256 
10 245.0418 [M + H]+ C9H13N2O2S2
+ 245.0413 
10 267.0233 [M + Na]+ C9H12N2NaO2S2
+ 267.0232 
10 203.0306 [M + H - C2H2O]
+ C7H11N2OS2
+ 203.0307 
11 219.0259 [M + H]+ C7H11N2O2S2
+ 219.0256 
11 241.0079 [M + Na]+ C7H10N2NaO2S2
+ 241.0076 
11 459.0253 [2M + Na]+ C14H20N4NaO4S4
+ 459.0260 
 
(B) Compound 7 UPLC/ESI+-HRMSMS analysis. The enriched sample of 
compound 7 (see Appendix B, section 8) was dissolved in 500 µL of acetonitrile. 10 µL 
of the sample was injected into the UPLC/ESI+-HRMS system described above, using a 
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water (0.1% formic acid)/acetonitrile (0.1% formic acid) gradient starting with 2 min at 
5% acetonitrile, followed by a linear increase to 100% acetonitrile over 10 min, ending 
with 6 min at 100% acetonitrile. The MS was run in ESI+ MSMS mode using a ramped 
collision energy of 15-45 eV. The range 50-500 m/z was scanned for daughter ions of 
[M + H]+ = 392.1124 m/z.  
 
Observed (m/z) Ion Ion Formula Calculated m/z 
392.1124 [M + H]+ C18H22N3O3S2
+ 392.1097 
350.1017 [M + H - C2H2O]
+ C16H20N3O2S2
+ 350.0991 
288.0497 [M + H - C8H8]
+ C10H14N3O3S2
+ 288.0471 
229.0122 [M - C10H12NO]
+ C8H9N2O2S2
+ 229.0100 
187.0006 [M - C10H12NO - C2H2O]
+ C6H7N2OS2
+ 186.9994 
171.9767 [M - C10H12NO - C2H2O - CH3]
·+ C5H4N2OS2 171.9760 
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(C) Targeted profiling of compounds in S. clavuligerus strains by MS. 
 
Figure B.1: Targeted compound profiling for strains: wild-type, ∆ORF15, and 
∆hlmI/∆ORF15. The amounts of compounds 1, 6, 8, and 10 were determined relative to 
∆hlmI/∆ORF15, arbitrarily set to 100 %. Relative values were measured using 
HPLC/ESI+-MS ion chromatogram peak areas. Where no bar is present, the indicated 
metabolite was not detected. Compounds 3, 5, 9, and 11are omitted from this plot 
because they are only found in the ∆hlmI/∆ORF15 strain. 
8. Chemical Derivatization Procedures: (A) S-alkylation of crude ∆hlmI/∆ORF15 
supernatant extract with iodoacetamide. A 10 mL culture of the ∆hlmI/∆ORF15 strain 
was grown at 30 °C for 4 days. A sample of 70 µL of the filtered culture supernatant was 
mixed with 10 µL of 300 mM iodoacetamide and 20 µL of 0.5 M NH4HCO3 buffer (pH 
7.8). The reaction was incubated at room temperature for 30 min (protected from light) 
and quenched with 0.1% formic acid. A sample of 10 µL of the resulting mixture was 
injected into a LC/ESI+-HRMS Q-Tof instrument (Agilent Technologies 6520) on a C18 
column (Phenomenex Gemini-NX 5 µ, 50 × 2 mm) for detection of alkylated 
dihydroholomycin via positive electrospray ionization (ESI+). The chromatography 
solvent consisted of a water (0.1% formic acid)/acetonitrile (0.1% formic acid) gradient 
starting with 2 min at 2% acetonitrile, followed by a linear increase to 100% acetonitrile 
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over 10 min, ending with 3 min at 100% acetonitrile. The ion chromatogram was 
generated using the mass spectral signal at m/z 288.0471 with 20 ppm error window. 
Holomycin was isolated and purified from S. clavuligerus following the same 
procedure as previously described.2 Alternatively, it was synthesized via the procedure 
of Hjelmgaard et al.3 A sample of 5 µL of 1 mM holomycin, dissolved in DMSO, was 
mixed with 5 µL of 1.5 mM TCEP, 10 µL of 500 mM NH4HCO3 buffer (pH 7.8), and 25 
µL of milli-Q water. A sample of 5 µL of 300 mM iodoacetamide was added to the 
reaction mixture and incubated at room temperature for 15 min. The reaction was 
quenched with 0.1% formic acid and filtered. A sample of 10 µL of the mixture was 
injected into the Q-Tof LC/ESI+-HRMS instrument, running in ESI+ mode, for detection of 
alkylated dihydroholomycin. Ion chromatograms were generated using the mass 
spectral signals at m/z 274.0315 (mono-IAA adduct) and 331.0529 (bis-IAA adduct, 4) 
using a 20 ppm error window.  
(B) Preparation of dimethyl-dihydroholomycin standards. Dimethyl-
dihydroholomycin was prepared from holomycin under similar conditions as the 
diacetamidio-derivative (4) in a larger scale substituting iodoacetamide with methyl 
iodide. A mixture of isomers was generated and purified by HPLC. 1H NMR (300 MHz; 
DMSO-d6): δ(ppm) 10.22 (s), 9.39 (s), 6.17 (s), 2.46 (s), 2.32 (s), 1.97 (s). 
13C NMR (75 
MHz; DMSO-d6) (ppm) 169.3, 166.8, 134.2, 133.2, 129.4, 112.9, 55.8, 49.5, 23.4, 18.0, 
16.8. ESI+-MS m/z, calculated 245.0413, observed 245.0410 [M + H]+.  
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(C) S-alkylation of enriched compound 3 with 2-iodo-N-(1-
phenylethyl)acetamide. An enriched sample of 3 (Appendix B, section 4, pool 1 
fractionation) was dissolved in 500 µL of dry DMF. While stirring, 50 µL of a DMF 
solution containing 2-iodo-N-(1-phenylethyl)acetamide (52 mM) and triethylamine (690 
mM) was added. The reaction was stirred for 4 h, followed by removal of volatiles under 
rotary evaporation. The residue was redissolved in 0.3 mL of CDCl3 and analyzed by 
NMR spectroscopy using a CDCl3 susceptibility-matched Shigemi tube.  
 
 
 
(D) TCEP reduction of disulfides in crude ∆hlmI/∆ORF15. HPLC/ESI+-MS ion 
chromatogram of ∆hlmI/∆ORF15 extracts showed three chromatographic peaks with 
m/z values and isotope patterns consistent with the molecular ion of compound 3 
(Figure 2), of which the earliest-eluting peak represented compound 3, whereas the two 
late-eluting peaks additionally included mass spectral signals at m/z 417.0 and 439.0. 
These signals had diagnostic isotopic patterns suggesting the presence of four sulfur 
atoms. It was hypothesized that the signals at m/z 417.0 and 439.0 belong to a 
heterodimeric oxidation product of 3, in which a disulfide bond has been formed 
between 3 and a non-N-acylated derivative of 3 (9, [M + H]+ = 417.0 m/z, [M + Na]+ = 
439.0 m/z). A putative homodimeric product of 3 was also observed (8, [M + H]+ = 459.0 
m/z). The structures of 8 and 9 (Figure 2) were investigated using both chemical 
modification and UPLC/ESI+-HRMS analysis.  
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To test the hypothesis that the disulfide homo (8) and heterodimers (9) stem from 
the oxidation of free 3, a sample of ∆hlmI/∆ORF15 extract was reacted with the 
reducing reagent tris(2-carboxyethyl)phosphine (TCEP) and changes in the distribution 
of 3, 8, and 9 were monitored via HPLC/ESI+-MS (see scheme below). 500 µL of a 
solution of TCEP (800 mM) in 10% water in acetonitrile (v/v) was added to 10 mg of 
∆hlmI/∆ORF15 extract. 500 µl of 10% water in acetonitrile was added to 10 mg of a 
crude ∆hlmI/∆ORF15 extract as a negative control. Solutions were allowed to stir for 1 
hour. The reaction mixtures were analyzed by HPLC/ESI+-MS as described above in 
section 6, which showed that the ∆hlmI/∆ORF15 extract treated with TECP did not 
contain 8 and 9, whereas the corresponding untreated ∆hlmI/∆ORF15 control produced 
peaks for both compounds. The HPLC/ESI+-MS ion chromatogram of the TCEP-treated 
∆hlmI/∆ORF15 extract contained four early eluting peaks with the mass and isotopic 
distribution of 3; likely a combination of regio and stereoisomers of 3. Follow-up 
UPLC/ESI+-HRMS analysis of 8 and 9 showed exact masses and MS fragmentation 
supporting our structural hypotheses (section 7 above). 
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9. UV Shifts of Holomycin and Derivatives: 
 
Figure B.2: UV spectra of holomycin and derivatives described in Chapter 2. Holo-
H2, dihydroholomycin; Me-holo-H2, monomethyl-dihydroholomycin from the culture of 
ΔORF15/ΔhlmI mutant strain; Me2-holo-H2, synthesized dimethyl-dihydroholomycin 
standard; Me-holo-H2-IAA, iodoacetamide adduct of monomethyl-dihydroholomycin 
from the culture of ΔORF15/ΔhlmI mutant strain. The X axis is wavelength in nm and 
the Y axis is UV absorbance normalized to 100% for each spectrum. 
 
10. Quantification of Compounds 3, 5, 6, 10 and 11 in ∆hlmI/∆ORF15 Extracts: A 
500 ml culture of ∆hlmI/∆ORF15 was extracted, fractionated into three pools, and 
analyzed by 1H NMR spectroscopy as described above. To estimate the amounts of 3, 
5, 6, 10, and 11, the methine 1H singlets, corresponding to H-1, were integrated relative 
to either the CHD2CN (99.8%-d, d3-acetonitrile) or CHD2SOCD3 (99.9%-d, d6-DMSO) 
signals, depending on the NMR solvent used. The amounts of 3, 5, 6, 10, and 11 
determined for each NMR sample were then divided by 500 mL to estimate the 
concentration of these metabolites in the ∆hlmI/∆ORF15 culture: 3, 0.6 µM; 5, 1.6 µM; 
6, 1.0 µM; 10, 0.4 µM; and 11, 0.3 µM.  
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11. Agar Diffusion Assay, Activity of Dimethyl-Dihydroholomycin: Spore stocks 
were prepared for wild-type, ΔhlmI, ΔORF15, and ΔhlmI/ΔORF15 strains. 
Approximately 5 × 105 spores were plated for each strain on MYM agar (4.0 g yeast 
extract, 10.0 g malt extract, 2.0 g dextrose, and 20.0 g agar per liter of media). Then a 
sample of 5 µL of 32.3 mM holomycin or dimethyl-dihydroholomycin dissolved in DMSO 
was added to the center of the plates. The plates were incubated at 30 °C for 4-7 days 
and the diameter of the inhibition zone was determined as a measurement for the 
sensitivity of these strains toward holomycin and dimethyl-dihydroholomycin. As 
observed previously, hlmI deletion strains (ΔhlmI and ΔORF15/ΔhlmI) were more 
sensitive to exogenously added holomycin than the wild-type and ΔORF15 strains, 
suggesting that the gene hlmI plays a role in self-protection in S. clavuligerus. In 
contrast, dimethyl-dihydroholomycin did not display any toxicity against all four strains 
tested. This result provides molecular evidence supporting the hypothesis that S-
methylation is a self-protection strategy that S. clavuligerus utilizes in the absence of 
hlmI. 
 
Figure B.3: Antimicrobial activities of dimethyl-dihydroholomycin and holomycin. Activity 
was compared amongst the S. clavuligerus wild-type (WT) and mutant strains.  
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Table B.1. Partial 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data, obtained 
in DMSO-d6 for a ∆hlmI/∆ORF15-derived sample containing mixture of the cis- and 
trans stereoisomer of 3. These data do not allow distinguishing between the cis and 
trans stereoisomers; therefore, the major metabolite is reported with the minor 
metabolite chemical shifts and correlations in parenthesis. Proton chemical shifts were 
referenced to δ(CHD2SOCD3) = 2.50 ppm and 
13C chemical shifts to δ(13CHD2SOCD3) 
= 39.5 ppm. 13C chemical shifts were determined via gHMBC spectra. gHMBC 
correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 13C atom. 
Abbreviation: s = singlet.  
 
Position δC Proton δH  gHMBC 
1 
103.0 
(101.9) 1-H 
5.97 (s) 
(5.90) (s) 
1-S-CH3, 6, 
(1-S-CH3, 6) 
1-S-CH3 
16.7 
(16.8) 1-S-CH3 
2.33 (s) 
(2.31) (s) 1, (1) 
2 
    3-N 
 
3-NH 
  4 
    5 
    
6 
165.1 
(160.6) 
   7-N 
 
7-NH 
  
8 
171.5 
(171.1) 
   
9 
 
9-CH3 
1.78 (s) 
(1.76) (s) 
 
NH
HS
H
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O
O
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6
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9
NH
HS
H
N
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Table B.2. 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 5 
in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via gHMBC and 
HMQC spectra. gHMBC correlations (optimized for 6 Hz) are from the proton(s) stated 
to the indicated 13C atom. ROESY correlations were observed using a mixing time of 
275 ms. Abbreviations: s = singlet, br. = broad. 
 
 
 
Position δC Proton δH  HMBC ROESY 
1 100.0 1-H 5.56 (s) 
1-S-CH3, 2, 
6  
1-S-CH3, 3-NH, 
6-SCH3  
1-S-CH3 17.3 1-S-CH3 2.33 (s) 1   
2 136.2         
3-N   3-NH 10.01 (s) 2, 5, 6   
4 165.2         
5 141.5         
6 99.2         
6-S-CH3 17.1 6-S-CH3 2.13 (s) 6, 6-S-CH3 7-NH2 
7-N   7-NH2 5.77 (br. s) 4, 6   
 
  
NH
S
H2N
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1
6
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Table B.3. 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 6 
in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via gHMBC and 
HMQC spectra. gHMBC correlations (optimized for 6 Hz) are from the proton(s) stated 
to the indicated 13C atom. ROESY correlations were observed using a mixing time of 
275 ms. Abbreviations: s = singlet, br. = broad. 
 
 
 
Position δC Proton δH  gHMBC ROESY 
1 112.7 1-H 6.18 (s) 1-S-CH3, 2, 6 
1-S-CH3, 1', 3'-
NH 
1-S-CH3 17.0 1-S-CH3 2.40 (s) 1 6'-S-CH3 (weak) 
2 131.8         
3-N   3-NH 10.32 (s) 4, 5, 6   
4 168.9         
5 128.0         
6 129.5         
7-N   7-NH not observed     
8 167.7         
9 22.3 9-CH3 1.95 (s) 8   
1' 91.2 1'-H 5.57 (s) 6, 2' 6'-S-CH3 
2' 141.5         
3'-N   3'-NH 10.27 (s) 2', 4', 5', 6'   
4' 165.4         
5' 142.8         
6' 98.1         
6'-S-CH3 17.2 6'-S-CH3 2.11 (s) 6' 7'-NH2 
7'-N   7'-NH2 6.13 (br. s) 4', 6'   
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Table B.4. 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 7 
in chloroform-d (and DMSO-d6 where indicated). Chemical shifts were referenced to 
δ(CHCl3) = 7.26 and δ(
13CHCl3) = 77.2 ppm. The gHMBC spectrum was referenced to 
δ(CHD2SOCD3) = 2.50 ppm and δ(
13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were 
determined by (g)HMBC and HSQC spectra. (g)HMBC correlations (optimized for 6 Hz) 
are from the proton(s) stated to the indicated 13C atom. J coupling constants were 
measured in the 1H spectrum. Abbreviations: s = singlet, d = doublet, q = quartet, m = 
multiplet. 
 
 
Position δC Proton δH (JHH [Hz]) (g)HMBC ROESY 
1 114.8 1-H 6.31 (s) 1-S-CH3, 2, 6 10-H 
1-S-CH3 17.8 1-S-CH3 2.49 (s) 1   
2 133.1         
3-N   3-NH 
10.33(s), DMSO-
d6  5, 6, DMSO-d6   
4 not observed         
5 
129.5, DMSO-
d6         
6 125.7         
7-N   7-NH not observed     
8 168.8         
9 23.8 9-CH3 2.15 (s) 8 10-H 
10 37.9 10-CH2 3.51 (s) 6, 11   
11 166.7         
12   12-NH not observed     
13 49.0 13-H 5.23 (dq, J = 7)  11, 15, 16, 20   
14 21.8 14CH3 1.44 (d, J = 7) 13, 15   
15 142.7         
16, 20 125.9 
16-H, 20-
H 7.24 (d, J = 8) 18   
17,19 126.1 
17-H, 19-
H 7.33 (m) 15, 17, 19   
18 127.3 18-H 7.28 (m)     
NH
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Table B.5. Partial 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for 
compound 10 in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 
ppm and δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via 
gHMBC spectra. gHMBC correlations (optimized for 6 Hz) are from the proton(s) stated 
to the indicated 13C atom. Abbreviation: s = singlet. 
 
 
 
Position δC Proton δH gHMBC 
1 111.7 1-H 6.18 (s) 1-S-CH3, 2, 6 
1-S-CH3 16.6 1-S-CH3 2.47 (s) 1 
2 131.9       
3-N   3-NH not observed   
4         
5         
6 133.0       
6-S-CH3   6-S-CH3 2.34 (s) 6 
7-N   7-NH not observed   
8 168.1       
9   9-CH3 1.98 (s) 8 
  
NH
S
H
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Table B.6. Partial 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for 
compound 11 in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 
ppm and δ(13CHD2SOCD3) = 39.5 ppm. 
13C chemical shifts were determined via 
gHMBC spectra. gHMBC correlations (optimized for 6 Hz) are from the proton(s) stated 
to the indicated 13C atom. Abbreviation: s = singlet. 
 
 
Position δC Proton δH  gHMBC 
1 105.4 1-H 5.90 (s) 1-S-CH3, 2, 6 
1-SO-CH3 40.8 1-SO-CH3 2.68 (s) 1 
2 145.2       
3-N   3-NH not observed   
4         
5         
6 95.6       
6-S-CH3   6-S-CH3 2.14 (s) 6 
7-NH2   7-NH2     
 
NH
S
H2N
O
11
S
O
1
6
7
 
 
134 
 
 
Figure B.4: Ion chromatograms representing [M + H]+ for compounds 3, 5, 6, and 
8-11. Chromatographic peak intensity was set relative to the that of the largest peak  
(compound 6). The solid red trace corresponds to compounds 3; yellow/orange trace, 
compound 11; black dotted line, compound 10; green trace, compound 8; blue trace, 
compound 6; solid black trace, compound 9; and dotted red, compound 5.
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Figure B.5: 1H NMR spectrum of crude ∆hlmI/∆ORF15 extract, 600 MHz, acetonitrile-d3.  
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Figure B.6: 1H NMR spectrum of crude ∆ORF15 extract, 600 MHz, acetonitrile-d3.  
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Figure B.7: 1H NMR spectrum of ∆hlmI/∆ORF15 pool 1 compound 3, 600 MHz, DMSO-
d6.  
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j 
Figure B.8: 1H NMR spectrum of ∆ORF15 pool 1, 600 MHz, DMSO-d6.  
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Figure B.9: 1H NMR spectrum of ∆hlmI/∆ORF15 pool 2 compounds 10 and 11, 600 
MHz, acetonitrile-d3.  
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Figure B.10: 1H NMR spectrum of ∆ORF15 pool 2, 600 MHz, acetonitrile-d3.  
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Figure B.11: 1H NMR spectrum of ∆hlmI/∆ORF15 pool 3 compounds 5 and 6, 600 MHz, 
acetonitrile-d3.  
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Figure B.12: 1H NMR spectrum of ∆ORF15 pool 3, 600 MHz, acetonitrile-d3. 
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Figure B.13: 1H NMR spectrum of synthetic dimethyl-dihydroholomycin, mixture of 
isomers, 300 MHz, DMSO-d6. 
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Figure B.14: 13C NMR spectrum of synthetic dimethyl-dihydroholomycin, mixture of 
isomers, 300 MHz, DMSO-d6.
 
 
145 
 
 
REFERENCES 
 
(1) Li, B.; Walsh, C. T. Biochemistry 2011, 50, 4615. 
(2) Li, B.; Walsh, C. T. PNAS USA 2010, 107, 19731. 
(3) Hjelmgaard, T.; Givskov, M.; Nielsen, J. Org Biomol Chem 2007, 5, 344. 
 
 
  
146 
 
Appendix C 
 
HOMOLOGOUS NON-CANONICAL NRPS GENE CLUSTERS MEDIATE 
REDUNDANT SMALL-MOLECULE BIOSYNTHESIS IN ASPERGILLUS FLAVUS 
 
1. Construction of A. flavus Strains: (A) Fusion PCR and Vector Construction. 
lnaA Constructs: Entire gene disruption and overexpression (OE) of lnaA constructs 
were created using fusion PCR.1 All gene names are listed in Table C.1, all primers 
used in this study are listed in Table C.2, all strains are listed in Table C.3. For 
replacement cassettes, 1.5 kb upstream and downstream of lnaA open reading frame 
were amplified with primers DM101700-5’For/DM101700-5’Rev for upstream and 
DM101700-3’For/DM101700-3’Rev for downstream using NRRL3357 wild-type gDNA 
as template for PCR. These PCR fragments were fused with the A. fumigatus AF293 
pyrG gene following.2 Final PCR products were amplified with nested primers; 
DM101700-nestedFor and DM101700-nestedRev. The final PCR products with nested 
primers were confirmed by endonuclease digestion. To create the OE::lnaA cassettes, 4 
PCR fragments were created and fused in this order: 1.5 kb of lnaA upstream fragment, 
1.97 kb A. fumigatus pyrG, 1.5 kb A. nidulans gpdA promoter, and 1.5 kb lnaA open 
reading frame. First, the A. fumigatus pyrG and A. nidulans gpdA PCR fragments were 
fused using the same A. fumigatus pyrG primer set as described above and 
gpdA(p)::pyrGFor and A. nidulans gpdA(p)Rev primers for the gdpA fragment. Next, the 
lnaA upstream (using OE101700-5’For and OE101700-5’Rev) and lnaA open reading 
frame (OE101700-ORFFor and OE101700Rev) PCR fragments were fused to the A. 
fumigatus pyrG::A.nidulans gpdA promoter PCR fragment. The final construct was 
confirmed with restriction endonuclease and sequencing.  
(B) Knockout and OE of lnaA. To create ∆lnaA and OE::lnaA mutants, 
protoplasts from freshly germinated conidia of A. flavus NRRL 3357.5 (pyrG auxotroph) 
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were used for transformation with a polyethylene glycol method.3 Six µg of the correct 
PCR products were used for transformation. Transformants were identified by PCR 
using A. fumigatus pyrG primers for both the ∆lnaA and OE::lnaA strains. Further PCR 
was used to identify the ∆lnaA mutant (DM101700For and DM101700Rev) while 
OE::lnaA strains were confirmed using A. nidulans gpdAFor and Seq101700Rev3. 
Southern analysis confirmed the correct strains using a PCR generated probe with 
DM101700nested For and Rev, Figure C.8.  
(C) lnbA Silencing. An RNAi silencing construct for lnbA from cluster 48 was 
generated in the following manner. First, a 528 bp PCR fragment of lnbA was amplified 
from wild-type gDNA using IRT121520 5FFor and 5FRev, and this was then inserted 
into the NcoI and AscI site of pTMH44.14 through quick-change method5 to create 
pSA20.3. After confirming the sequence and direction of the lnbA insert using PCR with 
primers with pTMH44.1seq1For and seq1Rev, the same PCR fragment was amplified 
with IRT121520 3FFor and Rev from wild-type gDNA and ligated into the NotI and 
BamHI site of pSA20.3 to create pSA21.7. The vector was confirmed by PCR with 
primers pTMH44seq1For and seq2Rev, endonuclease digestion, and sequencing using 
pTMH44seq2For and seq2Rev. For construction of the TSA 22.1 or TSA 22.6 (∆lnaA, 
KD::lnbA) strains were surveyed for stable genetic incorporation of KD::lnbA in the 
∆lnaA background via Southern analysis, see Figure C.9  
(D) lnaB Silencing. A RNAi silencing construct for the nmrA-like gene 
(AFLA_101710), lnaB, was generated in the following manner. First, a 579 bp PCR 
fragment was amplified from wild-type gDNA using IRT101710 5F For and 5F Rev, and 
inserted into the NcoI and AscI site of pTMH44.14 through quick-change method5 to 
create pSA6.1. After confirming the sequence and direction of the lnaB insert using 
PCR with primers with pTMH44seq1For and seq1Rev, the same PCR fragment was 
amplified with IRT101710 3F For and Rev from wild-type gDNA and ligated into the NotI 
and HindIII site of pSA6.1 in the opposite direction to create pSA7.3. The vector was 
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confirmed by PCR with primers pTMH44seq1For and seq2Rev, endonuclease 
digestion, and sequencing using pTMH44seq2 For and seq2Rev.  
(E) Northern Analysis lna Gene Cluster Expression. Total RNA was extracted 
from fungal cultures using the Trizol method. Blots were hybridized with DNA fragments 
amplified from NRRL3357 gDNA using the primers of all cluster genes: lnaA, lnaB, 
lnaC, lnaD, lnaE, lnaF, as well as laeA as listed in Table C.2. Detection of signals was 
carried out with a Phosphorimager-SI (Molecular Dynamics). 
 
2. Fungal Strains and Experimental Growth Conditions: (A) Fungal Strains. NRRL 
3357 (wild-type), NRRL 3357.5 (pyrG), TSA5.21 (∆lnaA), TSA 7.15 (OE::lnaA), TSA 
7.51 (OE::lnaA), TSA 22.1 (∆lnaA, KD::lnbA), TSA 22.6 (∆lnaA, KD::lnbA) and 
TSA16.7.31 (∆lnaA, KD::lnaB). See Table C.3 for corresponding genotypes.  
(B) Experimental Growth Conditions. All strains were maintained as glycerol 
stocks. To setup minimal media experimental cultures, approximately 2 wk old A. flavus 
cultures grown on solid glucose minimal media plates (GMM 6), amended with uridine 
[1.26 g/L], uracil [0.56 g/L], sorbitol [20 g/L], and for solid culture Difco Noble agar [15 
g/L]) were flooded with 1-5 mL of a 0.1 % Tween 20 solution. A sterile cell scraper was 
used to remove conidia from the mycelia, and the resulting spore suspension was 
diluted 100 fold. Conidia concentration were measured for the 100 fold diluted conidia 
suspensions using a hemocytometer, and appropriate dilutions, using the aqueous 
0.1% Tween 20 solution, were made to achieve desired conidia concentrations. Two 
methods were used to grow experimental GMM cultures (1) liquid stationary cultures: 
appropriate aliquots of conidia suspension were used to inoculate 6-cm Petri plates 
containing 11 mL of liquid GMM (initial plate conidia concentration 103 -107 spores / 
plate) (2) molten spore suspension: Petri plates containing 8 mL of solid GMM were 
overlaid with 3 mL of a molten solid GMM spore suspension (Difco Noble agar 7.5 g/L). 
Cultures were incubated in the dark at 29 °C for seven days. 
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3. Metabolite Extraction: To ensure chemical comparability among a given set of A. 
flavus strains, cultures were grown at the same time, on the same batch of media, and 
extracted using the same solvent mixtures and extraction protocols. (A) Generation of 
initial crude extracts for DANS. Solid rich media cultures of ∆lnaA, wild-type, and 
OE::lnaA, consisting of three plates each, were cultured as described above. Whole 
cultures were cut up into ~ 1 cm2 pieces. The cultures were transferred into individual 
round bottom flasks, frozen (-80 °C), and lyophilized. Cultures were then extracted with 
100 mL of ethyl acetate and filtered over ethyl acetate-washed cotton. The extraction 
process was repeated twice more with 25 mL of ethyl acetate. Solvent was removed 
from the extract solutions using rotary evaporation at room temperature.  
(B) Extraction of Additional Rich Media- and GMM-Cultured Fungal 
Samples. Whole liquid stationary cultures, media and cellular material, not immediately 
processed were frozen and stored at -80 °C. Subsequent processing of liquid cultures 
entailed thawing the frozen cultures, transferring the samples to glass Erlenmeyer 
flasks, freezing the samples (-80 °C), and lyophilizing. Solid plate cultures were 
processed up to the extraction step as described above. The lyophilized material from 
solid or liquid cultures was extracted using 10% methanol in ethyl acetate (10-20 mL 
solvent / plate in sample), and filtered over methanol and ethyl acetate-washed cotton. 
The extraction was repeated twice more using 2.5-5.0 mL solvent / plate. Solvent was 
removed as described above. 
 
4. Analytical Methods and Equipment Overview: (A) NMR spectroscopy. NMR 
spectrometers: Varian INOVA 600 MHz NMR spectrometer (600 MHz 1H reference 
frequency, 151 MHz for 13C), equipped with an HCN indirect-detection probe, and a 
Bruker AVANCE 600 MHz NMR spectrometer (601 MHz 1H reference frequency, 151 
MHz for 13C) equipped with a 5 mm TXI probe. Non-gradient phase-cycled dqfCOSY 
spectra were acquired using the parameters: 0.6 s acquisition time, 500-600 complex 
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increments, 8-32 scans per increment. ROESY spectra were acquired using the 
parameters: 0.25 s acquisition time, 0.2 s mixing time, 400 increments, 16 scans per 
increment. Gradient and non-gradient HSQC[AD], HMQC, and HMBC[AD] spectra were 
acquired with these parameters: 0.25 s acquisition time, 300-600 increments, 4-32 
scans per increment. 1H,13C-HMBC spectra were optimized for JH,C = 6 Hz. 
Susceptibility-matched NMR tubes (Shigemi) were used for sample amounts smaller 
than 2 mg. NMR spectra were processed and baseline corrected using Varian VNMRJ 
and MestreLabs MestReC and MNOVA software packages.  
(B) Mass spectrometry. High-resolution mass spectrometry was performed on a 
Waters nanoACQUITY UPLC system equipped with a Waters Acquity UPLC HSS C18 
column (2.1 x 100 mm, 1.8 µm particle diameter) connected to a Xevo G2 QTof Mass 
Spectrometer operated in either ESI+ or ESI- modes, or an LTQ Orbitrap Velos (Thermo 
Scientific) mass spectrometer operated in ESI+. HPLC/ESI+-MS data acquisition and 
processing was controlled by Waters MassLynx software.  
(C) Chromatography. Flash chromatography was performed using a Teledyne 
ISCO CombiFlash system. For semi-preparative HPLC a Supelco Discovery HS C18 
column (25 cm X 10 mm, 5 μm particle diameter) was employed. An Agilent Zorbax 
Eclipse XDB-C8 column (4.6 X 150 mm, 5 μm particle diameter) was used in the 
HPLC/ESI+-MS A. flavus mutant profiling analysis. 
 
5. Generation of OE::lnaA(TSA7.51) and ∆lnaA Pools 1-3 for DANS Comparison: 
Twenty rich media cultures of OE::lnaA and ∆lnaA were cultured and extracted as 
described above (section 2). Extracts were loaded onto a silica gel loading column 
using dichloromethane. Residual material was dissolved in 50/50 methanol/DCM 
solution (v/v) and pipetted onto the loading column. The sample was then flash 
chromatographed using a CombiFlash equipped with a 40 g silica gel Gold column. A 
DCM-methanol gradient was used (40 mL/min) starting with 0% methanol for 6 minutes, 
  
151 
 
followed by a linear increase to 10% methanol over 12 minutes, followed by a linear 
increase to 30% methanol over 12 minutes and holding at 30% methanol for an 
additional 6 minutes. Fractions were pooled, generating the least polar pool 1, fractions 
1-20 (0-2% methanol); pool 2, fractions 21-40 (2-10 % methanol); and the most polar 
pool 3, factions 40-76 (10-30 % methanol).  
 
6. Differential Analysis by 2D NMR Spectroscopy: High-resolution dqfCOSY spectra 
were acquired as described above. Spectra were zero-filled to 8192 complex data 
points in the directly detected dimension (F2) and 4096 data points in the indirectly 
detected dimension (F1). Bitmaps derived from absolute-value processed dqfCOSY 
spectra were then imported into Adobe Photoshop CS3 and overlayed as described in 
reference7.  
 
7. Purification and Characterization of Compounds 3-8: To setup rich media 
cultures, approximately 2 wk old A. flavus cultures grown on solid glucose minimal 
media plates (see section 2) were flooded with 1 mL of an aqueous 0.1% Tween 20 
solution. After light agitation, 7 µL of the resulting spore suspension was point-
inoculated onto solid Bacto tryptic soy media (30 g/L, rich media) plates (9-cm Petri 
dishes with 23 mL media/plate), and incubated at 25 °C in the dark for seven days. 
Extracts derived from 120 rich media-grown OE::lnaA (TSA7.51) cultures (media and 
mycelia) were divided into four portions and filtered through a RediSep silica gel 
column. Fractions were pooled, and solvent was removed using rotary evaporation at 
room temperature. The extract was then dissolved in methanol and adsorbed onto 1 g 
of octadecyl-functionalized silica gel. After removal of solvent under rotary evaporation, 
the sample was placed into a loading column. The sample was chromatographed using 
a Teledyne ISCO CombiFlash system equipped with a 100 g RediSep High 
Performance Gold C18 reverse phase column. The sample was chromatographed using 
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a 0.03% acetic acid in water and 10% acetonitrile in methanol ("organic") as solvents, 
using a gradient starting with 0% organic for 15 minutes, followed by a linear increase to 
25% organic over 21 minutes, followed by a linear increase to 50% organic over 9 
minutes, followed by a linear increase to 80% organic over 8 minutes, followed by a 
linear increase to 100% organic over 3 minutes, and holding at 100% organic for 15 
minutes. Fractions were evaporated to dryness individually using rotary evaporation at 
room temperature. Every other fraction in the polarity range 18–54% organic (fractions 
59–97) was dissolved in methanol-d4 followed by acquisition of
 1H and dqfCOSY. 
Fractions containing 3-8 were combined as appropriate and used to acquire additional 
dqfCOSY, (g)HMBC, and HMQC[AD] or HSQC[AD] spectra (see Tables C.4-C.11). 
 
8. Synthesis of Compounds 1 and 2: 
 
Scheme C.1: Total synthesis of compounds 1 and 2. The synthetic route to 1 (* = S 
configuration) starting with 24a; 2 (* = R stereo configuration) starting with 24b. 
Reagents and conditions: (A) PyBOP, HOBt, DIEA CH3CN, room temperature (rt), yield: 
26a, 60%; 26b, 25%. (B) 6 eq. piperidine in DMF, rt, yield: 27a/b, 50%. (C) LAH, Et2O, 
60 °C; yield: 28a, 25%; 28b, 77%. (D) H2(g), Pd/C in EtOH w/ and acetic acid, rt, yields: 
1, 90%; 2, 95%. 
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The four-step total synthesis of compounds 1 and 2 is depicted in Scheme C.1. In all 
cases product formation was confirmed by 1H NMR. In step A, (S)-tyrosine benzyl ester 
(25) was coupled with Fmoc-protected (R)- or (S)-tyrosine (24a/b) following the 
procedures used by Campo et al. in their synthesis of a similar diketopiperazine 
cyclo(Phe-Ser)8. In step B, 20a or 20b was cyclized to the corresponding 
diketopiperazines 27a or 27b respectively, using the procedures described by8. 
Products were characterized using 1H NMR, dqfCOSY, 1H,13C-HMQC, and 1H,13C-
HMBC spectra. 
  
Reduction and debenzylation. In step C, samples of the diketopiperazines of 27a or 27b 
(80 mg, 0.16 mmol) were reduced to the corresponding piperazines using LAH (60 mg, 
1.6 mmol) in dry ether (5 mL). The reaction was stirred in a sealed glass vial at 60 ˚C for 
1 hour. After cooling to room temperature, solvents were removed in vacuo. To the 
residue, 2 N aqueous HCl (6 mL) was added and the mixture was stirred for 10 minutes. 
After acidification, saturated Na2CO3 solution was added until basic. The mixture was 
extracted with 10% methanol in dichloromethane (4 x10 mL). The combined organic 
extracts were dried over sodium sulfate. The extract was adsorbed onto silica in vacuo 
and flash chromatographed using a DCM/methanol gradient. Products were obtained in 
25% (28a) and 77% (28b) yield. In step D, solutions of 28a or 28b (5 mg, 0.010 mmol) 
in ethanol (15 mL) containing ~50 µL acetic acid were hydrogenated using H2 gas and 
10% palladium on activated carbon (Pd/C, 2 mg). Starting material, solvent, and Pd/C 
were degassed under argon, followed by the introduction of H2 gas at atmospheric 
pressure. The reaction was stirred for 12 hours and then filtered through ethanol-
washed cotton using 100 mL of ethanol containing ~200 µL acetic acid. Purification was 
carried out by loading the filtrate onto Celite, followed by flash chromatography using a 
RediSep High Performance Gold C18 reverse phase column. Compounds 1 and 2 were 
obtained in 90% and 95% yields respectively. HPLC retention times, and NMR spectra 
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of the products matched those of natural 1 and 2 derived from A. flavus extracts (For 
NMR spectroscopic data of compounds 1, 2, 27a, and 27b see Tables C.4, C.5, C.12, 
and C.13 respectively). 
 
9. Chromatographic Enrichment Compound 10: Wild-type and OE::lnaA fractions 
containing 10 were combined in methanol, silica gel was added, and the solvent was 
removed using rotary evaporation. The resulting silica gel-loaded sample was flash 
chromatographed using the Teledyne ISCO CombiFlash system equipped with a 24 g 
RediSep silica gel column. A dichloromethane/methanol gradient was used (35 mL/min) 
starting with 3 minutes at 0% methanol, followed by a linear increase to 15% methanol 
over 11 minutes, followed by a more rapid linear increase to 45% methanol over 5 
minutes. Solvent was removed from the fractions using rotary evaporation, and resulting 
samples were dissolved in methanol-d4 and analyzed by 
1H NMR spectroscopy. The 
fraction containing 10 (eluting at 8-9% methanol) was purified further using reverse-
phase HPLC. The sample was dissolved in 500 µL of methanol, and 20 µL of this 
sample was injected onto the semi-preprative column running a water/methanol 
gradient (3 mL/min) starting with 5% methanol for 5 minutes, followed by a linear 
increase to 100% methanol over 50 minutes, and holding at 100% methanol for 15 
minutes. At the end of the separation, the column was equilibrated at 5% methanol for 
15 minutes, followed by reinjection of sample. This process was repeated until the entire 
sample was chromatographed. After evaporation of solvent, fractions containing 10 
(eluting at ~90% methanol) combined and characterized via 1H, dqfCOSY, ROESY, 
1H,13C-HSQCAD, and 1H,13C-gHMBCAD (dqfCOSY and ROESY spectra were acquired 
in both methanol-d4 and DMSO-d6). 
 
10. Heterologous lnaA- and lnbA-Expression: For heterologous production of N-
terminally tagged hexahistidine fusion proteins, E. coli soluBL (Genlantis) was 
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transformed with plasmids pSA14 and pSA15, carrying the NPRS genes lnaA and lnbA, 
respectively. E. coli x pSA14 was grown as an overnight seed culture in LB-medium (10 
mL), which was used to inoculate 500 mL of autoinduction medium as production 
culture. Ampicillin (100 µg/mL final) was added to all cultures. The production culture 
was incubated at 180 rpm and 37 °C until an OD600 of 0.6 - 0.8 was reached. The 
temperature was then lowered to 22 °C, shaking at 160 rpm, for further 12 h. E. coli x 
pSA15 was grown as described above, but in LB-medium as production culture. 
Expression was induced with 1 mM IPTG. (A) Protein purification. Cells were 
harvested by centrifugation (4 °C, 4.000 x g, 25 min). The cell paste was resuspended 
in 10 mL wash buffer (50 mM sodium phosphate / 300 mM sodium chloride, pH 8.0), 
amended with 20 mM imidazole, and the cells disrupted by a Branson sonifier (4 x 40 s 
pulses, pause between pulses: 60 s). Debris was removed by centrifugation (4 °C, 
6.000 x g, 25 min), and Ni-NTA slurry was added to the cleared supernatant and stirred 
on ice for 1 h. Purification was performed according to the manufacturer´s instruction 
(QIAGEN expressionist), except that the wash steps involved a step gradient from 50-
10 mM imidazole and that elution was done with 500 mM imidazole. The first elution 
fraction (ca. 1 mL) was discarded, the other fractions collected. Removal of imidazole 
and desalting was accomplished using a PD-10 column (GE healthcare) and assay 
buffer (below).  
(B) Biochemical characterization of Aspergillus flavus LnaA and LnbA. The 
ATP-[32P] pyrophosphate exchange assay was carried out as described9,10 with the 
following modifications: i) assay buffer was sodium phosphate 250 mM; MgCl2 12.5 mM; 
ATP 12.5 mM; pH 6,5; ii) the wash steps included 200 mL wash solution, 200 mL water, 
and 35 mL ethanol; iii) the substrates were provided as 4 mM solution. Scintillation was 
read out on a Beckman Coulter LS6500 counter. Chemicals and media components 
were purchased from Becton-Dickinson, Fisher, Fluka, Roth, and Sigma-Aldrich, except 
sodium [32P]pyrophosphate (activity: 62.9 Ci/mmol) which was from PerkinElmer. 
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Substrate specificity was assessed with five pools of L-amino acids and a sixth pool 
including 2-oxo acids: Pool 1: Ala, Gly, Leu, Ile, Val; Pool 2: Cys, Met, Pro, Ser, Thr; 
Pool 3: His, Phe, Tyr, Trp; Pool 4: Asp, Asn, Glu, Gln; Pool 5: Arg, Lys, Orn; Pool 6: 
phenylpyruvic acid, 4-hydroxyphenylpyruvic acid, indolyl-3-pyruvic acid, pyruvic acid, α-
keto glutaric acid. Water served as negative control throughout. For assays with pure 
amino acids, L-Ala was chosen as additional negative control. 
 
11. HPLC-MS-Based Profiling of 1-8 in the ∆lnaA KD::lnbA, ∆lnaA, Wild-Type, 
OE::lnaA KD::lnaB, and OE::lnaA A. flavus Strains: For comparing the relative 
abundances of 1-8 between different strains and conditions, cultures to be compared 
were grown on the same media, at the same time, and were processed and extracted 
under the same conditions. For measuring compounds 1 and 2 and studies comparing 
OE::lnaA and OE::lnaA, KD::lnaB, three biological replicates comprised of a pooling of 
10 GMM cultures each were used. Unless otherwise specified, HPLC-MS strain profiling 
was performed on extracts derived from cultures grown on GMM under conditions that 
support expression of the lna and lnb gene clusters. (A) HPLC chromatography. 
Samples were dissolved in 0.2-1.0 mL of methanol. If a precipitate formed upon addition 
of methanol, the sample was filtered through a methanol-washed cotton filter. 2.0 µL of 
crude extract sample was injected into an Agilent 1100 series HPLC equipped with a 
Zorbax Eclipse XDB-C8 column, using a flow rate of 2.0 mL/min, and a water (0.1% 
acetic acid) / methanol gradient starting with 1% methanol for 10 minutes followed by a 
linear increase over 20 minutes to 100% methanol, and ending with 10 minutes at 
100.0% methanol. Synthetic standards of 1 and 2 were used to determine which 
chromatographic peaks represent 1 or 2, and enriched samples of compounds 1-8 
served as retention time standards for the remaining analytes.  
(B) Electrospray positive ionization (ESI+) mass spectrometry. The eluent of 
the HPLC was split into a Quattro II triple quadrupole mass spectrometer operated in 
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either single ion monitoring (SIM) or centroid (m/z range 2.0–800.0) acquisition modes. 
See Figure C.11 for elution profile of 1-8.  
(C) Estimating production of 1 and 2 in the ∆lnaA, Wild-type and OE::lnaA 
strains. Synthetic standards of 1 and 2 were dissolved in 0.6 mL of methanol-d4 (99.8% 
D), and quantitative 1H spectra were acquired. After baseline correction, the doublet of 
doublets belonging to one of the benzylic hydrogens of 1 or 2 was integrated relative to 
the CHD2OD solvent signal. Using the CHD2OD signal as an internal standard 
(representing 0.2% of the 0.6 mL methanol-d4 sample) the amount 1 and 2 in the NMR 
sample was estimated (1, 0.2 mg; 2 0.6 mg). Solvent was removed from the standards 
using rotary evaporation and 1.0 mL of methanol was added. These standards were 
diluted up to 106-fold and analyzed by HPLC/ESI+-SIMMS, indicating roughly linear 
spectrometer response over the entire concentration range. Extracts of ∆lnaA, wild-type 
and OE::lnaA strains (derived from 20 GMM plates each) were dissolved in 1.0 mL 
methanol and analyzed by HPLC/ESI+-SIMMS. This analysis showed: ∆lnaA 1, 1 
pmol/plate; ∆lnaA 2, 9 pmol/plate; wild-type 1, 74 pmol/plate; wild-type 2, 97 pmol/plate; 
OE::lnaA 1, 560 pmol/plate; OE::lnaA 2, 600 pmol/plate.  
(D) Data workup. Ion chromatographic data were processed in MassLynx. Peak 
areas were measured in the HPLC/ESI+-(SIM)MS ion chromatograms. (1) Measuring 
the compound 1-to-compound 2 value: For measuring the compound 1-to-compound 2 
ratio for the ∆lnaA, wild-type and OE::lnaA strains, SIMMS ion chromatogram peak 
areas (ion monitored, 299.2 m/z) were measured. Given that the ∆lnaA strain produces 
~ 10 fold less 1 and 2 than wild-type (as determined by ion chromatogram peak areas), 
the wild-type extracts were diluted by a factor of 10 and rerun to determine if the 
decrease in the wild-type 1 and 2 S/N would significantly affect the measured 
compound 1-to-compound 2 ratio, which was not the case. This additional validation 
step was also used to re-analyze the compound 1-to-compound 2 ratio in the OE::lnaA 
extracts. Results from the ∆lnaA, wild-type, and OE::lnaA compound 1-to-compound 2 
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study were reproduced using a second, separately grown and extracted culture set. (2) 
Profiling the OE::lnaA, KD::lnaB and OE::lnaA strains: To measure changes in lna-
dependent metabolite profile as a result of lnaB knock down, compounds 1-8 were 
profiled for OE::lnaA, KD::lnaB and OE::lnaA extracts using HPLC/ESI+-SIMMS. This 
profiling method was also used to profile the presence or absence of compounds 1-8 in 
cultures of ∆lnaA, wild-type, and OE::lnaA grown on rich media and GMM.  
 
12. Wild-Type A. flavus 1 and 2 Feeding and lna Cluster Expression Experiment: 
Aqueous solutions (0.1 % acetic acid) of synthetic 1 and 2 (0.4 mM) were sterile-filtered 
using a 0.2 µm Thermo Scientific Nalgene syringe filter. A spore suspension of wild-type 
conidia was prepared as described in the main text methods, diluted, and used to 
inoculate in 20 mL liquid GMM cultures. 10 plates each were treated with either 300 µL 
of 1 solution, 2 solution, or vehicle control. The cultures were incubated at 29 °C in the 
dark as described above. Mycelia were collected after 6 days and portions were used to 
extract total RNA. RNA expression was assessed as described in Appendix C, section 
1(E). 
 
13. HRMS Analysis of Compounds 1, 2, 4-7, 10, 19, 20†, 22, and 23: Enriched 
samples of 4-6 were dissolved in 0.2-0.5 mL of methanol and injected into the 
UPLC/ESI+-HRMS system described in the main text methods. Various 
chromatographic solvent gradients were used; all based on gradients of 5-100% 
methanol in water containing 0.1% formic acid. Mass spectra were acquired in ESI+ 
and, for 4 and 6, ESI- modes. High resolution mass spectra were acquired for 
compounds 1, 2, 7, 10, 19, 20, 22, and 23 by dissolving the purified samples (~0.5 mg) 
in 1.0 mL of methanol and diluting an aliquot of the samples by a factor of 100 with 
methanol containing 0.1% formic acid. The resulting solutions were directly infused into 
an LTQ Orbitrap Velos mass spectrometer operating in ESI+ ionization mode. 7 was 
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additionally incubated in methanol-d4 resulting in the exchange of four H atoms for four 
D atoms (see table below). 
Compound ESI+/- HRMS 
Observed m/z 
Ion Calculated Ion 
Formula 
Calculated 
m/z 
1 299.1751 [M + H]+ C18H23N2O2
+ 299.1754 
2 299.1754 [M + H]+ C18H23N2O2
+ 299.1754 
4 371.0703 [M - H]- C18H15N2O5S
- 371.0707 
5* 309.1236 [M - O + H]+ C18H17N2O3
+ 309.1234 
5* 291.1133 [M - O - OH-]+ C18H15N2O2
+ 291.1128 
6 373.0865 [M + H]+ C18H17N2O5S
+ 373.0853 
6 371.0703 [M - H]- C18H15N2O5S
- 371.0707 
7 316.1546 [M + H]+ C18H22NO4
+ 316.1543 
7-d1 (after 
incubation in 
methanol-d4) 
317.1605 [M + H]+ C18H21DNO4
+ 317.1606 
7-d4(4H atoms 
exchanged, D) 
320.1788 [M + H]+ C18H18D4NO4
+ 320.1794 
10 474.2628 [M + Na]+ C28H37NNaO4
+ 474.2615 
19 543.2191 [M + H]+ C24H39N4O6Zn
+ 543.2156 
20† 511.2 [M + H]+ n/a n/a 
20 (21 frag.) 225.1 [M + H]+ n/a n/a 
22 774.3618 [M + H]+ C36H58FeN6O9
+ 774.3609 
23 726.3762 [M + H]+ C36H58FeN6O6
+ 726.3762 
 * See reference11 for ionization routes for aromatic N-oxides. 
 † Unit-resolution mass spectrum acquired using triple quadrupole MS. 
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14. Sclerotia Analysis: Because the lna and lnb clusters were found to be regulated by 
LaeA and highly expressed during sclerotia-forming conditions, we compared the lnaA 
and lnbA mutant strains with wild-type for sclerotial production. Sclerotia formation 
exhibits a quorum-like density-dependent growth pattern in A. flavus whereby sclerotia 
are abundantly produced at low population densities but suppressed at high population 
densities. For sclerotia analysis, plates were sprayed with 70% ethanol to remove 
conidia, and sclerotia were scraped off using a small spatula. The sclerotia were placed 
into pre-weighed microcentrifuge tubes, flash-frozen in liquid nitrogen, lyophilized, and 
weighed again, and the weight of the sclerotia was calculated by subtracting the initial 
weight of the empty tube from the final weight. The data were analyzed using Prism 5 
software to carry out a one-way ANOVA with a Tukey post-test and a p-value of <0.05. 
60-mm diameter plates containing 8 mL GMM + 2% sorbitol and 15 g/L agar were 
overlaid with 3 mL GMM + 2% sorbitol and 7.5 g/L agar containing 103 or 107 spores. 
Five replicates per set were placed in the dark at 29C for seven days. Sclerotial 
formation was assessed at 103 spores/plate (low density) and 107 (high density). All 
tested mutant strains were aberrant in sclerotial development, including total weight, 
size and pattern of production (Figure C.1). With the exception of the ∆lnaA, KD::lnbA 
strain, mutant strains showed abundant sclerotia production at low population densities, 
similar to wild-type. However, all strains produced significantly more sclerotia than wild-
type at high population densities. Notably, the ∆lnaA, KD::lnbA strain TSA22.1 exhibited 
a phenotype in which sclerotia production was suppressed at low rather than high 
population densities, opposite of what is observed in wild-type (Figure C.1). 
 
15. Compound 1-to-Compound 2 Ratio OE::lnaA, Wild-Type, ∆lnaA: As deletion of 
lnaA decreased the compound 1-to-compound 2 ratio, the compound 1-to-compound 2 
ratio was measured for OE::lnaA, expecting a higher 1 to 2 ratio relative to wild-type. 
However, it was found that the OE::lnaA compound 1-to-compound 2 ratio was not 
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increased relative to wild-type, but instead placed between that of wild-type and ∆lnaA 
(Figure C.6). Given that the OE::lnaA construct was shown to increase expression of 
both lnaA and lnaB, and both proteins contain a putative epimerase domain, it is 
possible that the compound 1-to-compound 2 ratio observed for OE::lnaA results in part 
from increased LnaB expression. 
 
16. Statistical Analysis: Statistical differences were analyzed using the JMP software 
package (version 9.0.2, SAS Institute, Inc, Cary, NC). Multiple comparisons of all strains 
were calculated for diameter growth, conidia production. Mean values with different 
letters or asterisk are significant in the group 
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Figure C.1: Sclerotia production by lna and lnb cluster mutants. (a) Images of 
plates after washing off conidia. The sclerotia are the dark structures left on the plate 
after conidia are washed off. (b) Quantification of sclerotia formed on plates inoculated 
with 103 and (c) 107 spores. Different letters represent significantly different groups with 
a p-value < 0.05, according to ANOVA analysis followed by a Tukey post-test, and error 
bars signify one standard deviation (n = 5).  
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Figure C.2: Northern expression analysis for the wild-type (WT), ∆lnaA, and 
OE::lnaA strains. GMM (glucose minimal media) GMM+UU (GGM with uracil and 
uridine) growth conditions were compared for expression influence on the lna gene 
cluster and surrounding genes. Genes listed on the left correspond to: AFLA_101670, 
AFLA_101680, lnaE (P450, AFLA_101690), lnaA (NRPS, AFLA_101700), lnaB (nmrA-
like gene, AFLA_101710), lnaC (dehydrogenase, AFLA_101720), lnaD (P450, 
AFLA_101730), lnaF (transporter, AFLA_101740), AFLA_101750, and AFLA_101760. 
Actin and rRNA serve as loading controls. 
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Figure C.3: Analysis of the ∆lnaA, KD::lnbA strain for the presence of absence of 
compounds 1 and 2. SIM ion chromatograms of m/z 299.18 for extracts corresponding 
to the wild-type and ∆lna, KD::lnbA (TSA22.1) strains as well as synthetic standards of 1 
and 2. The ∆lna, KD::lnbA strain showed no evidence for the presence of 1 nor 2. 
Analysis of the second ∆lna, KD::lnbA  strain (TSA22.6) gave the same result. 
 
Figure C.4: LnaA does not show substrate specificity for linear L-Tyr-L-Tyr. 
Recombinant LnaA was tested for its ability to adenylate L-Ala, L-Tyr, and L-Tyr-L-Tyr. 
The bar diagram shows the relative activity values, as determined via the amino acid-
dependent ATP [32P]-pyrophosphate exchange assay, for each substrate acid tested, 
referenced to the maximum turnover (L-Tyr). Error bars signify +/- one standard 
deviation (n = 3). 
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Figure C.5: Retro biosynthetic scheme for compounds 1, 2, and 7. Forward 
reaction steps with red lettering represent reductive steps in the biosynthesis. Note that 
the four reductive steps are required for the production of 1 or 2, whereas only 3 
reductive steps are required for the generation of 7. This model accommodates the 
observation that knocking down the expression of lnaB, encoding a putative NmrA-like 
reductase, results in a shift from 1 and 2 production towards greater production of 7.  
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Figure C.6: Ion chromatogram peak area ratios compound 1-to-compound 2 for 
∆lnaA, wild-type, and OE::lnaA (TSA7.15). Peak areas were determined from 
integration of HPLC/ESI+-SIMMS ion chromatograms (m/z 299.18) corresponding to 
three replicates for each strain. Error bars signify +/- one standard deviation (n = 3). As 
demonstrated previously the wild-type compound 1-to-compound 2 ratio is greater than 
that of ∆lnaA, whereas the OE::lnaA mutation lowers the compound 1-to-compound 2 
ratio to a value between that of wild-type and ∆lnaA. 
 
Figure C.7: Northern analysis of wild-type (WT), OE::lnaA, and OE::lnaA, 
KD::lnaB. A. flavus WT, OE::lnaA, and OE::lnaA, KD::lnaB strains were examined by 
Northern analysis with lnaA and lnaB probes. The loss of lnaB expression in the latter 
strain confirms silencing of lnaB.  
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Figure C.8: Southern analysis of wild-type (WT) and lna gene cluster mutants 
∆lnaA and OE::lnaA. Each sample was digested with NdeI and probed with the ORF of 
lnaA. WT: 5280bp, 2182bp, ΔlnaA: 3075bp, 2182bp, OElnaA: 5980bp, 2830bp, 2182bp. 
Bands are consistent with predicted restriction sites. 
 
 
  
Figure C.9: TSA22.1/22.6 strains confirmation by Southern analysis. Lane one, 
wild-type (WT) strain NRRL2257, in lanes 2-7 “*” indicates TSA22.1 and TSA22.6, 
which showed extra copy of lnbA from successful incorporation of the RNAi plasmid, 
pSA7.3. 
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Figure C.10: Overlay of ion chromatograms corresponding to compounds 1-8. 
Traces were derived from HPLC/ESI+-MS chromatograms acquired for enriched 
samples of 3-8 (traces for 1 and 2 are derived from single ion monitoring traces 
acquired for a crude wild-type extract). HPLC/ESI+-MS chromatographic and mass 
spectrometry acquisition parameters are outlined in Supporting Information section 
10(A). Peak intensities are scaled relative to the peak in the ion chromatogram with the 
largest intensity, 2. Compound 2, red dotted trace; 1, solid blue trace; 8, solid orange 
trace; 7 and isomers, solid green trace; 6 solid red trace; 5 blue dotted trace; 4 solid 
violate trace; and 3, black dotted trace. 
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Figure C.11 Comparison of dqfCOSY spectra for wild-type-light and TSA 22.1-
light. TSA 22.1-light shows dramatic increase in the production of compound 19. 
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Table C.1: Gene symbols and names used in this study as well as annotated functions 
(www.pubmed.org). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol Gene name Annotated function 
AFLA_101690 lnaE 
Alcohol dehydrogenase/NAD:flavin 
oxidoreductase 
AFLA_101700 lnaA NRPS 
AFLA_101710 lnaB 
nmrA-like gene (putative 
reductase/epimerase) 
AFLA_101720 lnaC Cytochrome P450 
AFLA_101730 lnaD Cytochrome P450 
AFLA_101740 lnaF Transporter 
AFLA_121470 Not named 
nmrA-like gene (putative 
reductase/epimerase) 
AFLA_121480 Not named dioxygenase 
AFLA_121490 lnbB 
nmrA-like gene (putative 
reductase/epimerase) 
AFLA_121500 lnbC Cytochrome P450 
AFLA_121510 n/a methyltransferase 
AFLA_121520 lnbA NRPS 
AFLA_121530 lnbE 
Alcohol dehydrogenase/NAD:flavin 
oxidoreductase 
AFLA_121540 lnbF Transporter 
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Table C.2: List of primers used in this study. 
Name Sequence 5'-3' 
DM101700-5' For GGT CGC GTC GTC AGC TTT AAT G 
DM101700-5' Rev CGA AGA GGG TGA AGA GCA TTG TTT GAG GCA CTA 
ACC TCC ATC CGC GAC AC 
A. fumigatus pyrG For TGCCTCAAACAATGCTCTTC 
A. fumigatus pyrG Rev CAAGGTATCGTCGGGAGGT 
DM101700-3' For GTG ACG ACA ATA CCT CCC GAC GAT ACC TGG 
GAC AAG CGG AAG AAG GGA GT 
DM101700-3' Rev CAT GCG TAT CAA AGGG CCT CCC A 
DM101700 nested For GAC TTG CGC GAT ACT CAT CGT C 
DM101700 nested Rev GCT GAC ACC GTG AAC GAA GTG A 
OE101700-5' For  CAA AAC TGC GGA TGT CGC TGA C 
OE101700-5' Rev CGA AGA GGG TGA AGA GCA TTG TTT GAG GCA 
CGA GGA TTT CGT TTT CCA GG 
A. nidulans gpdA(p)For AAG GCT TG GGC CGC TGC GTT GGT T 
gpdA(p)::pyrG For GTG ACG ACA ATA CCT CCC GAC ACC TGG CAT 
CCG GAT GTC GAA GGC TTG 
A. nidulans gpdA(p) Rev CAT GGT GAT GTC TGC TCA AG 
OE101700-ORF For AGC TAC CCC GCT TGA GCA GAC ATC ACC ATG CCT 
TCT CAA GTT TTG ACT CA 
OE101700-ORF Rev GCC TCG AGC TCA ATT CGA AAC C 
Seq101700 For1 GTT GAC AAG GTC GTT GCG TCA G 
NSeq101700 For2 CAT GGA TCC AAC CTT GCC TGA C 
Seq101700 For3 TGA TGA AGC TGG TCG ACC AGT C 
Seq101700 Rev1 CGA GCT CTT GGA AAA TGA CGC G 
Seq101700 Rev2 GAT TGA TGT ATC CGG GCG AGA C 
NSeq101700 Rev3 CGA GCC TGA TGA GGC TGC TAT T 
DM101700 For GGC CTT GCC CAA CAA TTC TTC GAT 
DM101700 Rev CAG CAA GCA AGA AAG AGC CCA CAA 
IRT101710 5F For CTA CCC CGC TTG AGC AGA CAT CAC CA 
IRT101710 5F Rev CTC TCT CCT GCA CAT AGC CCT CGG CG 
IRT101710 3F For HindIII GAA GAA CAA GCT TGA GCA GTA CGC AA 
IRT101710 3F Rev NotI CTA GTT TGC GGC CGC AGC AAA CCA GT 
pTMH44 seq1For CTA CAT CCA TAC TCC ATC CTT C 
pTMH44 seq1Rev GTG GCC GAG AAT GTT TCC ATC C 
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pTMH44 seq2For CAA GTT CGA AGG TGA CAC CCT G 
pTMH44 seq2Rev CCA TTT GTC TCA ACT CCG GAG C 
IRT121520 5F For CTA CCC CGC TTG AGC AGA CAT CAC CA 
IRT121520 5F Rev CTC TCT CCT GCA CAT AGC CCT CGG CG 
IRT121520 3F For BamHI GAA CGA GAG GAT CCA AAG CTC CCC TT 
IRT121520 3F Rev NotI GAT TGA CGC GGC CGC TCG ATC GAT CT 
IRTlaeA 5F For CTA CCC CGC TTG AGC AGA CAT CAC CA 
IRTlaeA 5F Rev CTC TCC TGC ACA TAG CCC TCG GCG C 
IRTlaeA 3F For BamHI GAA CGA GAG GAT CCG TCT TGA TGC CA 
IRTlaeA 3F Rev NotI GAT TGA CGC GGC CGC CCG ATT TCT AG 
1)NlaeA For CCT TGT ATG ATG TAT GTA TGA TGA GC 
NlaeA Rev GAC AGC GAA AGT GAA GAG GAC ATC 
Nactin For GAAGCGGTCTGAATCTCCTG 
Nactin Rev ACAGTCCAAGCGTGGTATCC 
N101670 For CTA TCC GAC ATT GAA AAG GTC GC 
N101670 Rev CCG AGA TAC AAT ACA CTT TGC TGA 
N101680 For GAT TTT CCT TGA GGC CAA TAG TTC 
N101680 Rev CAC GTT ACC ATT TTA TCT ACC TGC TG 
N101690 (lnaC) For GGA TCA GGA CAC GGA GAA CAA G 
N101690 (lnaC) Rev CGT AAC CGC TAA GAT GGT ATG CG 
N101710 (lnaB) For CTT GGA CGA CAT CGT GGG AAT G 
N101710 (lnaB) Rev CGT ATC CGT ATA GGC CTA CCC T 
N101720 (lnaD) For CGT AGT TGT CGA ATG CTG GAG C 
N101720 (lnaD) Rev GTC TCA GCG CCA ATT TCT GTC G 
N101730 (lnaE) For CAA GGA GCG AGC GTA TCC TTT C 
N101730 (lnaE) Rev GTC TCC TTC ACC ACA CTG ATG G 
N101740 (lnaF) For CAA TGG GAG AAG CTA GGG CCG ATG 
N101740 (lnaF) Rev GGA GAC AAA TAG TGG TCC ACG G 
N101750 For GGC TCA AGC TCC GAC CGG GAC 
N101750 Rev CCC GAA CTA ACA GGG GGA ATG A 
N101760 For TCC AAC ATT ACA GCC CGC AAT AC 
N101760 Rev CTA GCT CGA TAA GCT GGC ACA G 
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Table C.3: A. flavus strains, Abbreviations, and Genotypes. 
  
Name Abbreviation  Genotype References 
NRRL 3357 WT wild-type 12  
NRRL 3357.5 pyrG-WT pyrG 12  
TSA 5.21 ∆lnaA pyrG-, ΔAFLA_101700::A. fumigatus 
pyrG 
This study 
TSA 7.15 OE::lnaA pyrG-, gpdA(p)::AFLA_101700::A. 
fumigatus pyrG  
This study 
TSA 7.51 OE::lnaA pyrG-, gpdA(p)::AFLA_101700::A. 
fumigatus pyrG  
This study 
TSA 22.1 ∆lnaA, 
KD::lnbA 
pyrG-, A. fumigatus pyrG::AFLA_101700, 
IRT AFLA_121520, phleomycin R  
This study 
TSA 22.6 ∆lnaA, 
KD::lnbA 
pyrG-, A. fumigatus pyrG::AFLA_101700,  
IRT AFLA_121520, phleomycin R  
This study 
TSA 16.7.31 ∆lnaA, 
KD::lnaB 
pyrG-, A. fumigatus pyrG::A. nidulans 
gpdA(p)::lnaA, IRTlnaB, phleomycin 
This study 
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Table C.4: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 1 
in methanol-d4. Chemical shifts were referenced to δ(CHD2OD) = 3.31 ppm and 
δ(13CHD2OD) = 49.0 ppm.
13C chemical shifts were determined via HMBC spectroscopy. 
1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
13C atom. 
 
HN
NH
OH
HO 1
1 2
1'
1''
7
8
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1   1-NH     
2 52.6 2-H 2.87 (J2-H, 3-Ha = 4,  
J2-H, 3-Hb = 7,  
J2-H, 7-Ha = 8,  
J2-H, 7-Hb = 7)   
3, 7, 1' 
3 43.4 3-Ha 2.72 (J3-Ha, 3-Hb = 12) 2, 7 
    3-Hb 2.75 2, 7 
4   4-NH     
5 52.6 5-H 2.87 (J5-H, 6-Ha = 4,  
J5-H, 6-Hb = 7,  
J5-H, 8-Ha = 8,  
J5-H, 8-Hb = 7)   
6, 8, 1'' 
6 43.4 6-Ha 2.72 (J6-Ha, 6-Hb = 12) 5, 8 
    6-Hb 2.75 5, 8 
7 34.4 7-Ha 2.73 (J7-Ha, 7-Hb = 13,  
J7-Ha, 2'-H < 1,  
J7-Ha, 6'-H < 1) 
3, 1', 2', 6' 
    7-Hb 2.77 (J7-Hb, 2'-H < 1,  
J7-Hb, 6'-H < 1) 
3, 1', 2', 6' 
8 34.4 8-Ha 2.73 (J8-Ha, 8-Hb = 13,  
J8-Ha, 2''-H < 1,  
J8-Ha, 6''-H < 1) 
6, 1'', 2'', 6'' 
    8-Hb 2.77 (J8-Hb, 2''-H < 1,  
J8-Hb, 6''-H < 1) 
6, 1'', 2'', 6'' 
1' 126.8       
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2', 6' 127.4 2'-H, 6'-H 7.04 (J2'-H, 3'-H = 8,  
J6'-H, 5'-H = 8) 
7, 1', 4', 6' 
3', 5' 112.8 3'-H, 5'-H 6.73 1', 4', 5' 
4' 153.6      
    4'-OH     
1'' 126.8       
2'', 6'' 127.4 2''-H, 6''-H 7.04 (J2''-H, 3''-H = 8,  
J6''-H, 5''-H = 8) 
8, 1'', 4'', 6'' 
3'', 5'' 112.8 3''-H, 5''-H 6.73 1'', 4'', 5'' 
4'' 153.6       
    4''-OH     
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Table C.5: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 2 
in methanol-d4. Chemical shifts were referenced to δ(CHD2OD) = 3.31 ppm and 
δ(13CHD2OD) = 49.0 ppm.
13C chemical shifts were determined from HMBC spectra. 
1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
13C atom. 
 
HN
NH
OH
HO 2
1 2
1'
1''
7
8
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1   1-NH     
2 56.6 2-H 3.16 (J2-H, 3-Ha = 12,  
J2-H, 3-Hb = 3,  
J2-H, 7-Ha = 6,  
J2-H, 7-Hb = 8)   
3, 7, 1' 
3 49.1 3-Ha 2.69 (J3-Ha, 3-Hb = 12) 2, 7 
    3-Hb 3.12 2 
4   4-NH     
5 56.6 5-H 3.16 (J5-H, 6-Ha = 12,  
J5-H, 6-Hb = 3,  
J5-H, 8-Ha = 6,  
J5-H, 8-Hb = 8)   
6, 8, 1'' 
6 49.1 6-Ha 2.69 (J6-Ha, 6-Hb = 12) 5, 8 
    6-Hb 3.12 5 
7 38.3 7-Ha 2.67 (J7-Ha, 7-Hb = 14,  
J7-Ha, 2'-H < 1,  
J7-Ha, 6'-H < 1) 
2, 3, 1', 2', 
6' 
    7-Hb 2.76 (J7-Hb, 2'-H < 1,  
J7-Hb, 6'-H < 1) 
2, 3, 1', 2', 
6' 
8 38.3 8-Ha 2.67 (J8-Ha, 8-Hb = 14,  
J8-Ha, 2''-H < 1,  
J8-Ha, 6''-H < 1) 
5, 6, 1'', 2'', 
6'' 
    8-Hb 2.76 (J8-Hb, 2''-H < 1,  
J8-Hb, 6''-H < 1) 
5, 6, 1'', 2'', 
6'' 
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1' 127.3       
2', 6' 131.0 2'-H, 6'-H 7.06 (J2'-H, 3'-H = 8,  
J6'-H, 5'-H = 8) 
7, 2', 4', 6' 
3', 5' 116.5 3'-H, 5'-H 6.75 1', 3', 4', 5' 
4' 157.4      
    4'-OH     
1'' 127.3       
2'', 6'' 131.0 2''-H, 6''-H 7.06 (J2''-H, 3''-H = 8,  
J6''-H, 5''-H = 8) 
8, 2'', 4'', 6'' 
3'', 5'' 116.5 3''-H, 5''-H 6.75 1'', 3'', 4'', 5'' 
4'' 157.4      
    4''-OH     
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Table C.6: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 4 
in methanol-d4. Chemical shifts were referenced to δ(CHD2OD) = 3.31 ppm and 
δ(13CHD2OD) = 49.0 ppm.
13C chemical shifts were determined from HMBC and HSQC 
spectra. 1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY 
spectra. HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the 
indicated 13C atom. 
 
N
N
OH
O3SO 4
1
2
7
8
1'
2'
1''
2''
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1         
2 154.8       
3 144.1 3-H 8.40 (J3-H, 7-H2 < 1)  2, 5 
4         
5 155.6       
6 144.3 5-H 8.36 (J6-H, 8-H < 1) 2, 5 
7 40.7 7-H2 4.11 (J7-H2,8-H2 < 1,  
J7-H2,2'-H = J7-H2,6'-H < 1) 
2, 3, 1', 2', 6' 
8 40.6 8-H2 4.02 (J8-H2,2''-H = J8-H2,6''-H < 1) 5, 6, 1'', 2'', 6'' 
1' 135.9       
2', 6' 130.2 2'-H, 6'-
H 
7.23 7, 1', 2', 4', 6' 
3', 5' 122.3 3'-H, 5'-
H 
7.23 Not distinguisable 
from  
2'-H and 6'-H 
4' 152.4      
    4'-
OSO3
- 
    
1'' 130.0       
2'', 6'' 130.6 2'-H, 6'-
H 
7.06 (J2''-H,3''-H = 9) 8, 4''  
3'', 5'' 116.0 3'-H, 5'-
H 
6.7 2'', 4'', 6'' 
4'' 156.7      
    4''-OH     
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Table C.7: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 5 
in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm.
13C chemical shifts were determined from HMBC spectra. 
1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
13C atom. 
 
N
N
OH
HO 5
O
O
1 2
1'
1''
7
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1         
2 161.9       
3 132.5 3-H 9.04 2, 6 
4         
5 161.9       
6 132.5 3-H 9.04 3, 5 
7 39.4 7-H2 4.18 2, 3, 1', 2', 6' 
8 39.4 8-H2 4.18 5, 6, 1'', 2'', 
6'' 
1' 126.4       
2', 6' 129.4 2'-H, 6'-H 6.97 (J2'-H, 3'-H = J5'-H, 6'-H = 9) 7, 2', 4', 6' 
3', 5' 114.7 3'-H, 5'-H 6.70 1', 3', 5' 
4' 155.7       
    4'-OH 9.38 3', 4', 5' 
1'' 126.4       
2'', 6'' 129.4 2''-H, 6''-H 6.97 (J2''-H, 3''-H = J5''-H, 6''-H = 9) 8, 2'', 4'', 6'' 
3'', 5'' 114.7 3''-H, 5''-H 6.70 1'', 3'', 5'' 
4'' 155.7       
    4''-OH 9.38 3'', 4'', 5'' 
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Table C.8: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 6 
in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm.
13C chemical shifts were determined from HMBC and 
HMQC spectra. 1H,1H J-coupling constants were determined from the acquired 1H or 
dqfCOSY spectra. HMBC correlations (optimized for 6 Hz) are from the proton(s) stated 
to the indicated 13C atom. 
 
N
N
OH
HO 6
SO31
2
8
7
1''
2''
1'
2'
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1         
2 150.2       
3 154.3 3-H     
4         
5 150.5       
6 141.9   8.30 2, 3, 5  
7 37.1 7-H2 4.38 2, 3, 2', 6' 
8 38.4   3.94 5, 6, 1'', 2'', 
6'' 
1' 129.1       
2', 6' 129.4 2'-H, 6'-H 7.11 (J2'-H, 3'-H = J5'-H, 6'-H = 8) 7, 2', 4', 6' 
3', 5' 113.6 3'-H, 5'-H 6.58 1', 3', 4', 5' 
4' 154.2       
    4'-OH 9.05 4', 3', 5' 
1'' 127.7       
2'', 6'' 128.7 2''-H, 6''-H 7.04 (J2''-H, 3''-H = J5''-H, 6''-H = 8) 8, 2'', 4'', 6'' 
3'', 5'' 114.1 3''-H, 5''-H 6.66 1'', 3'', 4'', 5'' 
4'' 154.7       
    4''-OH 9.24 4'', 3'', 5'' 
  
  
181 
 
Table C.9: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 
afla#7 in methanol-d4. Chemical shifts were referenced to δ(CHD2OD) = 3.31 ppm and 
δ(13CHD2OD) = 49.0 ppm.
13C chemical shifts were determined from HMBC and HSQC 
spectra. 1H, 1H-J-coupling constants were determined from the acquired 1H or dqfCOSY 
spectra. HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the 
indicated 13C atom. 
 
O
NH
OH
HO
OH
7
1
2
1'
1''
7
 
 
Position δC Proton δH (JHH[Hz]) HMBC 
1         
2 93.8       
    2-OH     
3 50.1 3-Ha 2.93 (J3-Ha, 3-Hb = 12) 5 
    3-Hb 2.89 2, 5 
4   4-NH     
5 56.5 5-H 3.32 (J5-H, 6-Ha = 4, J5-H, 6-Hb = 11,  
J5-H, 8-H2 = 8)   
3 
6 61.5 6-Ha 3.66 (J6-Ha, 6-Hb = 13) 2 
    6-Hb   2 
7 45.4 7-H2 2.88 (J7-Ha, 2'-H = J7-Ha, 6'-H < 1) 2, 1', 2', 6' 
8 34.9 8-H2 2.74 (J8-Ha, 2''-H < 1, J8-Ha, 6''-H < 1) 1'' 
1' 126.2       
2', 6' 132.2 2'-H, 6'-H 7.07 (J2'-H, 3'-H = J6'-H, 5'-H = 9) 2', 4', 6' 
3', 5' 115.7 3'-H, 5'-H   1', 3', 5' 
4' 157.1      
    4'-OH     
1'' 125.8       
2'', 6'' 130.8 2''-H, 6''-H 7.05 (J2''-H, 3''-H = J6''-H, 5''-H = 9) 8, 1'', 2'', 4'', 
6'' 
3'', 5'' 116.4 3''-H, 5''-H   3'', 4'', 1'' 
4'' 157.5       
    4''-OH     
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Table C.10: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 
7 in DMSO-d6. Chemical shifts were referenced to δ(CHD2SOCD3) = 2.50 ppm and 
δ(13CHD2SOCD3) = 39.5 ppm.
13C chemical shifts were determined from HMBC spectra. 
1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. 
Key ROESY correlations were observed using a mixing time of 0.2 s. HMBC 
correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 13C atom.  
O
NH
OH
HO
OH
7
1
2
1'
1''
7
 
Position δC Proton δH (JHH[Hz]) HMBC ROESY 
1          
2 92.7         
    2-OH 6.72 2, 3 3-Ha, 6-Hb 
3 48.2 3-Ha 3.33 (J3-Ha, 3-Hb = 13)     
    3-Hb 4.10     
4   4-NH 8.08     
5 54.7 5-H  3.23 (J5-H, 6-Ha = 3,  
J5-H, 6-Hb = 11, J5-H, 8-Ha = 6,  
J5-H, 8-Ha = 8, J5-H, 8-Hb = 6) 
    
6 60.1 6-Ha 3.54 (J6-Ha, 6-Hb = 13) 2   
    6-Hb 3.90 2, 5   
7 43.7 7-Ha 2.82 (J7-Ha, 2'-H = J7-Ha, 6'-H < 1) 3, 1', 2', 6'   
    7-Hb 2.80 3, 1', 2', 6'   
8 33.3 8-Ha 2.64 (J8-Ha, 8-Hb = 13,  
J8-Ha, 2''-H = J8-Ha, 6''-H < 1) 
5, 6, 1'', 2'', 
6'' 
  
    8-Hb 2.73 5, 6, 1'', 2'', 
6'' 
  
1' 124.8         
2', 6' 131.0 2'-H, 6'-H 7.03 (J2'-H, 3'-H = J6'-H, 5'-H = 9) 7   
3', 5' 114.6 3'-H, 5'-H 6.70 3', 4', 5'   
4' 155.8       
    4'-OH 9.36 3', 4', 5'   
1'' 124.9         
2'', 6'' 129.9 2''-H, 6''-H 7.04 (J2''-H, 3''-H = J6''-H, 5''-H = 9) 8   
3'', 5'' 115.1 3''-H, 5''-H 6.67 1'', 3'', 4'', 5''   
4'' 156.0         
    4''-OH 9.27 3'', 4'', 5''   
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Table C.11: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 
10 in methanol-d4
 (DMSO-d6, square brackets). Spectra acquired for 10 dissolved in 
methanol-d4 were referenced to δ(CHD2OD) = 3.31 and δ(
13CHD2OD) = 49.0 ppm. 
Spectra acquired for 10 dissolved in DMSO-d6 were referenced to δ(CHD2SOCD3) = 
2.50 ppm and δ(13CHD2SOCD3) = 39.5 ppm.
13C chemical shifts were determined from 
gHMBCAD and HSQC spectra. 1H,1H J-coupling constants were determined from the 
acquired 1H or dqfCOSY spectra (δHDMSO-d6 chemical shifts and coupling constants in 
square brackets). ROESY correlations were observed using a mixing time of 0.2 s. Key 
HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 
13C atom, weak correlations are indicated by (w). 
  
Position δC Proton δH (methanol-d4)  
[δH (DMSO-d6) (JHH[Hz])] 
HMBC ROESY 
1   1-NH [10.6 (J1-NH, 2-H = 2)]     
2 127.9 2-H 7.90 [7.82] 3, 4, 9 11-OH, 25-Ha(w),  
26-H3, 29-H3 
3 116.8         
4 128.6         
5 121.9 5-H 7.86 [7.79 (J5-H, 6-H = 8)] 9 22-H, 23-H 
6 119.1 6-H 6.93 [ 6.88 (J6-H, 7-H = 8)] 4   
7 121.5 7-H 7.03 [6.99 (J7-H, 8-H = 8)] 9   
8 111.5   7.30 [7.28]     
9 136.9         
10 88.8         
11 81.4        12-H, 13-H, 26-
H3 
    11-OH [4.79]     
12 86.3 12-H 3.93 [3.84 (J12-H, 13-Ha = 6)] 10, 11, 14, 15 24-H 
13 29.6 13-Ha 1.83 [1.67 (J13-Ha, 13-Hb = 12)] 11, 12 28-H3 
    13-Hb 2.36 [2.18]   20-H, 29-H3 
14 50.6         
15 85.5 15-H 4.75 [4.55 (J15-H, 16-Ha = 14,  
J15-H, 16-Hb = 6)] 
23 16-Hb, 18-H, 23-
H  
16 27.1 16-Ha 1.63 [1.49 (J16-Ha, 17-Ha = 9)]     
O O
HO
OH
NH
27
28
15
13
26
1
3
20
19
14
10
11
4
9
29
24
25
2
H
10
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    16-Hb 1.73 [1.58] 14 18-H 
17 29.3 17-Ha 1.34 [1.17 (J17-Ha, 17-Hb = 13)]     
    17-Hb 1.34 [1.61]     
18 30.3 18-H 2.12 [1.99 (J18-H, 27-CH3 = 7)]     
19 45.5         
20 75.4 20-H 3.78 [3.60 (J20-H, 20-OH = 7,  
J20-H, 21-Ha = 4, J20-H, 21-Hb = 13)] 
  21-Ha, 28-H3, 29-
H3  
    20-OH [4.11]     
21 38.1 21-Ha 1.25 [1.14 (J21-Ha, 21-Hb = 13, 
 J21-Ha, 22-H = 13)] 
  22-H, 29-CH3 
    21-Hb 1.67 [1.48 (J21-Hb, 22-H = 5)] 19   
22 31.7 22-H 1.54 [1.39 (J22-H, 23-H = 5,  
J22-H, 29-CH3 = 7)] 
  23-H,  
23 51.6 23-H 2.87 [2.73]  10, 11, 14, 15   
24 41.5 24-H 2.40 [2.31 (J24-H, 25-Ha = 8,  
J24-H, 25-Hb = 9)] 
  12-H, 25-Hb, 26-
H3  
25 72.6 25-Ha 2.77 [2.59 (J25-Ha, 25-Hb = 9)]    26-H3 
    25-Hb 3.90 [3.79] 10, 11   
26 15.1 26-H3 0.88 [0.81] 11  25-Ha 
27 18.7 27-H3 1.02 [0.94] 17, 19 13-Ha, 20-H, 
20-OH, 21-Hb, 
28-H3 
28 19.3 28-H3 1.18 [1.07] 14, 18, 19, 20   
29 16.5 29-H3 1.03 [0.94]    13-Hb, 18-H, 20-
OH(w), 20-H, 21-
Ha
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Table S12: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 
27a in chloroform-d. Chemical shifts were referenced to δ(CHCl3) = 7.26 ppm and 
δ(13CHCl3) = 77.2 ppm.
13C chemical shifts were determined from HMBC spectra. 1H,1H 
J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. HMBC 
correlations (optimized for 6 Hz) are from the proton(s) stated to the indicated 13C atom.  
 
Position δC Proton δH (JHH[Hz]) HMBC 
1   1-NH 5.71 (J1-NH, 2-H = 3) 2, 3 
2 56.0 2-H 
4.09 (J2-H, 7-Ha = 8,  
J2-H, 7-Hb = 5)   3, 1' 
3 165.8       
4   4-NH 5.71 (J4-NH, 5-H = 3) 5, 6 
5 56.0   
4.09 ( J5-H, 8-Ha = 8,  
J5-H, 8-Hb = 5)   6, 1'' 
6 165.8       
7 39.1 7-Ha 
2.31 (J7-Ha, 7-Hb = 14,  
J7-Ha, 2'-H < 1, J7-Ha, 6'-H < 1) 2, 3, 1', 2', 6,' 
    7-Hb 
3.03 (J7-Hb, 2'-H < 1,  
J7-Hb, 6'-H < 1) 2, 3, 1', 2', 6,' 
8 39.1 8-Ha 
2.31 (J8-Ha, 8-Hb = 14,  
J8-Ha, 2''-H < 1, J8-Ha, 6''-H < 1) 5, 6, 1'', 2'', 6,'' 
    8-Hb 
3.03 (J8-Hb, 2''-H < 1,  
J8-Hb, 6''-H < 1) 5, 6, 1'', 2'', 6,'' 
9 69.3 9-H 
5.05 (J9-H, 3'-H < 1, J9-H, 5'-H 
< 1, J9-H, 2'''-H  < 1,  
J9-H, 6'''-H < 1)   4', 1''', 2''', 6''' 
10 69.3   
5.05 (J10-H, 3''-H < 1,  
J10-H, 5''-H < 1,  
J10-H, 2''''-H  < 1,  
J10-H, 6''''-H < 1)   4'', 1'''', 2'''', 6'''' 
1' 127.0       
2', 6' 130.5 2'-H, 6'-H 
7.04 (J2'-H, 3'-H = 8,  
J6'-H, 5'-H = 8) 7, 2', 4', 6'  
3', 5' 115.2 3'-H, 5'-H 6.95 1', 3', 4', 5'  
4' 157.8       
1'' 127.0       
HN
NH
O
O
27a
O
O
1
4
1''
1'''
1'
1''''
10
8
9
7
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2'', 6'' 130.5 2''-H, 6''-H 
7.04 (J2''-H, 3''-H = 8,  
J6''-H, 5''-H = 8) 8, 2'', 4'', 6''  
3'', 5'' 115.2 3''-H, 5''-H 6.95 1'', 3'', 4'', 5''  
4'' 157.8       
1''' 136.3 1'''-H     
2''', 6''' 126.9 2'''-H, 6'''-H 
7.39 (J2'''-H, 3'''-H = 8,  
J6'''-H, 5'''-H = 8) 9, 4''' 
3''', 5''' 128.2 3'''-H, 5'''-H 
7.33 (J3'''-H, 4'''-H = 7,  
J5'''-H, 4'''-H = 7) 1''', 3''', 5'''  
4''' 127.4 4'''-H 7.30 2''', 6''' 
1'''' 136.3       
2'''', 6'''' 126.9 2''''-H, 6''''-H 
7.39 (J2''''-H, 3''''-H = 8,  
J6''''-H, 5''''-H = 8) 10, 4'''' 
3'''', 5'''' 128.2 3''''-H, 5''''-H 
7.33 (J3''''-H, 4''''-H = 7,  
J5''''-H, 4''''-H = 7) 1'''', 3'''', 5''''  
4'''' 127.4 4''''-H 7.30 2'''', 6'''' 
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Table S13: 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compounds 
27b in chloroform-d. Chemical shifts were referenced to δ(CHCl3) = 7.26 ppm and 
δ(13CHCl3) = 77.2 ppm.
13C chemical shifts were determined from HMBC and HMQC 
spectra. 1H,1H J-coupling constants were determined from the acquired 1H or dqfCOSY 
spectra. HMBC correlations (optimized for 6 Hz) are from the proton(s) stated to the 
indicated 13C atom.  
 
Position δC Proton δH (JHH[Hz]) HMBC 
1   1-NH 5.61 (J1-NH, 2-H = 3) 3 
2 55.7 2-H 3.68 (J2-H, 7-Ha = 8,  
J2-H, 7-Hb = 3)   
3 
3 167.2       
4   4-NH 5.61 (J4-NH, 5-H = 3) 3 
5 55.7   3.68 (J5-H, 8-Ha = 8,  
J5-H, 8-Hb = 3)   
3 
6 167.2       
7 38.8 7-Ha 2.83 (J7-Ha, 7-Hb = 15,  
J7-Ha, 2'-H < 1, J7-Ha, 6'-H < 1) 
3, 1' 
    7-Hb 3.15 (J7-Hb, 2'-H < 1,  
J7-Hb, 6'-H < 1) 
3 
8 38.8 8-Ha 2.83 (J8-Ha, 8-Hb = 15,  
J8-Ha, 2''-H < 1, J8-Ha, 6''-H < 1) 
6, 1''  
    8-Hb 3.15 (J8-Hb, 2''-H < 1,  
J8-Hb, 6''-H < 1) 
6 
9 70.0 9-H 5.05 (J9-H, 3'-H < 1, J9-H, 5'-H 
< 1, J9-H, 2'''-H  < 1,  
J9-H, 6'''-H < 1)   
4', 1''', 2''', 6''' 
10 70.0   5.05 (J10-H, 3''-H < 1,  
J10-H, 5''-H < 1,  
J10-H, 2''''-H  < 1,  
J10-H, 6''''-H < 1)   
4'', 1'''', 2'''', 6'''' 
1' 126.7       
2', 6' 130.5 2'-H, 6'-H 7.05 (J2'-H, 3'-H = 9,  
J6'-H, 5'-H = 9) 
7, 4' 
3', 5' 115.3 3'-H, 5'-H 6.92  
4' 158.3      
1'' 126.7      
HN
NH
O
O
27b
O
O
1
4
1''
1'''
1'
1''''
10
8
9
7
  
188 
 
2'', 6'' 130.5 2''-H, 6''-H 7.05 (J2''-H, 3''-H =,  
J6''-H, 5''-H =) 
8, 4'' 
3'', 5'' 115.3 3''-H, 5''-H 6.92  
4'' 158.3      
1''' 136.7 1'''-H    
2''', 6''' 127.3 2'''-H, 6'''-H 7.44 (J2'''-H, 3'''-H = 9,  
J6'''-H, 5'''-H = 9) 
 
3''', 5''' 128.5 3'''-H, 5'''-H 7.40 (J3'''-H, 4'''-H = 8,  
J5'''-H, 4'''-H = 8) 
 
4''' 128.2 4'''-H 7.34  
1'''' 136.7      
2'''', 6'''' 127.3 2''''-H, 6''''-H 7.44 (J2''''-H, 3''''-H = 9,  
J6''''-H, 5''''-H = 9) 
 
3'''', 5'''' 128.5 3''''-H, 5''''-H 7.40 (J3''''-H, 4''''-H = 8,  
J5''''-H, 4''''-H = 8) 
 
4'''' 128.2 4''''-H 7.34  
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